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ABSTRACT 
Chemical heterogeneity is a fundamental property of multicellular organisms. Multiple 
classes of biomolecules exhibit complex spatial and temporal variations and interactions during 
different biological processes. One way to investigate this chemical diversity is to visualize 
biomolecule localization in an organism, which may then translate into insight on how chemicals 
participate in organism functions and states. In this dissertation, multiple methodologies are   
applied using mass spectrometry imaging (MSI) toward analyzing peptide distributions within the 
nervous system. The nervous system contains a variety of signaling molecules that are used for 
cell-to-cell communication, such as small molecule neurotransmitters and neuropeptides. MSI is a 
multiplex and non-targeted chemical imaging technique that can reveal the localization of many 
compounds in one experiment without having to pre-select a specific analyte. It is compatible with 
multiple compound classes, covering metabolites, lipids, peptides, and proteins. These properties 
make MSI particularly useful for de novo analysis of complex biological systems, generating a 
comprehensive data set of chemical distributions for data mining and hypothesis generation. 
 This dissertation applies MSI to a variety of biological samples ranging from tissues to 
dissociated cell populations, demonstrating the applicability of the approach for analyzing many 
systems. Sample preparation protocols are developed to prepare tissue sections for MSI. Multiple 
approaches are explored to improve ion image quality, enhance signal, and preserve tissue section 
integrity during sample processing. A couple of these include comparing spraying and sublimation 
for applying MALDI matrix, and different tissue rinsing and drying techniques. A variety of 
statistical methods are also applied on the collected data sets for visualizing chemical trends and 
for determining chemical markers. The developed MSI protocols are used to study different 
biological systems. One study reveals peptide changes in the spinal cord in response to a painful 
stimulus from the peripheral nervous system applied via the formalin test. Another study visualizes 
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chemical distribution trends during planarian nervous system regeneration, revealing complex 
patterns in peptide content and distribution at different regeneration time points.  
In addition to traditional MSI, a high-throughput single cell MS analysis approach is 
developed to classify cell types and reveal rare cells based on their characteristic peptide markers. 
This approach modifies how MSI is typically conducted in order to specifically target features of 
interests on a substrate (e.g. cells), reducing analysis time and instrument wear. The improved 
efficiency enables hundreds to thousands of cells to be analyzed per experiment. Along with 
protocol developments are also instrument advances. Software are created for a modified mass 
spectrometer that has dual MALDI and SIMS capabilities. The software provides automatic 
control of parts of the instrument, enabling new functionalities, such as depth profiling, to be 
conducted. The development of these new methodologies and software tools allows new 
measurements to be obtained via MSI, generating insight into the chemical and spatial relationship 
involved in different biological processes. 
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CHAPTER 1 
 
INTRODUCTION AND DISSERTATION OVERVIEW 
 
Chemical heterogeneity is a fundamental feature of multicellular organisms. Although 
morphological traits are often used to characterize biological systems, oftentimes chemical 
contents and distributions are better linked to organism functions and states. Toward the goal of 
chemical characterization, many chemical analysis methods can be used to study the chemical 
composition of different biological systems. Analysis can be conducted on a variety of sample 
types, such as on tissue homogenate of dissected organs or on live animals for in vivo imaging. 
Analyzing tissue homogenates can often generate in-depth chemical data, but information on 
chemical spatial heterogeneities is lost during the homogenization process. In order to provide 
spatial context, a variety of imaging techniques have been developed, typically trading off between 
generating more structural or chemical information. Chemical probes are routinely used to label 
biomolecules, such as proteins and RNA, to visualize their distribution via optical microscopy.1 
Imaging without labels are also common, and many techniques, like secondary electron 
microscopy (SEM), can produce high quality images of the sample, but the obtained information 
tend to be more morphological than chemical.1,2  
Mass spectrometry imaging (MSI) is a technique that effectively combines chemical and 
spatial data.3 MSI achieves spatially resolved mass spectrometry (MS) to enable untargeted 
visualization of molecular distributions.4 MSI is typically conducted in the microprobe mode, in 
which an ionization probe used for MS is rastered across the sample in a grid while MS spectra 
are collected.5 The multiplex nature of MS enables many compounds to be detected and localized 
per experiment. Many MS ionization techniques can be used for MSI. One of the most common is 
matrix assisted laser desorption / ionization (MALDI). MALDI can be used to directly detect large 
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biomolecules such as peptides and proteins, and it is generally tolerant of salt contents, making it 
compatible with biological samples. The MALDI laser ablation process is also amenable to the 
point-by-point data acquisition nature of MSI. In this dissertation, MALDI MS is applied in a 
variety of projects on imaging and profiling chemical distributions in the nervous system. Projects 
include effective sample preparation, determining fundamental features of MALDI MS, and 
applying MALDI MSI to study different biological systems. The primary analyzed biomolecules 
are neuropeptides, which are short chains of amino acids that are typically at most about 50 amino 
acids long.6 These peptides function in the nervous system as neurotransmitters, neuromodulators, 
and neurohormones, influencing many biological processes such as hunger/satiation, pain 
signaling, and circadian rhythm, etc.7  
To start off, Chapter 2 of this dissertation provides an overview of MSI, covering various 
aspects of sample preparation, instrument development, and data analysis. In addition to MALDI, 
other ionization techniques, including desorption electrospray ionization (DESI), and secondary 
ion mass spectrometry (SIMS) are also discussed. The end of the chapter includes several examples 
of MSI application, such as imaging the nervous system and determining disease biomarkers. The 
remaining chapters will, in a way, mirror the structure of Chapter 2, moving from sample 
preparation to instrument development and ending with technique application. Because sample 
preparation is a key part of any chemical analysis, Chapter 3 will cover a project on developing 
methods to conduct MALDI MSI analysis of neuropeptides in the rat spinal cord. The focus will 
be on comparing two MALDI MSI matrix application methods, and the protocol is demonstrated 
in a preliminary experiment on spinal cord response to a painful stimulus. Chapter 4 discusses an 
experiment to elucidate the detection limit of MALDI MS by using a chemical inkjet printer to 
deposit microscopic MALDI sample spots containing peptide standards. A low detection limit is 
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important for conducting micro-analysis of small biological samples such as single cells. Chapter 
5 covers instrument development for a hybrid MALDI/C60-SIMS mass spectrometer, and the focus 
is temporarily shifted away from MALDI MS to SIMS. The project is part of a larger experiment 
in which a MALDI mass spectrometer is modified to have dual MALDI and SIMS capability.8 
Custom software are developed to enable new instrument functionalities by semi-automating 
operation of parts of the instrument.  
After discussing multiple projects on sample preparation and instrument development, 
Chapters 6 and 7 center on two MALDI MSI applications. Chapter 6 focuses on applying MALDI 
MSI toward imaging peptide distributions in the planarian Schmidtea mediterranea during tissue 
regeneration. Planarians can recover from almost any physical injury due to a distribution of stem 
cells throughout their body.9 In this experiment, their cephalic ganglia is amputated, and chemical 
distribution during regeneration is monitored at different time points. Aspects of sample 
preparation discussed in earlier chapters are used to prepare S. mediterranea tissue sections for 
imaging. Chemical and structural trends associated with regeneration are revealed by examining 
ion images and are validated with multiple imaging and statistical techniques. Chapter 7 describes 
a project that modifies the typical MALDI MSI procedure to enable single cell MS analysis of 
large cell populations. A cell population is first deposited on a microscope slide. Optical 
microscopy is then used to determine the cell coordinates on the slide, which enables automatic 
MALDI MS analysis to interested cell locations. With this new approach, hundreds to thousands 
of cells can be individually profiled via MALDI MS and can be categorized based on their 
characteristic peptide profile. 
Beyond the major chapters, several appendices are added to provide more information on 
newly developed hardware and software tools. Appendix A describes a small heater made using 
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nichrome wire for subliming MALDI matrix. The heater can rapidly heat up to enable many 
samples to be quickly coated with MALDI matrix. Appendices B and C detail the block diagrams 
for two LabVIEW virtual instruments that were developed for the custom MALDI/C60-SIMS mass 
spectrometer (Chapter 5). Appendix D contains a Python script developed by Dr. David Kissick 
for conducting principal component analysis (PCA) and PCA-based outlier detection, which was 
used to classify cell types and reveal chemically unique cells from a collection of hundreds to 
thousands of single cell MALDI MS spectra.  
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CHAPTER 2
MASS SPECTROMETRY IMAGING OF NEUROPEPTIDES AND OTHER 
BIOLOGICAL APPLICATIONS
2.1 NOTES AND ACKNOWLEDGMENTS
This  chapter  contains  materials  adapted  from  two published  review  articles.  One,  titled  “Mass 
Spectrometry-based characterization of endogenous peptides and small molecules in small volume 
samples”  (DOI:  10.1016/j.bbapap.2015.01.008),  is  published  in  Biochimica  et  Biophysica  Acta 
(BBA)  - Proteins  and  Proteomics 2015,  1854,  732-740,  with  coauthors  E. G.  Tillmaand,  M. 
Makurath, S. S. Rubakhin, and J. V. Sweedler, adapted here with permission from Elsevier. The 
other article is titled “Biomarker Discovery using Mass Spectrometry Imaging” and is submitted 
as a book chapter for the 2nd edition of Proteomics for Biological Discovery with coauthors E. J. 
Lanni,  and  J. V.  Sweedler,  adapted  here  with  permission  from  Wiley.  The  chapter  presents  an 
overview  of  mass  spectrometry  imaging,  covering  different  aspects  of  sample  preparation, 
ionization,  mass  analysis,  and  instrument  development.  Multiple  applications  of  MSI  are  also 
presented,  with  a  particular  focus  on  neuropeptide  imaging.  This  work  was  supported  by  the 
National Institute of Health through grant P30 DA018310.
 
2.2 MASS SPECTROMETRY IMAGING OVERVIEW 
2.2.1 Chemical Complexity of the Nervous System. Multicellular organisms are complex 
systems composed of chemicals that vary spatially and temporally with organism states.  Many 
classes of biomolecules participate in the functioning of organisms, including atomic ions, small 
molecule metabolites, lipids, and proteins, among others. One system where chemical diversity is 
particularly evident is the nervous system, where signaling molecules are localized between 
specific cells. Small molecule neurotransmitters, like dopamine, serotonin, and nitric oxide, 
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transmit signals across synapses between neurons. Neuropeptide is another class of signaling 
molecules. These peptides are typically 3 to 50 amino acids long and have diverse structure, 
function, and distribution within an organism. Structurally, neuropeptides are cleaved from larger 
protein prohormones, which can have many cleavage sites and post-translational modifications, 
generating a large array of possible neuropeptide sequences and structures.1,2 Functionally, while 
they are found in neuronal synapses acting as neurotransmitters, they can also act as 
neuromodulators and neurohormones with long term and long distance effects.2 As such, 
neuropeptides have receptors in many parts of a neuron, including the soma and axon. Their 
functional diversity is further reflected in their wide distribution in addition to the nervous system. 
In fact, many neuropeptides were initially known as gut peptides before being discovered to be 
present in the brain,2 illustrating their complex role in organism functions. 
2.2.2 Multiplex Analysis via Mass Spectrometry Imaging. An in-depth analysis of a 
chemically and spatially complex environment like the nervous system represents an analytical 
challenge. Much has been learned about the nervous system using different imaging and chemical 
analysis methods, but many of those techniques tradeoff between chemical and spatial information. 
Methods like magnetic resonance imaging (MRI) can generate high quality images of the nervous 
system and is non-invasive, but it reveals relatively little about the identity of chemicals that are 
participating in different processes. On the other hand, analysis of extracts from tissue 
homogenates can produce a large amount of chemical data, but spatial context is lost during the 
homogenization process. A technique that combines spatial and chemical information would 
therefore generate new insights into the nervous system and the organism as a whole. One such 
method is mass spectrometry imaging (MSI), which utilizes mass spectrometry (MS) to image 
chemical distributions. MS is a multiplex analytical method that detects many compounds per 
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analysis without analyte pre-selection. When used as an imaging technique, it enables many 
compounds to be simultaneously localized. This multiplex and non-targeted nature is a particular 
strength compared to imaging techniques like immunostaining and autoradiography, which are 
limited to analyzing a few compounds at a time.  
MS is conducted by vaporizing and ionizing the sample and then manipulating the motion 
of the generated gas phase ions to determine their mass-to-charge ratios (m/z), subsequently 
gaining information about the sample’s chemical composition. Developments in soft ionization 
methods like electrospray ionization (ESI) and matrix assisted laser desorption / ionization 
(MALDI) in the past couple decades have enabled many large biomolecules like proteins to be 
directly detected, expanding the applicability of MS to many biological fields. To apply MS as an 
imaging modality, a probe that ionizes the sample, such as a laser, electrospray, or ion beam, is 
rastered across a sample to conduct location-resolved MS. An image is then generated in a pixel 
by pixel manner by picking the ion of interest from the collected data set. While MSI is typically 
conducted in such microprobe fashion, there are also examples of “microscope” MSI, in which a 
large area is ionized and ion optics are used to preserve the ions’ birth locations.3-7 MSI has been 
used to image a variety of biological samples ranging from tissues and single cells, probing the 
localization of many biomolecules such as metabolites, lipids, and proteins.8-11  
 
2.3 SAMPLE PREPARATION AND INSTRUMENTATION 
2.3.1 Dissection, Preservation, and Section. Sample preparation for mass spectrometry 
imaging generally proceeds with dissecting, preserving, and sectioning the tissue sample.12 The 
animal is first dissected to isolate the tissue of interest, which is then flash-frozen to stop post-
mortem degradation.13 Rapid heating is also sometimes conducted before freezing to denature 
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proteolytic enzymes.14-16 Although effective for sample preservation, heating can also compromise 
tissue quality to make sectioning and discerning histological regions difficult.17 For sample 
storage, flash-frozen tissues are typically kept in -80 oC until further processing. Formalin fixation 
and paraffin embedding (FFPE), although common in histology studies, is often not used for MSI 
because cross-linking proteins negatively affects their signal in MS.18 However, the popularity and 
effectiveness of formalin fixation are driving advances to make it more compatible with MSI.18-22 
Of note, the Caprioli group has demonstrated the effectiveness of antigen retrieval and in situ 
enzymatic digestion to generate peptide fragments from domains that are not cross-linked, 
enabling protein imaging and identification.19,22 Alternative fixation methods that do not cross-
link proteins, like ethanol preservation, have also been used.23 For sectioning, cryosectioning is 
the preferred method for flash frozen, non-fixed samples. A variety of embedding media, such as 
agarose, gelatin, and ice, can be used to assist in the sectioning process. However, care has to be 
taken to avoid embedding media that introduce interfering MS signals, such as optimal cutting 
temperature compound (OCT).13 Sections are usually taken at 5 – 30 µm thickness and are thaw-
mounted onto a conductive substrate such as indium tin oxide (ITO) coated slides by warming to 
ambient temperature. A conductive substrate is important for minimizing charging effects during 
MS. For particularly fragile sections, a physical backing like carbon tape has been used to provide 
additional support when transferring onto the substrate.17  
2.3.2 Rinses. After sectioning, chemical washes are commonly used to remove compounds 
that may interfere with MS detection of the interested analyte. During this step, a combination of 
solvent, temperature, pH, and drying conditions have to be optimized to balance between removing 
interfering chemicals and minimizing analyte lateral diffusion.24,25 Successive washes in alcohols 
and other organic solvents can remove lipids for enhancing peptide and protein signal.13,25 
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Ammonium salt buffers have been used to remove inorganic salts, which is useful for simplifying 
mass spectra and improving signal.26-28 For sections from FFPE tissue blocks, deparaffinization is 
first done with xylene rinses, followed by more rinses in a graded alcohol series. Because each 
solvent generally has a specialized purpose, a combination of rinses is typically used to achieve 
signal enhancement. 
2.3.3 Ionization. Once the sample is prepared, multiple ionization methods can be used for 
MSI.13,29 Because of its high sensitivity, good salt tolerance, and large mass range extending to 
megadaltons, MALDI has become one of the most popular ionization methods. The MALDI 
process starts by mixing the sample with a matrix compound that strongly absorbs UV. 
Compounds like 2,5-dihydroxybenzoic acid (DHB), α-cyano-4-hydroxycinnamic acid (CHCA), 
and sinapinic acid (SA) are all commonly used organic matrices. Inorganic matrices like 
nanoparticles are also used, which can produce a cleaner spectrum at the lower masses.30-34 Once 
matrix is applied, a laser is used to irradiate the sample to produce a gas plume containing gas 
phase ions and neutrals. Ion optics then separates ions for analysis in the mass analyzer. Successful 
application of MALDI MSI requires a homogeneous application of matrix to minimize 
inconsistent ionization. Many techniques have been used toward this end, balancing between 
sufficiently wetting the sample to extract analytes and not “flooding” the sample, which leads to 
unwanted analyte diffusion and creates large matrix crystals that limit imaging resolution.35 
Pneumatically spraying the matrix solution is one of the most commonly used methods. The small 
droplets extract compounds from the tissue section and restrict how far molecules can diffuse. The 
droplets may also be charged to further promote extraction from the sample.36 Dry application 
methods, like sublimation and through a sieve, have also been used. These techniques do not use 
a solvent, enabling high imaging resolution at the expense of signal strength.26,28,37-43 Printing an 
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array of matrix spots using a robotic spotter is another option.44-46 Printing provides precise control 
over how much matrix is deposited on the sample, but the large size of each matrix spot lowers 
spatial resolution.44,45 In a similar vein, desktop inkjet printers can be modified for matrix 
deposition by filling the ink cartridge with matrix solution.47,48 Beyond changing the physical 
matrix application process, ionic liquid matrices, which pair traditional MALDI matrices with 
organic bases as counter ions, have shown promise for MSI by exhibiting homogeneous 
crystallization.49-52 
Ionization methods other than MALDI have also been used for MSI. Many of these 
techniques are complementary to MALDI, offering a multitude of tradeoffs on ease of sample 
preparation, and imaging resolution, among others. Two of the more common methods are 
desorption electrospray ionization (DESI) and secondary ion mass spectrometry (SIMS).29,53 DESI 
functions by aiming an electrospray at the sample to “splash” secondary ions into the mass 
spectrometer. It is conducted in ambient conditions directly on samples without matrix, 
simplifying sample preparation to improve analysis throughput.54 Like MALDI, DESI is a soft 
ionization method that enables biomolecules like lipids to be directly detected and identified.54 
The angle and distance of the spray to the sample as well as the spray solvent composition are all 
factors that can be optimized for detecting different compound classes. SIMS, unlike DESI, 
bombards the sample with a focused ion beam to generate secondary ions. It is often conducted 
using atomic primary ion beams, such as Au+ and Bi+.55 In many ways, SIMS is a complementary 
technique to MALDI. The lateral resolution of MALDI MSI is typically limited to tens of 
micrometers, but SIMS MSI can reach submicrometer resolution in state of the art 
instrumentations.56-60 The ion beam can also be used to etch away materials to enable depth 
profiling experiments.61-71 However, SIMS conducted with an atomic ion beam is a harsh 
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ionization method, and the beam damages the sample by fragmenting compounds that are near the 
surface. To overcome this drawback, developments in large cluster ions like argon clusters and 
C60
+ are improving the SIMS mass range to where biomolecules like lipids and peptides can be 
analyzed.71-75 Compared to atomic primary ions, cluster ions deposit energy closer to the sample 
surface to more effectively generate secondary ions and minimize damage below the sample 
surface.70,76 Like DESI, SIMS can be conducted on samples without a matrix compound, but signal 
enhancement has been observed after depositing a matrix like glycerol or a metal coating,10,50,51,77-
81 enabling more parameters to be used for optimizing detection.  
2.3.4 Mass Analysis. MSI has been conducted using many types of mass analyzers. 
Coaxial time-of-flight (TOF) analyzer is common because it offers a large mass range, short 
analysis time, and pulsed ion introduction that is well-suited for the pixel-by-pixel data acquisition 
manner of MALDI MSI. A TOF analyzer determines an ion’s m/z based on its flight time over a 
certain distance. After ions are generated, they are elevated to a high potential and accelerated into 
a flight tube. Because all ions are given the same kinetic energy, their velocities and therefore 
flight times through the tube differ based on m/z. To improve mass resolution, ion mirrors 
(reflectron) and delayed extraction can be used to account for spread in initial ion location and 
velocity in the mass spectrometer’s source. In addition to TOF, high resolution mass analyzers like 
Fourier transform-ion cyclotron resonance (FTICR) and orbitraps are also used. These analyzers 
function by trapping ions and sending them into a stable orbital flight. The frequency of the ions’ 
orbital flight is measured and Fourier transformed to determine their m/z. High mass resolution 
and accuracy enable exact mass data to be obtained for compound identification, and more 
compounds are resolved. Image contrast is also improved because of less interference from peaks 
with similar masses (Figure 2.1).82 However, the mass range for these analyzers is narrower 
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compared to TOF, and more sample is often required. Two more instruments of note are the 
NanoSIMS N50 and NanoSIMS N50L, which are SIMS instruments capable of ~50 nm imaging 
resolution. Both instruments use double-focusing magnetic sector mass analyzers that separate 
ions of different m/z by the Lorentz force.83 Unlike the other discussed instruments, this mass 
analyzer can only analyze a few pre-selected m/z at a time. 
2.3.5 Statistical Analysis. A variety of techniques have been used to conduct statistical 
analysis of MSI data. Similar to non-imaging MS analysis, MSI spectra are often smoothed, 
baseline subtracted, and normalized. Normalization is particularly important for minimizing image 
artifacts because many factors in addition to analyte concentration can contribute to signal 
variation. Factors that affect the entire spectrum, such as uneven matrix coatings and changes in 
instrument performance, can be accounted using global normalization techniques such as 
normalizing to the total ion count (TIC).84,85 While TIC normalization is effective, compound 
specific effects like ion suppression require a different approach.84,86 One method is to use 
isotopically labeled compounds as internal standards.86-89 These standards behave chemically 
similar to their non-labeled counterpart and are useful when only one or a few structurally similar 
molecules are of interest. The Yost group has developed a methodology revolving around printing 
internal standards onto the slide using an inkjet printer and then placing the sample on top.86,88,89 
The internal standard is extracted through the sample during matrix application to mimic 
endogenous compounds. This method not only improves image quality, it also increases the 
quantitative capability of MSI. Normalizing to the internal standard produces more linear 
calibration curves and standard addition curves than when only using the analyte signal.86-89  
Another aspect of MSI data analysis is to use multivariate statistics to discriminate between 
experimental groups, determine chemically different regions within an image, and general data 
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mining.85,90,91 MSI experiments can generate large data files due to the multiplex nature of MS. 
While data sets can be analyzed by manually examining and comparing ion images, it is often 
more efficient and thorough to conduct multivariate analysis on the data set as a whole. A primary 
feature of multivariate statistics is dimension reduction, which aims to minimize the number of 
dimensions that have to be considered during data analysis. Rather than examining all ions 
individually to find data trends, only a few, newly created variables are considered. A common 
multivariate analysis method is principal component analysis (PCA), which creates linear 
combinations (principal components) of ions to account for data spread (variance). Trends in the 
data are visualized by projecting data points onto principal components. Ions that account for any 
observed patterns are revealed by looking at the magnitude in which they load into a particular 
principal component. In addition to PCA, other analysis techniques, including hierarchical 
clustering, partial least square analysis (PLS), linear discriminant analysis (LDA), and maximum 
autocorrelation factor analysis (MAFA), have all been used.85,90,92-98 These techniques make 
different assumptions about the nature of the data, and their outputs differ on which part of the 
data is most prominently highlighted.85 Care therefore has to be taken to choose the proper 
statistical technique. However, while differences do exist, a comparison of multiple statistical 
methods by Jones et al. shows a general agreement between all techniques,90 illustrating the 
robustness of combining MSI and multivariate statistics for conducting molecular histology. 
 
2.4 IMPROVING THE INFORMATION CONTENT OF MASS SPECTROMETRY 
IMAGING VIA INSTRUMENT DEVELOPMENT AND CORRELATED IMAGING 
2.4.1 Correlated Imaging. It is often beneficial to combine multiple MS methodologies 
to expand analyte coverage when characterizing a biological system. In one experiment, repeated 
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MALDI MSI is conducted on one tissue section by incorporating wash steps and changing matrices 
between images.99 The different performance characteristics between matrices enable multiple 
compound classes to be visualized and correlated. Another option is to combine different 
ionization methods. In one example by Eberlin et al., DESI MSI is conducted in sequence with 
MALDI MSI by first using DESI to image lipids and then MALDI to analyze proteins.100 The low 
destructive nature of DESI allows tissues to remain largely intact after imaging, enabling 
subsequent analysis to be conducted using other approaches. SIMS has also been used extensively 
with MALDI because it covers dissimilar lateral resolutions and mass ranges.10,101-108 In one 
experiment by the Sweedler group on imaging Pseudomonas aeruginosa biofilms,10 MALDI MSI 
is first conducted at low resolution over a large area to identify chemically interesting locations. 
These locations are then imaged at high resolution via SIMS. The combination of the two 
techniques allows the sample to be imaged over a wide spatial range to cover the colony and single 
cell scale, which would have been difficult to achieve with only MALDI or SIMS. To further 
combine the two methods, the Winograd and Sweedler group have constructed two custom 
instruments with dual MALDI and SIMS capability.102-104 The instruments offer multiple 
ionization modalities, high mass resolution, and tandem MS capability for MALDI and SIMS.   
Beyond combining MS ionization methods, it is also common to correlate other imaging 
modalities with MSI.58,109 The most common may be to include light microscopy, which when 
coupled with histology stains are useful for selecting regions of interest and for validating ion 
images.12,84,100,110-116 Hematoxylin and eosin (H&E) staining is particularly common and has been 
done on serial or the same tissue section used for MSI.95,97,100,111,117-125 The benefit of using the 
same section is potentially greater agreement between image types, but it requires the sample to 
be prepared in a way that is compatible with all imaging approaches. Beyond optical microscopy, 
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other techniques such as Raman microscopy,11,126 atomic force microscopy (AFM),127 and 
scanning electron microscopy (SEM),128 have also been used. These techniques all produce higher 
resolution images than MSI, and in the case of AFM and SEM, topographical information is also 
generated to supplement the two-dimensional MSI data. To align the images together, fiduciary 
marks that natively exist in sample or placed during the experiment may be used. Mathematical 
approaches have also been developed to fuse low resolution ion images with high resolution optical 
or electron images, producing a final hybrid image that has high lateral resolution and high 
chemical information.128  
2.4.2 Improving Imaging Resolution and Throughput. Much effort has been made to 
improve MSI lateral resolution, which in most applications is currently limited to tens of 
micrometers. This limitation largely results from the size of the ionization probe that is used, but 
other physical constraints also play a role. The analyte concentration limits how small the probe 
spot can be before reaching the instrument’s detection limit. For MALDI MSI, large matrix 
crystals can also introduce image artifacts when small laser spots are used. Even with these 
challenges, impressive progresses have been made to enable high quality imaging of at least the 
more abundant analytes. The Sweedler group introduced the “oversampling” approach for MALDI 
MSI, which improves spatial resolution by completely ablating the sample at each laser location 
and stepping the laser in a smaller distance than the beam diameter.129 Ionization only occurs at 
the leading edge of the laser, shrinking the size of each pixel. The same group also developed the 
stretch sample method, which involves physically stretching the sample to enlarge it before 
imaging.130-134 The process breaks the sample into small isolated pieces, allowing a wetter matrix 
application procedure and a large laser size to be used without sacrificing lateral resolution. New 
instrumentations are also being developed.48,135-137 The Spengler group constructed and is 
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continually improving an instrument in which the laser is focused onto the sample coaxially with 
respect to the ion path. A central bore is added to the laser objective for the ion path.48,136 The laser 
diameter for this instrument can be focused down to 262 nm, and the effective resolution for the 
instrument is ~1 µm. The Caprioli group has built another instrument with the laser positioned 
behind the sample in a transmission geometry. The laser shoots through the sample slide to ablate 
the sample into the mass spectrometer.137 This instrument was used to image the distribution of 
lipids in Human Embryonic Kidney 293 (HEK-293) and RKO cells at ~1 µm resolution. The 
potential for sub-cellular peptide and protein MS imaging was also demonstrated in a profiling 
experiment that showed insulin localization to the cytoplasm of human pancreas islet cells.  
The capability to quickly acquire images becomes important with advances in high 
resolution imaging. The traditional “point and shoot” method of MALDI microprobe MSI is 
problematic when unrealistic data acquisition time is needed to collect the large number of spectra 
in a high resolution image. One way to reduce imaging time is to minimize wait time between 
different parts of the mass spectrometer. Work is therefore progressing to conduct MALDI MSI 
by constantly moving the sample stage while pulsing the laser,138 a technique already utilized in 
DESI MSI with a constant electrospray. With this method, an image pixel is dictated by data 
acquisition and binning time. Another option is to conduct stigmatic imaging (microscope mode 
MSI), which uses a diffused laser to quickly image an area. The Heeren group has made multiple 
advances in this regard,3-7 enabling cellular-scale images to be quickly collected from tissue 
sections. The tradeoff with this approach is that a relatively narrow m/z range is detected for each 
image, so chemical information is reduced although spatial resolution and imaging speed is 
increased. 
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2.5 MASS SPECTROMETRY IMAGING OF NEUROPEPTIDES 
MSI has been broadly utilized in studying neuropeptide distribution.139 In one example, the 
Salzet group identified several peptides associated with CNS regeneration in the medicinal leech 
Hirudo medicinalis.140,141 The Sweedler group has also imaged neuropeptides in multiple model 
animals.101,130-134,142-144 One example is an early application of single cell MSI conducted on a 
culture of A. californica bag cell neurons.145 Even at 50 µm lateral resolution, the cell body and 
neuronal processes can already be resolved based on peptide signal. Several more recent examples 
revolve around imaging the spinal cord, covering the metabolome, peptidome, and proteome.101,131 
MALDI MSI was conducted on transverse sections of the rat spinal cord and revealed many 
neuropeptides, such as Substance P, to localize to the dorsal horn of the gray matter, where sensory 
information is received into the spinal cord from the dorsal root ganglia.101,146 SIMS imaging was 
also conducted in the same study to generate complementary data on small molecule distributions. 
A separate study imaged protein distribution using the stretch sample method by placing spinal 
cord sections on a monolayer of beads that are modified with trypsin and chymotrypsin.131 
Digested peptides from proteins such as myelin basic protein, actin, and neurofilament were all 
imaged at high resolution. The Li group has extensively studied crustacean model systems.16,139,147-
149 Of note, neuropeptides and lipids in the brain of the crab Cancer borealis were imaged and 
identified in 2D and 3D imaging experiments.147 In another study, a novel tachykinin-related 
peptide (TRP), CalsTRP, was found to co-localize with CabTRP in the brain of the blue crab 
Callinectes sapidus.149 The abundance of the two peptides was further discovered to change in a 
similar manner in relation to satiation states. Beyond imaging biological tissues, the Li group also 
coupled MSI to separation platforms. The process functions by printing separation output as a line 
on a MALDI target and then imaging the line. Using this technique, in one experiment multi-stage 
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liquid chromatography-capillary electrophoresis-mass spectrometric imaging (LC-CE-MSI) 
detected 19 putative neuropeptides from the orcokinin family in extracts from the sinus gland of 
C. sapidus.150  
High resolution neuropeptide imaging has also been conducted, achieving lateral 
resolutions close to the mammalian cell scale. Cellular scale MSI provides not only chemical 
distribution on the tissue level, it also sheds light on cell-to-cell chemical heterogeneity because 
the chemical content of hundreds to thousands of cells can be analyzed in one experiment. The 
Spengler group has imaged mouse pituitary sections at 5 µm resolution.151 A distribution of the 
POMC peptide, α-melanocyte-stimulating hormone (α-MSH), is observed within the intermediate 
pituitary between two mixed cell types, illustrating the potential of MALDI MSI to reveal cellular 
subpopulations. Similarly, the Heeren group has used their mass microscope to image the pituitary 
from mouse, rat and human at 4 µm resolving power, achieving single cell resolution imaging over 
a large range of tissue sizes.  
 
2.6 BIOLOGICAL APPLICATIONS OF MASS SPECTROMETRY IMAGING 
What follows is adapted from a book chapter titled “Biomarker Discovery using Mass 
Spectrometry Imaging” from Proteomics for Biological Discovery, 2nd Edition. The chapter 
focuses on protein biomarker discovery via MSI and is included to illustrate the flexibility of MSI 
in multiple applications. 
2.6.1 Cancer. Cancer is a disease of abnormal cell growth, often characterized by tumor 
formation that invades and affects organ function. Chemical signatures for several cancer types 
have been investigated using MSI, such as brain,152-154 breast,95,110,155,156 kidney,157 liver,96 lung,158 
ovarian,159,160 prostate,97,161-163 and thyroid.164 In addition to proteins, many other biomolecules, 
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including lipids, have also been identified as putative biomarkers.92,121,123,165 Many of these 
compounds have been further incorporated into statistical models that discriminate between 
healthy and diseased tissues with high accuracy and specificity. Results from the studies cited 
above have contributed to our understanding of disease function, shortening diagnosis times, and 
providing targets for drug design.  
 Because many tumor types have a well-defined histology, cancer studies are often 
histologically directed, with tissue staining and optical imaging used to guide MSI analysis. An 
example study in a single tissue was conducted by Le Faouder and colleagues to discriminate 
between hepatocellular carcinoma (HCC),96 a liver cancer, and liver cirrhosis, the long-term 
scarring of liver tissue that may develop into cancer. Histology correlation was conducted by 
taking sequential tissue sections for MSI and H&E staining (Figure 2.2); MSI images show the 
distribution of two discriminating ions in HCC tissue, m/z 8450,  (Figure 2.2A) and in cirrhosis 
tissue, m/z 3195 (Figure 2.2B) in relation to H&E staining (Figure 2.2C). The ion at m/z 8450 was 
overexpressed in HCC while m/z 3195 was more abundant in the cirrhosis area, a contrast that is 
made clear by the overlaid ion images (Figure 2.2D). The authors conducted statistical analyses 
using a support vector machine (SVM) model by applying the detected discriminating peaks to a 
validation dataset. Model quality was verified by comparing the generated classification maps with 
the histology. One of the most discriminating ions was identified using bottom-up proteomic 
approaches and verified with immunohistochemical staining to be the human ubiquitin monomer. 
The ubiquitin system is involved in many cellular processes such as protein degradation and 
controlled cell death.166 These results suggest a disruption of the ubiquitin system during HCC 
development, and the authors note that ubiquitin detection may be a complementary diagnostic 
method for HCC.  
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 Because subtle chemical changes often precede more obvious phenotypical alterations, 
histology-guided analysis does have limitations. Using histology to distinguish between healthy 
and diseased tissues is not always a straightforward process, and can be problematic when 
determining surgical cancer treatments because accurately mapping tumors before their excision 
is critical. Currently, tumor location and shape are often determined prior to surgery using imaging 
methods such as MRI. However, it can be difficult to correlate these images to the patient during 
the actual operation, leading to less than ideal situations in which surgeons must make judgment 
calls based on visual indicators alone.  
 The differences that can exist between histological and biochemical margins have been 
investigated by the Caprioli group in clear cell renal carcinoma,157 a type of kidney cancer. By 
comparing H&E stains and MS profiling data, an area on the healthy side of the histological border 
was shown to contain chemical characteristics that were similar to the tumor. Some of the 
implicated proteins included calcyclin, cytochrome c, and the NADH-ubiquinone oxidoreductase 
MLRQ subunit. Although instrument limitations currently prevent on-site application of MSI, with 
the development of several ambient ionization techniques such as DESI and the miniaturization of 
mass spectrometers, it may eventually be possible to conduct MS profiling and imaging 
experiments during surgery to ensure the complete excision of diseased tissues.167 
 The ability to diagnose based on histology requires considerable experience by the 
histopathologist, forcing subjective decision-making in borderline cases. Diagnosis based on MS 
profiles may be helpful in these situations.168 A study by the Hogendoorn group used MSI to 
distinguish between myxofibrosarcoma and myxoid liposarcoma tumors, two soft-tissue cancers 
that show similarities in histology.123 PCA of the MSI data showed low-grade tumors from each 
cancer to be separated on principal component (PC) 1 and 2, while PC 3 was needed to separate 
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the high-grade tumors. Since subsequent PCs encompassed decreasing amounts of variance within 
the data, these results suggest that the two cancer types have distinct chemical profiles in the early 
stages, but the differences diminish with disease progression. Several of the proteins loaded into 
the PCs, such as calgizzarin and calcyclin, were consistent with prior studies differentiating 
between soft-tissue tumor grades,169 providing a validation of the statistical approach used in the 
Hogendoorn study.  
 In that same study, the authors also examined chemical heterogeneity found within 
myxofibrosarcoma tumors.123 Upon statistical examination of the MSI data using hierarchical 
clustering, low- and high-grade tumors were separated, but intermediate-grade tumors were split 
into low or high classifications. Analysis using an SVM model also displayed a mix of low- and 
high-grade regions within the intermediate-grade tumors. These results suggest the presence of 
two chemical characteristics within one cancer grade. By probing chemical distributions, MSI 
allows users to differentiate between histologically similar cancers and reveal complex shifting of 
tumor conditions.  
 MSI has also been used to determine specific disease status. The human epidermal growth 
factor receptor 2 (HER2) is a protein involved in some cases of breast cancer, and typically 
indicates a poorer prognosis. Currently HER2 status is commonly diagnosed through 
immunohistochemical staining and fluorescence in-situ hybridization. As an alternative, Rauser 
and colleagues have worked to determine HER2 status using protein expression profiles obtained 
from MSI.95 Rather than directly detecting HER2, which can be difficult due to its high molecular 
weight, their analysis focused on finding surrogate protein markers. From 30 samples with known 
HER2 status, seven discriminating ions were detected. Using MS/MS, one of the relevant peaks 
was determined to be the cysteine-rich protein 1 (CRIP1), which is involved in cell proliferation 
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and has been previously implicated in breast cancer through gene expression studies.170,171 Future 
work will involve identifying the six other discriminating ions and may further our understanding 
of why HER2-positive cancer is more aggressive, as well as help to advance new therapies for this 
type of breast cancer. 
2.6.2 Neurodegenerative disease. There is currently no cure for Alzheimer’s disease (AD) 
or Parkinson’s disease (PD), two of the most common neurodegenerative disorders in the United 
States.172 Finding biomarkers for these illnesses may therefore aid research efforts towards 
improving current therapeutics. MSI has been used both to find new molecular signatures and to 
localize previously implicated compounds in these neurodegenerative disease tissues.173-180 
 AD is clinically characterized by the degradation of cognitive abilities such as language 
skills and memory formation.181 One pathological characteristic of AD appears to be an 
accumulation of plaques containing amyloid beta (Aβ) peptides in blood vessels. These peptides 
are fragments of the amyloid precursor protein, which has been shown to play many roles in neural 
function.182 Rohner and colleagues have imaged the brain of AD model mice and found several 
species of Aβ peptides that localize strongly in the hippocampus,177 the occipital lobe, and the 
parietal lobe, with two intense signals coming from Aβ-(1-40) and Aβ-(1-42). These results are 
generally consistent with a separate MSI study conducted by the Caprioli group,178 and with earlier 
non-imaging MS work.183  
 PD is characterized by the death of dopamine-producing cells in the substantia nigra, 
leading to an overall dopamine deficiency in the brain. PD largely disrupts motor function, but 
non-motor symptoms are also common.184 Non-imaging proteomic studies have been conducted 
across many PD models;180 MSI offers an alternative for identifying and localizing protein 
biomarkers in these models. One potential cause for neuron death in PD is oxidative stress 
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mediated through dopamine oxidative metabolites.185 Stauber and colleagues used MSI to study 
6-hydroxydopamine-treated rat PD models.180 Data from MSI and liquid chromatography (LC)-
MS showed differential expression of several proteins, many of which, such as peroxidoxin and 
ubiquitin, have previously been implicated in PD.186-188 The collapsin response mediator protein 2 
splice variant B (CRMP2B) was specifically mentioned as a potential new biomarker detected 
using MSI. Collapsin response mediator proteins have been correlated to dopamine-related cell 
death, and cell dopamine toxicity can be reduced by using antibodies raised against the active site 
of collpasin.185,189 The detection of CRMP2B as a PD biomarker therefore is not surprising. In 
addition to discovering molecular signatures, the study by Stauber et al. also showed that MSI can 
be successfully applied to analysis of formalin-fixed, paraffin-embedded samples that have been 
stored for many years.180 Thus researchers are not limited to fresh frozen tissues but may also draw 
specimens from existing biomedical tissue libraries, which already offer large collections of many 
sample types.  
 2.6.3 Arthritis. Arthritis is a chronic joint disorder caused by a variety of factors. There 
are many forms of arthritis, and a quick diagnosis is important for early treatment. Kriegsmann et 
al. conducted H&E stain-guided MS profiling experiments to investigate protein expression 
differences between osteoarthritis (OA) and rheumatoid arthritis (RA).120 OA is currently the most 
common form of arthritis in the United States.190 Its exact cause is unknown because there is not 
always a clear link between symptoms and structural changes in the joint.191 However, recent work 
had begun to elucidate protein markers between OA and healthy cartilage,124 and markers that 
distinguish aging and OA cartilage had also been investigated.192 RA, on the other hand, is an 
autoimmune disease in which the immune system attacks the joint to cause cartilage and bone 
destruction.193 In MSI and MS profiling experiments by Kriegsmann,120 many proteins were 
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putatively identified to be up-regulated in RA compared to OA. These included thymosin-β-4, 
various defensins, and members of the S100 protein family. Many of these proteins are involved 
in the immune system and have been previously implicated as possible RA biomarkers.193-195 
Being an inflammatory disease, the characterization of immune-related proteins as biomarkers for 
RA is not surprising.  
2.6.4 Drug Localization and Effects. MSI is a useful tool for drug discovery and for 
studying pharmacodynamics and pharmacokinetics.87,177,196-205 Unlike labeling techniques, MSI 
can differentiate between a parent compound and its metabolites in a straightforward manner, 
reducing potential noise that can interfere with determining the original drug-action site. However, 
because imaging small chemicals typically requires different sample preparation protocols than 
imaging larger molecules like proteins,202,206 determining the co-localization of drugs and proteins 
using MSI can be an issue. Furthermore MALDI, while well-suited for protein analysis and 
commonly used for MSI, produces interfering matrix signals at the lower mass range. Even with 
these challenges, the multiplexed and non-targeted nature of MSI makes it potentially useful for 
simultaneously probing drug localization and protein expression changes resulting from drug 
actions. 
 One approach used to determine drug localization is to image whole-body 
slices.125,177,199,207 Without showing concurrent protein localization, Takai and colleagues 
conducted a quantitative MSI study of the distribution of raclopride,207 a dopamine D2 receptor 
antagonist, in mouse whole-body slices. Raclopride was shown to localize initially in multiple 
organs, followed by a prolonged localization in the liver, consistent with positron emission 
tomography and autoradiography results. Although it is useful for determining the global 
distribution of drugs in an organism, whole-body MSI can be time consuming, especially for 
25 
 
 
obtaining images with high spatial resolutions.208 Alternatively, prior knowledge of potential drug-
action sites can be used to narrow down the region to be imaged.24,177,196,209,210 One study was 
conducted by Reyzer et al. to examine the effects of OSI-774,196 an anti-cancer drug used to treat 
HER2-expressing tumors. MS images showed drug localization in the tumor, along with a clear 
decrease in ubiquitin expression post-treatment (Figure 2.3). In contrast, little change was found 
with histone expression, suggesting that it is less related to OSI-774 action.  
 Drug efficacy can also be investigated by analyzing protein expression changes without 
imaging the drug itself. Cole and colleagues examined tumors treated with the vascular disrupting 
agent, combretastatin A-4-phosphate,211 which weakens the vascular integrity of tumors to cause 
hemorrhage and necrosis. A gradual increase of hemoglobin signal in the tumor was detected post-
treatment, suggesting the onset and progression of hemorrhage. PCA and discriminant analysis 
also showed groupings based on post-treatment time, indicating a regular alteration of tumor 
chemical conditions.  
 Beyond the intended drug actions, unintended side effects are important considerations 
when making therapeutic decisions. Meistermann et al. investigated the renal toxicity of 
gentamicin,212 an antibody commonly used to treat Gram-negative bacterial infections. Profiling 
and imaging experiments on treated rats showed several differentially expressed ions in the kidney 
cortex. One peak, highlighted by both profiling and imaging, was identified using top-down 
proteomics to be transthyretin, a marker used to monitor nutrition after kidney injuries.213 Another 
study was conducted by Ljungdahl et al. on L-DOPA-induced dyskinesia (LID).173 L-DOPA is a 
precursor of dopamine and is used to treat PD; however, prolonged treatments can lead to 
complications in motor functions (dyskinesia).214 The authors found that MALDI MSI and high 
performance liquid chromatography (HPLC)-FTICR analysis of high-LID-exhibiting rat models 
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revealed elevated levels of dynorphin B and alpha-neoendorphin in the lateral part of the substantia 
nigra. Immunohistochemical staining for dynorphin B showed consistent localization with MSI, 
providing a validation of the MS results.  
2.6.5 Aging. Aging, a particularly intriguing area of study because chemical changes are 
occurring globally in an organism, is related to the development of many diseases.192 Studying 
age-related chemical changes may lead to advances in preventive care. Because aging impacts the 
entire organism, the range of possible analytical targets extends well beyond major organs. Hair, 
for example, has been analyzed with MSI to investigate metabolite changes related to age, and 
may lead to future applications in cosmetics and forensics.215  
 The impact of aging on the eye has also been examined using MSI.216-218 The human lens 
is characterized by a gradient of cell age, with younger cells in the lens periphery (cortex) and 
older ones in the center (nucleus). Typically with aging, the crystallin proteins in lens cells are 
post-translationally modified to a greater extent, leading to water insolubility and aggregation. 
These changes lead to the lens growing opaque and may contribute to cataract development.219 
Grey and Schey studied the extent of protein modification in the human eye lens that takes place 
with aging.216 Their MSI analysis showed increased truncation of α-crystallin, a subunit of the α-
crystallin protein, with age. Protein fragments were localized predominantly in the lens nucleus, 
while more intact forms appeared in the cortex, in general agreement with the known distribution 
within cells as they age. This increase in protein modification with lens age was validated with gel 
electrophoresis and Western blot analysis.  
 In the same work, healthy and cataract lenses were found to have similar distributions of 
truncated α-crystallin, a result consistent with prior work showing that the amount of truncated 
crystallin proteins does not directly correlate to cataracts.218 Interestingly, the authors observed a 
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+34 Da mass shift to many α-crystallin fragment ions in the cataract samples. Using HPLC-
MS/MS this shift was identified to be a possible L52F mutation. Therefore a single amino acid 
modification, rather than truncations, may be a biomarker for cataracts. 
2.6.6 Reproductive Biology. We conclude our discussion of biomarkers in medicine with 
the field of reproductive biology. Burnum et al. investigated lipid and protein distributions in the 
uterus of mice during and right after embryo implantation.220,221 Because many pregnancies are 
lost before implantation, a deeper understanding of the chemical changes that take place at this 
stage is important.222,223 Implantation typically starts on day four of pregnancy. On day five, 
decidual cells begin to form zones near the embryo to provide nutritional support, with the primary 
decidual zone (PDZ) forming first, followed by the secondary decidual zone (SDZ). MS profiling 
and imaging experiments showed differential expression of several proteins near the implantation 
site (IS). Bottom-up proteomics was used to determine that ubiquitin was up-regulated at the IS. 
Expression of calcyclin and calgizzarin was higher in the PDZ compared to the SDZ, while 
transthyretin was more abundant in the SDZ.  
MSI studies have also been conducted in the male reproductive system.224-227 Of note, 
Lagarrigue and colleagues imaged the rat testis to investigate chemical distributions during 
spermatozoa development.227 Because spermatogenesis is characterized by a regular ordering of 
cells along the seminiferous tubules,228,229 protein localization in the tubules may be related to their 
involvement at different points of germ-cell maturation. MSI and top-down proteomic experiments 
identified and localized thymosin β-4, thymosin β-10, and a fragment of long-chain-fatty-acid-
CoA ligase, ACSL-(19-48). Thymosin β-4 and thymosin β-10, in particular, were noted to localize 
in the periphery of the seminiferous tubules and were validated using immunohistochemical 
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staining. Their distribution pattern coincided with the presence of spermatogonia and 
spermatocytes, precursors of spermatozoa. 
 
2.7 SUMMARY AND FUTURE DEVELOPMENTS 
Biological systems contain a wide array of chemicals that exhibit complex interactions and 
changes with organism states. MSI is a multiplex chemical imaging technique that can 
simultaneously localize many compounds to generate insight into their role in biological processes. 
MSI has been applied in many biological fields, including studies on the nervous systems, aging, 
cancer, and reproductive biology, among others.  
 Instrument and methodological advances are continually improving the figure of merit of 
MSI. These developments are increasing the amount of information that can be obtained from MSI 
and also making MSI easier to apply toward different scientific problems. Custom instruments 
with high lateral resolution and fast data acquisition speed are enabling chemical distributions to 
be revealed for a wide spatial range. New detectors like timepix and medipix are also enhancing 
sensitivity as well as improving the capability of microscope mode MSI.5 Along with instrument 
advances are methodological developments. Much work has focused on simplifying sample 
preparation to enable MSI to be more widely used outside of the research setting. Many ambient 
ionization methods are being investigated for this purpose because they can be conducted directly 
on samples with minimal preparation.54,165,167  The Caprioli group is also developing 
methodologies revolving around slides pre-coated with MALDI matrix,230,231 simplifying one of 
the most difficult and time-consuming steps of MALDI MSI sample preparation. 
Another development area is to couple multiple analytical platforms with MSI. Correlated 
imaging is useful for data validation and can add new information that may not be obtained via 
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MSI alone. Non-destructive methods, such as optical microscopy, are already commonly 
conducted before MS. However, challenges still exist on how to effectively align multiple images 
that may have different pixel sizes and dimensions.109 Different imaging methodologies also have 
different sample preparation requirements. Effective application of correlated imaging will 
therefore require expertise in multiple imaging modalities as well as an understanding of image 
correlation. While daunting, correlated imaging presents a platform for collaborations and holds 
promise for generating new insights into biological systems.  
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2.9 FIGURES 
 
Figure 2.1. Ion images of m/z 754.536 for HeLa cells with 7 μm (B and D) and 49 μm (A and 
C) pixel sizes. High mass accuracy (C and D) improves image contrast by reducing interference 
from neighboring peaks. Reprinted (adapted) with permission from Schober, Y., et al., Single Cell 
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Analytical Chemistry, 
2012. 84(15): p. 6293-6297. Copyright 2012 American Chemical Society. 
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Figure 2.2. Histology correlation between H&E staining and MSI.96 (A) m/z 8450, 
overexpressed in HCC. (B) m/z 3195, overexpressed in cirrhosis. (C) H&E stain, star indicates 
HCC. (D) Combined image of m/z 8450 and m/z 3195. Reprinted (adapted) with permission from 
Le Faouder, J. et al., Imaging mass spectrometry provides fingerprints for distinguishing 
hepatocellular carcinoma from cirrhosis. Journal of Proteome Research, 2011, 10, 3755-3765. 
Copyright 2012 American Chemical Society. 
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Figure 2.3. Localization and effect of OSI-774 on histone and ubiquitin expression.196 Left. 
Optical images of tissue sections. Middle. Histone distribution in control and treated tissues. Right. 
Ubiquitin distribution in control and treated tissues. Reprinted (adapted) with permission from 
Reyzer, M. L. et al., Early changes in protein expression detected by mass spectrometry predict 
tumor response to molecular therapeutics. Cancer Research, 2004, 64/24, 9093-9100. Copyright 
2004 AACR.  
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CHAPTER 3 
 
METHOD DEVELOPMENT FOR MALDI MASS SPECTROMETRY IMAGING OF 
NEUROPEPTIDES USING THE RAT SPINAL CORD 
 
3.1 NOTES AND ACKNOWLEDGMENTS 
This chapter presents a study that was done in collaboration with many members of the Sweedler 
group. I am grateful to Dr. Stanislav Rubakhin for isolating the rat spinal cord and for conducting 
the formalin test when studying the spinal cord response to a noxious stimulus. Dr. Eric Lanni was 
a close collaborator who helped with many aspects of sample preparation and general scientific 
discussions. Dr. Eric Monroe conducted the initial experiments that form the foundation of this 
study. He was a Sweedler group alum at the time and provided help over email and during 
conferences. Finally, Shuo Han, a visiting undergraduate scholar, optimized the final protocol and 
collected many data sets. This work was supported by the National Institute of Health through 
grant P30 DA018310. 
 
3.2 INTRODUCTION 
Mass spectrometry imaging (MSI) is an information-rich technique that combines chemical and 
spatial information. Unlike many other imaging methods, MSI is multiplex and does not require 
analyte pre-selection, allowing de novo analysis to be conducted on chemically complex systems. 
MSI is often conducted in the microbe mode, where a probe, such as a laser, ion beam, or 
electrospray, is rastered across the sample to collect position-resolved mass spectra. Intensity maps 
that show the chemical distribution of different compounds in the sample can then be generated. 
Because of its many analytical merits, including a wide mass range and good salt tolerance, 
matrix assisted laser desorption/ionization (MALDI) is one of the most commonly used ionization 
methods for biological applications of MSI. The quality of MALDI MS images depends on several 
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aspects of sample preparation.1-6 One of which is matrix application. It is important to apply matrix 
in a manner that effectively extracts analyte out of the sample while minimizing analyte lateral 
diffusion, which can blur the resulting ion images. Good extraction is achieved by sufficiently 
wetting the sample, but too much solvent will “flood” the sample to cause lateral diffusion. One 
common application method is to use a pneumatic spray to deposit small droplets of matrix 
solution onto the sample surface. Other “drier” methodologies, such as through sublimation or a 
sieve, have been developed as well.7-13 Because no solvent is used, these methods generally 
produce improved lateral resolution at the expense of lower signal. Recent developments have 
worked to achieve both good signal and lateral resolution by coupling dry application methods to 
a recrystallization step, which introduces solvent to the matrix layer in a controlled manner to 
improve analyte extraction.14-16 
In this study, a methodology is developed to image neuropeptide distribution in mammalian 
tissue using the rat spinal cord as the model system. The spinal cord has a well-defined morphology 
that makes it useful for method development. It is characterized by a “butterfly-shaped” gray 
matter consisting of cell bodies surrounded by white matter that is composed of nerve fibers.17 The 
Sweedler group has extensively imaged the spinal cord using a variety of MSI methods.18,19 For 
example. Monroe et al. imaged and identified several neuropeptides and small molecules using 
MALDI MSI and SIMS imaging,18 and Tucker et al. used the stretch sample approach to obtain 
high lateral resolution images of spinal cord lipids, peptides, and proteins.19 The goal of this project 
is to improve the robustness and reproducibility of using MALDI MSI to image spinal cord 
peptides. Previous work in the group relied on manually spraying MALDI matrix onto the sample 
to extract peptides into the matrix layer, which led to low reproducibility between replicates. The 
Yost group had utilized an inkjet printer to deposit MALDI matrix for spinal cord MSI, which 
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should improve reproducibility because the matrix is applied robotically.20 However, they 
primarily reported the detection of lipids, which are much more abundant than peptides in the 
spinal cord. To develop a robust protocol for peptide imaging, we started by comparing two 
MALDI MSI matrix application methods: pneumatic spray and sublimation. We then tested two 
matrix recrystallization methods for improving peptide extraction from the tissue section. The 
optimized protocol was used in a preliminary study on the spinal cord’s response toward a noxious 
stimulus, which was conducted via the formalin test by injecting the rat’s hindpaw with a formalin 
solution. A previous immunohistochemical staining study conducted by Zhang et al. shows 
increased concentration of several peptides in the dorsal horn of the spinal cord that is ipsilateral 
to the injection.21 With MSI, analysis will proceed in an untargeted manner and will 
simultaneously uncover concentration changes of multiple peptides. 
 
3.3 EXPERIMENTAL 
 3.3.1 Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
unless noted otherwise. 
3.3.2 Tissue Dissection. Protocols for animal care were approved by the UIUC Laboratory 
Animal Care Advisory Committee and were in compliance with federal guidelines for the humane 
care and treatment of animals. For MSI method development, adult Long-Evan rats were 
euthanized via decapitation using a guillotine. The spinal cord was quickly isolated, frozen in dry 
ice, and stored in -80 oC until further processing.  
The formalin test was conducted to study the rat spinal cord’s response to a noxious 
stimulus. The detail of the test is described in detail elsewhere.22 Briefly, the animal (n = 1) was 
decapitated 30 minutes after injecting the right hindpaw with a formalin solution. The spinal cord 
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was then immediately isolated and frozen in dry ice. A control animal (n = 1) was treated similarly 
but saline was injected. A length (~1 cm) of spinal cord immediately rostral to the dorsal root 
ganglion that connects the hindpaw nociceptors was removed for further processing (designated 
“proximal”). Another length of spinal cord a further 1-2 cm rostral was also isolated (designated 
“rostral”).  
3.3.3 Tissue Preparation. For MSI method development, the frozen spinal cord was 
mounted onto a sectioning stage using deionized water mixed with fast green as the embedding 
medium. Transverse sections (10 µm) were taken at -20 oC using a Leica CM3050 S cryostat 
(Leica Biosystems, Buffalo Grove, IL) and thaw mounted onto an indium tin oxide (ITO) coated 
slide. The sections were warmed to ambient conditions and rinsed for 30 s twice in 100% ethanol 
with gentle shaking. The sections were dried after each rinse under a N2 stream. 
For analyzing spinal cord response toward a noxious stimulus, one 12 µm thick spinal cord 
section from each of the “proximal” and “rostral” segments for the formalin-injected and control 
animals were taken at -20 oC and thaw mounted onto an ITO slide. The slide was then warmed to 
ambient condition under a stream of N2 and placed in a desiccator for an additional 10 min. The 
sections were rinsed for 15 s in ice-chilled 150 mM ammonium acetate buffer with pH adjusted to 
10 using 5 M ammonium hydroxide, then for 30 s in 70% ethanol, and finally another 30 s in 100% 
ethanol, drying after each rinse under N2 stream.  
3.3.4 Matrix Application. MSI method development compared pneumatic spray versus 
sublimation for matrix application. For application via pneumatic spray, a 20 mg/mL solution of 
the MALDI matrix α-cyano-4-hydroxycinnamic acid (CHCA) in 1:1 acetonitrile:water and 0.5% 
trifluoroacetic acid (TFA) was sprayed using an artist airbrush (Paasche Airbrush Company, 
Chicago, IL). The airbrush was propelled via N2 at 40 psi and held ~ 1 ft from the sample. The 
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matrix coating was applied gradually, allowing the sample to dry whenever droplets of matrix 
solution were visible on the sample. For application via sublimation, 300 mg of CHCA was placed 
inside a sublimation chamber (Ace Glass, Vineland, NJ). The chamber was heated using a heating 
mantle powered with a variable autotransformer set to 55% of 120 V (Staco Energy Products Co., 
Dayton, OH). A vacuum was created using an Edwards 30 E2M30 rotary pump (Edwards, 
Sanborn, NY). The setup ran for ~23 min to create a coating of ~0.2-0.3 mg/cm2 that was measured 
by weighing the sample slide before and after matrix application.  
For studying spinal cord response to the formalin test, MALDI matrix was deposited using 
sublimation. A custom heater was used to reduce matrix application time. The heater consisted of 
a coil of nichrome wire (NiCr60; 21 AWG; Mor Electrical Company/Heaters Plus, Comstock Park, 
MI) connected to a power supply (CS13005x5; Circuit Specialists, Mesa, Az) and was placed 
under the matrix reservoir inside the sublimation chamber. The coil was heated by supplying a 
current of 3.75 A for 4.5 min and was allowed to cool for 30 s before venting the sublimation 
chamber to atmospheric pressure. This generated a matrix coating of ~0.2-0.3 mg/cm2. Detail 
instructions on how to construct and operate this heater is included in Appendix A.  
3.3.5 Matrix Recrystallization. Two methods were used for matrix recrystallization. The 
first method was used on the pneumatically sprayed matrix layer. The sample slide was placed in 
a humidity controlled chamber that condenses small water droplets onto the sample.23 First, the 
chamber’s relative humidity was raised to over 90% by sending in N2 that bubbled through water. 
The sample was then cooled to 14 oC over 60 s and maintained for 90 s for water to condense onto 
the sample. The sample temperature was then raised to 28 oC over 60 s and maintained for 150 s, 
drying the sample to prevent large water droplets from forming. This cooling-warming cycle was 
repeated five times.  
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The second recrystallization method was used on matrix layers applied via sublimation and 
was described previously.15 A chamber was constructed by stacking a 95 mm and a 100 mm glass 
petri dishes facing each other. A discarded 89 spot AB MALDI plate was taped to the top (inside) 
of the chamber. The sample slide was taped to the AB plate facing down using conductive copper 
tapes. The entire assembly was placed inside a natural convection oven (ON-01E; Lab Companion, 
Seoul, Korea) set to 85 oC for 2 min. A filter paper soaked with 1 mL of 5% acetic acid was then 
placed at the bottom of the chamber before returning the set up to the oven for another ~4 min. 
The sample was removed immediately afterward and allowed to dry.  
3.3.6 Secondary Electron Microscopy (SEM). Secondary electron microscopy was used 
to characterize matrix layers generated using different application methods. Matrix coatings were 
sputter coated with 7 nm of gold palladium using a Desk II TSC sputter coater (Denton Vacuum, 
Moorestown, NJ). SEM images were acquired using a Philips XL30 ESEM-FEG SEM SEM (FEI 
Company, Hillsboro, OR). A beam voltage of 5-10 kV was used at a working distance of 10 mm.  
3.3.7 MALDI Mass Spectrometry Imaging. Mass spectrometry imaging was conducted 
using an UltrafleXtreme MALDI-TOF/TOF mass spectrometer with a frequency tripled Nd-YAG 
solid state Smart Beam II laser (Bruker Daltonics, Billerica, MA). Signal from 250 shots fired at 
1000 Hz were summed. The laser footprint was set to either the “small” or “minimum” setting at 
30 µm or 10 µm respectively, and the laser was rastered at 30-50 µm steps.  
3.3.8 Statistical Analysis. Linear discriminant analysis (LDA) was conducted on the MSI 
dataset of rats subjected to the formalin test (n = 1 for formalin-injected and control). Mass spectra 
from the dorsal horn were manually exported as delimited text files and imported into R for 
processing using the two R packages, “MALDIquant”, and “MALDIquantForeign”. Mass spectra 
49 
 
 
were baseline subtracted, smoothed, and peaks picked with a signal to noise cutoff of 10. LDA 
was conducted using the package “MASS” on masses m/z 1100 and above.  
 
3.4 RESULTS AND DISCUSSION 
3.4.1 Method Optimization for MALDI Mass Spectrometry Imaging of Peptides in 
the Rat Spinal Cord. Matrix application is one of the most important steps of sample preparation 
for MALDI MSI. Sufficiently wetting the sample with the MALDI matrix solution is necessary to 
extract analytes into the matrix layer for analysis, but applying too much solvent will lead to 
unwanted analyte lateral diffusion. Previous application of MALDI MSI on spinal cord imaging 
conducted by Monroe et al. produced good peptide signal and localization, but reproducibility was 
low because the matrix solution was sprayed manually onto the sample,18 hindering the application 
of the protocol toward other studies. We therefore aim to improve the robustness of spinal cord 
peptide MALDI MSI by reexamining the matrix application step.  
Two methods were investigated. The first method still relies on manually spraying the 
matrix solution, but analyte extraction is prolonged by placing the sample into a humidity chamber 
after matrix deposition. The humidity chamber systematically moistens the sample over multiple 
cycles of cooling and warming, allowing the sample to get wet but never flooded. Humidity 
chambers had been used successfully to improve MALDI MS analysis of salty biological 
samples,16 to facilitate enzyme reactions,19 and to improve peptide signal from Aplysia californica 
neuronal tissues.24 While it was successful in those studies, in this experiment peptide signal 
remained poor even after five cycles of solvent condensation. Typically, signal from only a few 
peptides were detected in the dorsal horn, and no peptide signals were present elsewhere in the 
spinal cord (Figure 3.1A). This discrepancy may be because previous experiments used 2,5-
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dihydroxybenzoic acid (DHB) as the MALDI matrix. DHB is more soluble than the MALDI 
matrix (CHCA) used in this study, allowing the solvent to more easily dissolve and access the 
tissue section underneath for analyte extraction. Efforts were made to change the matrix to DHB. 
However, DHB re-crystallizes poorly in the humidity chamber due to the coffee-ring effect.25 The 
quality of the recrystallized DHB layer may have been sufficient for profiling small ganglia tissue 
sections,16 or when the tissue is broken in to pieces that are separately located,24 but it is insufficient 
for imaging entire intact spinal cord tissue sections. We therefore continued to use CHCA as the 
MALDI matrix.   
Sublimation was examined as an alternative matrix application method.8,15 Even though 
sublimation does not utilize a solvent and therefore has poorer analyte extraction compared to 
spraying, it provides better control over how the matrix layer is deposited. Rather than having to 
subjectively judge the solvent and matrix amount on the sample, sublimation can produce 
consistent results using predefined settings. To improve analyte extraction with sublimation, we 
utilized a matrix recrystallization method developed by Yang et al.15 Unlike the humidity chamber 
used with the sprayed matrix layer, this method is conducted in only a few minutes and is done in 
a warmer and more acidic environment to improve matrix and analyte solubility. The combination 
of sublimation and this recrystallization method produces stronger and more consistent peptide 
signal compared to spraying and the humidity chamber (Figure 3.1B). Ion images also show 
improved contrast. For example, substance P (SP), typically the strongest detected peptide, shows 
distinct localization to the dorsal horn (Figure 3.2). Other peptides, such as Little SAAS, are also 
detected, but their signal is weaker compared to SP, and they do not show as distinct of a 
localization pattern. Based on peptide signal, the sublimation and recrystallization approach is 
superior to manual spraying. Because the sublimation process does not used any solvent, most 
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peptide extraction likely occurs during matrix recrystallization. We therefore believe this 
alternative recrystallization method will also produce strong peptide signal when coupled to 
manual spraying. However, because manual spraying is less reproducible and the generated matrix 
coating is less homogeneous than sublimation, this combination was not pursued.  
 To further study the differences between the two application methods, secondary electron 
microscopy (SEM) was used to image the matrix layers (Figure 3.3). Matrix crystals produced via 
sublimation are small, often less than 1 µm in length, and are homogeneous distributed before and 
after recrystallization (Figure 3.3A and B). There are faint residue marks on the recrystallized 
layer, possibly a result of differential solvent drying times. Crystal size is more varied for the 
sprayed matrix layer, especially before placing the sample in the humidity chamber.  At this point, 
islands composed of large crystals can be seen (Figure 3.3C). These islands are ~20 µm in length, 
making them potential artifacts when imaging at high spatial resolutions. Interestingly, matrix 
crystals become elongated after being placed in the humidity chamber, and crystal size and shape 
become more consistent (Figure 3.3D). The islands are also no longer present. We speculate that 
these changes are caused by homogeneous solvent deposition conditions in the humidity chamber 
smoothing out imperfections created by the manual spray. While this can be thought of as an 
improvement, the dramatic shift in the crystal size and position are risks for analyte delocalization.  
3.4.2 Analysis of Spinal Cord Response Toward a Noxious Stimulus. Once a matrix 
application protocol was established, we conducted a preliminary analysis of spinal cord response 
toward a noxious stimulus. To do so, the rat was subjected to the formalin test, in which the right 
hindpaw is injected with formalin before euthanasia. A separate control animal was made by 
injecting saline instead of formalin. For MSI sample preparation, matrix was applied via 
sublimation and recrystallization. A few changes were made to expedite sample preparation and 
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to further enhance peptide signal. First, a custom heater that is placed inside the sublimation 
chamber was made, which reduced sublimation time from 20 min to ~4 min (Appendix A). Second, 
to better remove inorganic salt, the samples were rinsed with ice-bath chilled 150 mM ammonium 
acetate buffer before additional alcohol washes.26-28 Removing inorganic salt improves matrix 
crystallization and minimizes alkali salt adducts in the mass spectrum, simplifying data 
interpretation and improving signal. To minimize peptide loss from this aqueous rinse, the buffer 
pH was increased to 10 because many previously detected spinal cord peptides have a basic pI.18,29 
Third, rather than rinsing the sample twice with 100% ethanol, the first alcohol rinse was changed 
to 70% ethanol to more gradually dehydrate the sample to reduce tissue damage. 
Sections were taken from two different regions of the spinal cord. One set of sections was 
taken immediately rostral to the dorsal root ganglion that connects the right hindpaw to the spinal 
cord (designated as “proximal”). Another set was taken a further 1-2 cm rostral from the first set 
(designated as “rostral”). Generally, ion images for the rostral sections show no difference in 
peptide signal intensity between the two dorsal horns of the spinal cord. In the proximal sections, 
however, SP is observed at slightly higher intensity on one side of the spinal cord for both formalin-
injected and control animals (Figure 3.4). SP is known to be involved in nociception and has been 
shown in immunohistochemical studies to increase in the spinal cord after the formalin test is 
administered.21 The observation of an increase in the control animal indicates that even a saline 
injection may be causing nociception-related chemical changes, so no injection may have to be 
pursued as an alternative control. Interestingly, while the SP increase in the formalin-injected 
animal is on the right, ipsilateral to the injection, in the control animal it is on the left, contralateral 
to the injection. An increase on the contralateral side of the injection is unexpected, as is an 
opposite response between formalin and saline injections. Care was taken to thaw-mount all 
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sections in a consistent orientation to remove uncertainties in sample positioning, but technical 
noise is still a possibility. The current data cannot resolve this ambiguity, which may be better 
accounted for by increasing the number of technical and biological replicates.   
Linear discriminant analysis (LDA) was conducted to further differentiate between each 
dorsal horn. Because peptide changes are stronger in the proximal sections, analysis was focused 
only on that region. Spectra from the dorsal horn were manually selected and processed in R. To 
focus on peptide signal, only peaks above m/z 1100 were used. A plot of LD 1 and LD 2 shows 
good separation of all dorsal horns on LD 1 (Figure 3.5), suggesting a chemical difference between 
all dorsal horns and corroborating what is observed in ion images. Spectra from the formalin-
injected rat are located more negatively on LD 1 than spectra from the control. LD 2 further 
separates the two dorsal horns of the formalin-injected rats, suggesting that formalin injection is 
causing a more pronounced chemical change than saline injection. The dorsal horn ipsilateral to 
the formalin injection is loaded more positively on LD 2 than the contralateral dorsal horn. 
Examination of peptides loaded negatively into LD 1 and positively into LD 2, which is the plot 
region most relevant to the dorsal horn ipsilateral to formalin injection, reveals several peptides 
associated with nociception, including SP, little SAAS, and neurokinin A. Multiple unidentified 
peptides are also detected, such as m/z 1140.4, 1263.2, 1802.1, and 1857.0. These results 
demonstrate the usefulness of MSI to detect changes over multiple chemical species as well as 
uncover potential new biomarkers.  
 
3.5 CONCLUSION 
MALDI MSI is a chemical imaging method that can reveal the localization of many compounds 
in an untargeted manner. MALDI matrix application is one of the most important steps in the 
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MALDI MSI process. In this study, a protocol is developed to image neuropeptides in mammalian 
tissues using the rat spinal cord as the model system, focusing in particular on matrix application. 
Compared to manual spraying, sublimation and recrystallization is used to generate MALDI matrix 
coatings with higher reproducibility and enhanced peptide signal. SEM analysis also shows smaller 
crystals that are homogeneously distributed over the sample surface. The method is used to analyze 
spinal cord response toward a noxious stimulus introduced via the formalin test. For spinal cord 
sections near the injection site, ion images show stronger SP signal in the dorsal horn ipsilateral to 
the injection. LDA reveals additional peptides, such as Little SAAS, that differentiate between the 
two dorsal horns. While many of these peptides have been identified, several of them are still 
unknown, illustrating the potential of MSI to generate new insights into the chemical and spatial 
relationship of biological systems. Current result for this preliminary experiment is obtained from 
only one biological replicate, which leads to difficulties in interpreting data trends, such as the 
opposite response between formalin-injected and control animals. Future work will involve 
increasing the number of technical and biological replicates to resolve these ambiguities and 
strengthen statistical power.  
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3.7 FIGURES  
 
Figure 3.1. Representative mass spectra from a rat spinal cord section obtained using two 
matrix application methods. (A) Matrix was applied via manual spraying and was placed in a 
humidity chamber.23 Few spinal cord peptides are detected, and signal is weak and inconsistent. 
(B) Matrix was applied via sublimation and was rapidly recrystallized.8,15 More peptides are 
detected compared to manually spraying the matrix solution. 
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Figure 3.2. Mass spectrum from the dorsal horn of the spinal cord and ion images of several 
putatively identified peptides. SP is consistently the strongest detected peptide and shows the 
clearest localization toward the dorsal horn. Only the dorsal half of the spinal cord is imaged to 
speed up analysis and reduce instrument wear. All images are normalized to the total ion count.  
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Figure 3.3. SEM images of matrix layers applied under different conditions. The top and 
bottom rows show two different magnifications of the same matrix layer. (A) Matrix layer 
applied via sublimation contains small crystals that are homogeneously distributed. (B) Sublimed 
matrix crystals become larger after recrystallization. Residue marks are observed on the matrix 
surface, possibly a result of differential drying time. (C) Matrix layer applied via manual spraying 
is uneven and contains islands of larger crystals. (D) After being placed in the humidity chamber, 
sprayed matrix crystals become enlongated, and islands of large crystals are no longer present.  
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Figure 3.4. Ion images of SP in rats subjected to the formalin test. No intensity difference is 
observed between dorsal horns in the rostral sections. In the proximal sections, a small intensity 
increase is observed on the right dorsal horn of the formalin-injected animal, ipsilateral to the 
injection. For the control animal, the left dorsal horn appears to be more intense, contralateral to 
the injection. Inset shows zoomed-in images of the dorsal horns for the proximal section. All 
images are normalized to the total ion count.  
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Figure 3.5. LDA plot for the dorsal horns of proximal sections. All dorsal horns are separated 
on LD1, with data points from the formalin-injected animal located more negatively than the 
control. Dorsal horns from the formalin-injected animals are further separated on LD2, suggesting 
larger chemical difference than the control.  
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CHAPTER 4 
 
INVESTIGATION OF MALDI DETECTION LIMIT WITH PICOLITER-DROPLET 
PRINTING 
 
4.1 NOTES AND ACKNOWLEDGMENTS 
This chapter presents work on elucidating the detection limit of MALDI MS. The experimental 
protocol used here builds on previous work done by Dr. Kevin R. Tucker, who is a Sweedler group 
alum at the time this work was conducted. He provided valuable advice on method optimization 
from his past experiences. Dr. Eric J. Lanni was helpful with discussions on mass spectrometer 
maintenance and tuning. This project was supported by the National Institute of Health through 
grant P30 DA018310. 
 
4.2 INTRODUCTION 
An analytical method with a low limit of detection (LOD) is necessary for effective trace 
measurement of small volume and concentration samples. Low LOD reduces sample consumption 
to allow repeated analysis with multiple analytical platforms, enhancing chemical coverage and 
validating results. More targeted sampling techniques can also be used to better isolate the feature 
of interest from complex systems. A number of analytical approaches have been developed for 
trace analysis. At its extreme, multiple spectroscopy techniques can be used to detect single 
molecules,1 and even electron orbitals can be visualized.2 For biological applications, trace 
analysis often involves the capability to characterize single cells, which is important for 
understanding biological processes because cells represent a fundamental biological unit. Many 
methods have been developed toward this end. Optical microscopy can routinely visualize single 
cells,3,4 and flow cytometry can quickly analyze and sort thousands of cells.5,6 Because their 
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analytical volumes scale favorably with single cell samples, microfluidic devices and capillary 
electrophoresis coupled to different detection platforms are also common.7-10  
Mass spectrometry (MS) has seen extensive utilization for trace biological analysis because 
of its many analytical figures of merit. MS is a sensitive analysis method, and unlike techniques 
that rely on molecular recognition, MS is untargeted and multiplex, capable of covering many 
biochemical classes at once. Soft ionization methods like electrospray ionization (ESI) and matrix 
assisted laser desorption / ionization (MALDI) have been used to analyze the metabolome, 
peptidome, and proteome of single cells.3 MALDI MS, in particular, is useful because of its high 
sensitivity and good salt tolerance. MALDI MS can be conducted on biological sample extracts as 
well as directly on tissue and cellular samples to minimize sample preparation and potential analyte 
loss. Although broadly used, the LOD of current MS techniques, including MALDI MS, cannot 
completely characterize the content of a single cell. Several studies have therefore investigated and 
improved the detection limit of different variants of laser desorption ionization MS. Of note, 
femtomoles of peptide standards have been detected using surface assisted laser desorption 
ionization (SALDI).11,12 Hundreds of attomoles of xenobiotic standards in rat serum can be 
detected using nanostructure initiated mass spectrometry (NIMS).13 For MALDI MS, roughly 0.4 
zmol of angiotensin I has been detected from a microfluidics platform,10 and detection of 50 zmol 
of substance P has been reported using a microspotting technique to prepare MALDI sample 
spots.14 
Even with advances of other variants, MALDI remains the most common method of laser 
desorption ionization. The goal of this project is to study the detection limit of MALDI MS under 
near optimal conditions. This understanding will aid in the utilization of MALDI toward trace 
analysis of small volume biological samples such as single cells and vesicles. To investigate 
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MALDI MS LOD, we use a chemical inkjet printer to deposit microscopic MALDI spots 
containing peptide standards. The printer produces picoliter-size droplets of peptide standards to 
create MALDI spots that are roughly 100 µm in diameter on indium tin oxide (ITO) coated slides. 
These spots are small enough for the MALDI laser to cover completely without having to be 
rastered. Previous work often estimated MALDI detection limit by coating a large area with a 
standard, then systematically probing the sample with smaller laser spots and calculating the 
amount that is sampled.10 Our approach better reproduces conditions associated with small volume 
samples (i.e. small sample spot), reduces uncertainty in the amount of material that is analyzed, 
and minimizes chances where signal arises from hot spots in the MALDI sample. 
Detection limit was investigated for two common MALDI MS sample preparation 
methods: dried droplet and thin film. The dried droplet method mixes the MALDI matrix solution 
with the sample solution before spot deposition, allowing the two to mix thoroughly for good 
analyte incorporation into matrix crystals. The thin film method deposits sample onto a film of 
matrix crystals, which can concentrate the sample closer to the spot surface to potentially enhance 
signal. Although analyzing standards differ from analyzing complex biological samples, this 
project establishes a baseline for MALDI MS LOD under near optimal conditions. 
 
4.3 EXPERIMENTAL 
 4.3.1 Chemicals. All chemicals were purchased from Sigma-Aldrich unless otherwise 
noted.  
 4.3.2 Peptide Standard Solutions For dried droplet sample preparation, angiotensin I and 
bradykinin were used to make two separate peptide standard solutions. Standards were dissolved 
in solutions of 30 mg/mL of the MALDI matrix 2,5-dihydroxybenzoic acid (DHB) in 50% 
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isopropanol. For angiotensin I, 500 µL of a 800 pg/mL solution was made. For bradykinin, 500 
µL of a 270 pg/mL solution was made. For thin film sample preparation, four standard solutions 
of angiotensin I were made in 50% isopropanol in increasing concentration (10, 20, 30, and 40 
ng/mL).  
 4.3.3 DHB Sublimation onto ITO Coated Slides. To produce a matrix film for thin film 
preparation, DHB was sublimed onto an ITO slide using a glass sublimation chamber (Ace Glass, 
Vineland, NJ). A custom heater built using nichrome wire was used to heat a matrix reservoir 
(Appendix A), and an ice bath was used to cool an ITO slide. Vacuum was pulled on the system 
using an Edwards 30 E2M30 rotary pump (Edwards, Sanborn, NY). The assembly ran for ~3.5 
min to generate a 0.2 mg/cm2 DHB coating.  
 4.3.4 Picoliter Droplet Printing. MALDI spots were deposited using a ChIP-1000 
chemical printer (Shimadzu; Tokyo, Japan). All printing was conducted with 100 pL droplets. 
Dried droplet spots were printed in six grids of 2 x 20 spots. The first grid contained six-droplet 
spots of DHB blanks (30 mg/mL in 50% isopropanol). The remaining five grids were printed using 
the same peptide standard solution but with increasing number of droplets per spot, starting with 
two droplets per spot in the first grid and ending with ten droplets per spot in the last grid. To 
minimize spot size, all spots were printed over multiple cycles by depositing two droplets at a time 
and pausing for ten seconds between cycles to allow spots to dry.  
Thin film spots were printed in four grids of 2 x 20 spots on an ITO slide coated with 
sublimed DHB. All spots were printed using two droplets. The standard solution was changed 
from the lowest concentration in the first grid to the highest concentration in the last grid. Separate 
2 x 2 grids of blanks (50% isopropanol; 2 droplets per spot) were printed before the first grid and 
in between switching peptide solutions. 
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4.3.5 MALDI MS Analysis. Mass spectrometry analysis was conducted using an 
UltrafleXtreme MALDI-TOF/TOF mass spectrometer with a frequency tripled Nd-YAG solid 
state Smart Beam II laser (Bruker Daltonics, Billerica, MA). For analyzing dried droplet spots, 
signal was summed from 1000 shots fired at 250 Hz. The laser footprint was set to “ultra”, which 
has a diameter of ~100 µm. The laser fluence was optimized using the first 20 spots in each grid 
of standards. Optimized conditions were then used on the remaining 20 spots for investigating 
MALDI detection limit. Thin film spots were analyzed via mass spectrometry imaging (MSI). 
Random spot raster was used with 180 µm raster step size. The laser footprint was set to “ultra”, 
and signal from 250 shots fired at 250 Hz were summed. Mass spectra were analyzed using 
flexAnalysis and mass spectrometry images were visualized using flexImaging.  
 
4.4 RESULTS AND DICUSSIONS 
An analysis method with low LOD is important for analyzing cellular samples that are limited in 
sample size and concentration. MALDI MS is a commonly used technique for biological analysis. 
To investigate the detection limit of MALDI MS, we created microscopic MALDI spots containing 
peptide standards by using a chemical inkjet printer that is capable of producing picoliter droplets. 
These spots can be ablated by the MALDI laser without rastering, allowing precise amounts of 
sample to be analyzed.  
 4.4.1 MALDI MS Detection Limit for Dried Droplet Preparations. MALDI samples 
are often prepared using the dried droplet method, which incorporates sample into the matrix by 
mixing the sample and matrix solutions together before spot deposition. In this experiment, rather 
than printing the standard and matrix solutions separately and having the two mix on the MALDI 
substrate, the peptide standard is premixed with 30 mg/mL of DHB prior to printing. Premixing 
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the sample with the matrix has several advantages. First, the printing process is simplified because 
a separate printing cycle for the MALDI matrix is not necessary. Second, optimal mixing between 
the matrix and the standard is ensured. Third, a consistent matrix to standard ratio can be 
maintained when more droplets are printed to increase the amount of standards in each spot. 
 The detection limit for two peptides, angiotensin I and bradykinin, were investigated with 
dried droplet MALDI spots. Each peptide was printed individually in separate five grids of 2 x 20 
spots. The first 20 spots in each grid were used to optimize MALDI laser fluence. The optimized 
conditions were then used on the last 20 spots to investigate LOD. The same standard solution 
concentration was used to print all spots, but more droplets were deposited per spot in each grid, 
starting with two droplets per spot in the first grid and ending with ten droplets per spot in the last 
grid. Each spot was built up gradually by printing two droplets at a time and allowing the spot to 
dry completely between each cycle. This printing method enables different amount of peptide to 
be deposited without having to change solutions, removing the potential for cross-contamination 
across peptide solutions. Optical micrographs of the dried droplet spots are shown in Figure 4.1. 
The spot size increases when more droplets are deposited, but still remains roughly the same size 
as the laser footprint. For angiotensin I, the printed amounts were 120 zmol, 250 zmol, 370 zmol, 
500 zmol, and 620 zmol. The lowest amount that produced a signal is 250 zmol, which was 
detected from all spots with an average signal to noise ratio (S/N) of 7±1 (Figure 4.2). No 
conclusive signal was observed from the next lowest printed amount at 120 zmol. Bradykinin was 
printed at 60 zmol, 120 zmol, 180 zmol, 240 zmol, and 300 zmol. The lowest consistently detected 
amount is 180 zmol, which was detected from all 20 spots with an average S/N of 3.5±0.5. Signal 
was observed from most spots that contain 120 zmol, but several spots are below S/N 3. This 
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pattern is attributed to typical experimental variations causing a distribution of signal to be 
observed. No signal was observed from 60 zmol spots.  
Calibration curves were made for both peptides in order to estimate the minimal amount of 
peptide necessary to produce a S/N of 3. Interestingly, the calibration curves appear more 
logarithmic than linear, with signal from the ten-droplet spots tailing off rather than increasing 
linearly (Figure 4.3). This pattern suggests that the ten-droplet spots are larger than the laser 
footprint, causing some deposited peptide to not be sampled. Separate linear calibration curves 
were therefore made by discarding the ten-droplet spots (Figure 4.4). However, discarding the ten-
droplet spot leads to the undesirable situation of having only three data points per calibration curve. 
Regardless, using the logarithmic model, the peptide amount necessary to produce a S/N of 3 is 
145 zmol for angiotensin I and 118 zmol for bradykinin. With the linear model that discards the 
ten-droplet spots, the amounts are 51 zmol for angiotensin I and 119 zmol for bradykinin. For 
angiotensin I, the detection limits predicted by both linear and logarithmic models are higher than 
the ~0.5 zmol previously reported when analyzing peptide standards in a microfluidic channel.10 
However, previous experiment relied on coating a long channel (5 mm) with a standard solution 
(1.3 pM). The detected amount is then estimated based on the area sampled by the MALDI laser, 
assuming a homogeneous peptide distribution within the channel and an accurate measurement of 
the laser spot size. The detected amount reported in this study reflects the total amount of standard 
in the sample and does not require additional assumptions or a specialized substrate. 
4.4.2 MALDI MS Detection Limit for Thin Film Preparations. MALDI MS detection 
limit for samples prepared using the thin film method was also investigated. By depositing sample 
onto a film of MALDI matrix, thin film preparation may improve signal by concentrating sample 
to the surface. For this experiment, sublimation was used to coat an ITO slide with 0.2 mg/cm2 of 
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DHB. Sublimation is useful for creating a homogeneous matrix coating and has been used in MSI 
for this purpose.15 For printing, peptide standards were not pre-mixed with DHB like for dried 
droplet preparations, and all spots were printed with only two droplets to avoid completely 
dissolving DHB at the print location, which can cause holes to form in the DHB layer due to the 
coffee-ring effect and how DHB naturally crystallizes.16 Four grids were printed using solutions 
with increasing concentration (10, 20, 30, and 40 ng/mL) to create spots containing 1.5 amol, 3.1 
amol, 4.6 amol, and 6.2 amol of angiotensin I. An optical micrograph of a thin film spot is shown 
in Figure 4.5. These spots are larger than spots printed on bare ITO slides, indicating that DHB is 
more hydrophilic than ITO. Although larger, spots printed on DHB are difficult to visualize using 
the sample camera equipped on the MALDI mass spectrometer. Therefore, MSI was conducted 
over each grid to ensure that all spots are adequately analyzed. Figure 4.6 shows the ion images 
for angiotensin I prepared in thin film spots. Angiotensin I was detected from all spots with an 
average S/N of 6±3 in the spots containing the lowest deposited amount (1.5 amol).  
Similar to the dried droplet experiment, calibration curves were made for angiotensin I 
prepared using the thin film method (Figure 4.7). Regions of interest corresponding to each spot 
were exported from the MSI data set, and the S/N of angiotensin I within each region was averaged. 
Unlike dried droplet preparations, signal does not tail off because all spots are the same size and 
are sampled consistently. Using this calibration curve, the minimum amount of angiotensin I 
needed to produce S/N of 3 is 0.5 amol. This amount is again higher than the 0.5 zmol that was 
reported from previous work.10 However, similar to studying LOD for dried droplet samples, the 
LOD determined in this experiment does not rely on coating a large area with standards and instead 
reflects the total amount that is deposited. 
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 4.4.3 Comparing Dried Droplet and Thin Film Sample Preparation. Table 4.1 
summarizes the MALDI LOD from the two sample preparation methods. A direct comparison 
between dried droplet and thin film would seem to indicate that dried droplet preparation produces 
a superior LOD. However, in this experiment the thin film spots are several times larger than dried 
droplet spots (Figure 4.1 and Figure 4.5). The diameter of a thin film spot in this experiment is 
~500 µm with an area of ~200,000 µm2. A dried droplet spot has a diameter of ~100 µm diameter 
and an area of ~8,000 µm2. Assuming a homogeneous peptide distribution, a dried droplet spot of 
angiotensin I at the predicted LOD (51 zmol using the linear model) has an analyte density of ~5 
molecules/µm2 for a 100 µm diameter spot. For the predicted thin film LOD (0.5 amol), the analyte 
density is ~2 molecules/µm2 for a ~500 µm spot, which suggests better performance compared to 
dried droplet preparations. To further emphasize improved LOD in thin film spots, a 100 µm 
diameter MALDI laser spot is 25 folds smaller in area than a 500 µm diameter sample spot. The 
MALDI laser therefore only sampled ~20 zmol out of the entire 0.5 amol sample spot. The 
estimated LODs from dried droplet and thin film spots suggest that under near optimal conditions 
MALDI MS should be able to detect sample spots with analyte densities of 10 molecules/µm2 or 
less regardless of either sample preparation method.  
 
4.5 CONCLUSION 
An analytical method with low detection limit is important for biological analysis because the 
sample is often complex and contains low amount of analyte. MALDI MS has been used 
extensively for biological analysis because of its low detection limit and because MS is an 
information-rich analytical method. In this study, the detection limit of MALDI MS is investigated 
using picoliter-droplet printing to deposit microscopic spots containing angiotensin I and 
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bradykinin. Two common MALDI MS sample preparation methods, dried droplet and thin film, 
were investigated. With the dried-droplet method, amounts as low as 250 zmol of angiotensin I 
and 180 zmol of bradykinin were detected. When angiotensin I was printed on sublimed DHB in 
a thin film preparation, the lowest detected amount was 1.5 amol. Although a direct comparison 
based on detected amounts suggests better LOD for dried droplet preparations, the thin film 
method is superior when comparison is made based on analyte density within sample spots, which 
indicate a detection limit of 5 molecules/µm2 for dried droplet spots and 2 molecules/µm2 for thin 
film spots. While both methods can potentially produce zeptomole detection limits, results from 
this experiment suggest that thin film preparation produces superior LOD.  
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4.7 FIGURES 
 
Figure 4.1. Optical micrographs of dried droplet spots printed with increasing number of 
droplets. Spot size increases with the number of droplets, but still remains similar to the laser 
footprint size. 
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Figure 4.2. Mass spectrum for 250 zmol of angiotensin I. Average S/N from 20 spots is 7±1. 
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Figure 4.3. Calibration curves for dried droplet preparations of angiotensin I and 
bradykinin. The curves appear more logarithmic than linear, with signal from the ten-droplet spots 
tailing off rather than increasing linearly, suggesting that the ten-droplet spots are larger than the 
MALDI laser diameter.   
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Figure 4.4. Calibration curves for dried droplet preparations of angiotensin I and bradykinin 
excluding ten-droplet spots. A more linear curve is generated than when excluding the ten-
droplet spots. 
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Figure 4.5. Optical micrograph of a thin film spot printed on sublimed DHB. The spot is 
produced by printing 200 pL of an angiotensin I standard solution. Printing on sublimed DHB 
produces spots that are bigger than printing on bare ITO slides. 
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Figure 4.6. Ion images and mass spectra for thin film spots of angiotensin I. All deposited 
amount can be detected down to 1.5 amol.  
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Figure 4.7. Calibration curves for thin film preparations of angiotensin I on DHB. 
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4.8 TABLES 
Table 4.1. Summary of MALDI LOD for angiotensin I and bradykinin prepared using the 
dried droplet or thin film method. Two predicted LODs, from the linear and logarithmic 
calibration curves, are presented for dried droplet spots.  
Dried Droplet Limit of Detection 
Peptide 
Detected by MALDI  
(zmol) 
Calibration Curve 
(Linear; zmol) 
Calibration Curve  
(Logarithmic; zmol) 
Angiotensin I 250 zmol 51 145 
Bradykinin 180 zmol 119 118 
    
Thin Film Limit of Detection 
Peptide 
Detected by MALDI  
(amol) 
Calibration Curve 
(Linear; amol)  
Angiotensin I 1.5 0.5  
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CHAPTER 5 
 
ENHANCING THE PERFORMANCE OF A DUAL MALDI/SIMS INSTRUMENT: 
SOFTWARE DEVELOPMENT FOR A C60-SIMS TRIPLE QUADRUPOLE TIME-OF-
FLIGHT MASS SPECTROMETER 
 
5.1 NOTES AND ACKNOWLEDGMENTS 
This project is part of a larger work that is done over many years in collaboration with multiple 
graduate students and post-doctoral scholars in the Sweedler group. Dr. Peter Nemes, who is now 
an assistant professor at George Washington University, played a key role in designing the dual 
MALDI/C60-SIMS instrument. Dr. Eric J. Lanni modified, optimized, and maintained the 
instrument for operation. Dr. Christopher Dailey was helpful for discussions regarding 
programming in LabVIEW. Support also came from the Winograd research group at Penn State 
University, which had previously undertaken a similar project. Funding was provided by the 
Department of Energy Office of Biological and Environmental Research through grant DE 
SC0006642 and the National Instrument of Health through grant P30 DA018310. 
 
5.2 INTRODUCTION 
Mass spectrometry imaging (MSI) is typically conducted in the microprobe mode, in which a laser, 
spray, or ion beam is rastered across the sample in a grid while mass spectra are collected. Each 
probe type has its associated pros and cons and are suitable for different applications. One of the 
most commonly used probes is a laser used for conducting matrix assisted laser desorption / 
ionization (MALDI). MALDI has a large mass range, high sensitivity, and good salt tolerance, 
making it useful for many biological applications where the sample amount may be limited. 
MALDI MSI has been applied extensively to image many classes of biochemical, including lipid, 
peptide, and protein, among others.1-6 However, MALDI requires a matrix compound to be applied 
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onto the sample prior to analysis, complicating sample preparation and in some cases limiting its 
application. Matrix crystals can also restrict imaging resolution. Depending on a combination of 
matrix crystal size, analyte abundance, and the laser footprint, the spatial resolution of MALDI 
MSI is currently limited to tens of micrometers in most cases.   
 One alternative to MALDI is to use an ion beam as the probe for conducting secondary ion 
mass spectrometry (SIMS). Several atomic and small cluster ion beams, such as Au+, Bi+, Bi3
+, 
and O-, have been used for SIMS applications.7-16 In many ways, SIMS is a complementary 
technique to MALDI MS. SIMS in general does not require a matrix, and the lateral resolution of 
SIMS imaging can reach sub-micrometer level in state of the art instrumentations.8,15,17 The ion 
beam can also be used to etch materials to enable depth profiling experiments.18 While the lateral 
resolution is improved, SIMS is a harsher and less efficient form of ionization than MALDI, 
limiting its utility when analyzing larger chemical species because the molecular ion often cannot 
be observed. Bombardment with an ion beam also damages the sample by fragmenting compounds 
that are close to the surface, further reducing the amount of molecular ions that can be detected. 
To overcome some of these drawbacks, developments in large cluster ion sources, such as C60
+ 
and large argon clusters, are improving the SIMS mass range by demonstrating softer ionization 
and reduced surface damage.7,10,11,18-21 There are many examples of C60
+ and other cluster ions 
being used in biological SIMS applications,19,20,22-24 demonstrating the growing versatility of SIMS 
imaging for analyzing a wide array of materials. 
 Based on previous work done by the Winograd group,20,21 this project is part of a larger 
work in the Sweedler group on modifying a MALDI Q-TOF mass spectrometer to have dual 
MALDI and SIMS capability. The primary physical modification involves attaching a C60
+ ion 
gun to the original MALDI instrument. Along with the ion gun, another quadrupole ion guide is 
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installed between the sample plate and the first quadrupole (Q0), which is necessary to create space 
for accommodating the ion gun. The hybrid MALDI/C60-SIMS instrument offers multiple 
ionization modalities, high mass resolution, and tandem MS for MALDI and SIMS. The new 
instrument performance as a result of hardware modifications have been published previously.24 
Here, we present additional instrument enhancements by creating two pieces of software to enable 
automatic control of parts of the instrument. The two programs are not required for typical 
instrument operation and are not included in the prior publication, but can be used to further 
improve performance. One program is used to set and scan through a range of voltages on the 
added ion guide. A single, constant voltage can be set for continuous operation, or many voltages 
can be scanned through for optimizing ion transmission. A second program is made to deflect the 
C60
+ beam in a raster pattern. It moves the primary ion beam in step sizes smaller than what is 
capable with the current instrument sample stage. Its capability is demonstrated here in a depth 
profiling experiment, but may also be developed further to enable high lateral resolution imaging. 
 
5.3 EXPERIMENTAL 
 5.3.1 Hybrid MALDI/C60-SIMS Mass Spectrometer. A QSTAR XL MALDI Q-TOF 
mass spectrometer (AB SCIEX; Framingham, MA) was modified by adding a 20 kV C60
+ ion gun 
(Ionoptika; Manchester, UK). To accommodate the ion gun, a custom rectilinear quadrupole ion 
guide was installed between the sample plate and Q0 (Figure 5.1A). A 2.8 MHz radio frequency 
(RF) power supply was used to supply the rectilinear quadrupole RF (Ardara Technologies; 
Ardara, PA), and three separate channels of an eight channel DC power supply (Ardara 
Technologies; Ardara, PA) was used to power the quadrupole entrance lens, exit lens, and DC 
offset.  
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To raster the C60
+
 ion beam, the installed ion gun is equipped with four deflector plates to 
move the beam in the x-y plane (Figure 5.1B). These deflector plates were connected to another 
four separate channels of the same eight channel DC power supply as the rectilinear quadrupole. 
Beam deflection was achieved by setting two opposite facing plates to a voltage that is opposite in 
sign but equal in magnitude. A setting of ±0.2 V on opposite-facing plates was observed to deflect 
the beam by ~1 µm. 
5.3.2 External Control Setup. External control of the RF and DC power supplies was 
achieved via two data acquisition (DAQ) modules. The cDAQ-9264 (National Instruments; 
Austin, TX) has 16 analog voltage outputs ranging from -10 to 10 V and was used to dictate power 
supply outputs. The USB-6008 DAQ (National Instruments; Austin, TX) was used to take 
feedback measurements on the power supply output. Software controls were built using LabVIEW 
2011 (National Instruments; Austin, TX). Two virtual instruments were developed to control the 
rectilinear quadrupole and to raster the C60
+
 ion beam. 
5.3.3 Demonstrating C60+ Etching on a Metal Substrate. A piece of indium was 
manually flattened and sputter-coated with ~3 nm of gold palladium using a Desk II TSC sputter 
coater (Denton Vacuum; Moorestown, NJ).  A 1 x 1 mm area of the material was first imaged via 
C60
+ SIMS using a 20 µm probe spot size and a 30 µm raster distance. The incident current on the 
sample was 1 nA, and signal was accumulated for 1 s per pixel. A 100 x 100 µm area within the 
imaged region was then etched by moving the C60
+ beam in 5 µm steps in the x direction and 10 
µm steps in the y direction. All C60
+ beam parameters were kept the same during etching and 
imaging. The C60
+ beam was stationary at each raster spot for 10 s during etching. After etching, 
the same 1 x 1 mm area imaged before etching was imaged again. MSI data sets were imported 
into BioMap (Novartis, Switzerland) for visualization.   
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5.4 RESULTS AND DISCUSSION 
A variety of probes can be used to conduct MSI. A hybrid instrument with multiple ionization 
methods can take advantage of the potential complementary nature between probe types. The 
Sweedler group has developed such a hybrid MALDI/C60-SIMS mass spectrometer by installing 
a C60-SIMS ion gun on a MALDI mass spectrometer.
24 To further enhance instrument operation, 
two programs are developed to control an RF power supply and a DC power supply, allowing a 
quadrupole ion guide to be controlled externally via software, and the C60
+ primary ion beam to be 
rastered. 
 5.4.1 Software Control for the Rectilinear Quadrupole Ion Guide. Software control for 
the rectilinear quadrupole is built as a virtual instrument using LabVIEW 2011. The virtual 
instrument is structured as a state machine with 5 states (Figure 5.2A), with each state having a 
corresponding tab on the front panel (Figure 5.2B). The default state (state 0) is used to set constant 
voltage outputs and to set parameters for scanning through voltages for each part of the quadrupole 
(entrance lens, exit lens, quadrupole RF, and quadrupole DC offset). The scanning capability is 
added to facilitate optimizing ion transmission. The virtual instrument starts in state 0 and can 
remain in this state indefinitely. States 1 through 4 are used to scan through voltages as defined in 
state 0. Multiple voltages can be automatically scanned through while monitoring the total ion 
count to determine the settings that produce the strongest signal. When a voltage scan is initiated, 
the state machine switches to one of states 1 through 4. After the scan, the state machine 
automatically returns to state 0 until another scan is initiated.   
 Software commands are sent to the quadrupole power supplies using two DAQs. The first 
DAQ (cDAQ-9264; designated DAQ 1) provides a voltage output between -10 and 10 V and 
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dictates the power supply output. The second DAQ (USB-6008; designated DAQ 2) takes 
feedback measurements from each power supply. These feedback measurements reflect the actual 
power supply setting and are used to correct for discrepancies between the software setting and the 
actual power supply output. Without this “self-correcting” feature, the power supply output was 
found to be unstable (Figure 5.3). Self-correction is conducted by first using an empirically 
determined conversion factor to change the feedback voltage to the actual power supply setting. 
The converted reading is then compared to the software setting, and DAQ 1 is adjusted to bring 
the hardware setting in line with the software. While small differences between the software and 
hardware setting is still observed, the assembled system can hold a stable voltage over many hours 
of constant use. Further comments on the conversion factor and the block diagram for the virtual 
instrument are provided in Appendix B.   
 5.4.2 Rastering the C60+ Primary Ion Beam for Depth Profiling. The added C60
+ ion gun 
is equipped with four deflector plates that can move the C60
+ beam in the x-y plane. A virtual 
instrument is developed to control the voltages on these plates in order to raster the C60
+ beam in a 
serpentine manner. Similar to controlling the quadrupole ion guide, DAQ 1 is used to control the 
power supply that set the deflector voltages, and the virtual instrument is also structured as a state 
machine. The default state (state 0) is used to set parameters for rastering, which includes step 
sizes in x and y as well as how long the beam is stationary at each raster location. During the raster, 
the software cycles between four states (states 1 – 4), alternating between scanning the beam in 
the x direction and making a step in the y direction. At the destination, the software automatically 
returns to state 0. A separate state (state 5) can then be manually entered to remove all deflections. 
In-depth comments on the block diagram for this virtual instrument are provided in Appendix C. 
With this design, continuous beam movement is approximated by designating step sizes that are 
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smaller than the beam diameter.25 This oversampling approach has also been utilized in the past 
for improving MALDI MSI lateral resolution.26  
 To test the virtual instrument for depth profiling, a substrate consisting of indium coated 
with 3 nm of gold palladium is analyzed (Figure 5.4A). A 1 x 1 mm area of the substrate is first 
imaged via C60
+ SIMS. A 100 x 100 µm region within that area is then etched with C60
+ 
bombardment before the same 1 x 1 mm area is imaged again. Visualization of indium ion at m/z 
114 shows stronger overall signal in the post-etching image, indicating that taking the first image 
has removed enough gold palladium to begin revealing the underlying indium layer. However, the 
strongest signals are in the etched area (Figure 5.4B), showing successful implementation of 
precise beam control for etching surfaces, enabling depth profiling to be conducted. 
 
5.5 CONCLUSION 
Many types of probes can be used to conduct MSI. A mass spectrometer with multiple probe types 
can use these probes in a complementary manner to generate new data on chemical distribution. 
In this project, two custom programs are developed to improve the performance of a hybrid 
MALDI/C60-SIMS mass spectrometer.
24 These two programs are not required for typical 
instrument operation, but can further enhance instrument performance in addition to hardware 
modifications. One program enables external and automatic control of a rectilinear quadrupole. 
The program allows one voltage to be set or a range of voltages to be cycled, which can facilitate 
optimizing ion transmission. A self-correcting feature that uses feedbacks from the power supply 
to correct for discrepancies between hardware and software settings is used to achieve stable 
voltage settings over several hours. Another program is developed to raster the C60
+ primary ion 
beam to enable depth profiling experiments. Etching capability is tested on a piece of indium 
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coated with gold palladium and shows precise control of the beam position over a 100 x 100 µm 
area.  
 Continuing software developments will further enhance the capability of the hybrid mass 
spectrometer. Of the two already developed programs, external control of quadrupole voltages can 
be modified to automatically jump between voltages to optimize ion transmission of distinct mass 
ranges, allowing improved mass selection to reduce interfering signals. The program for rastering 
the C60
+ primary ion beam holds promise for improving the spatial resolution of the mass 
spectrometer. The sample stage of the instrument currently limits imaging lateral resolution to ~10 
µm, but the focus limit of the C60
+
 ion gun is around 1 µm. By precisely controlling the beam 
position, it will be possible to increase the instrument lateral resolution to take advantage of the 
smaller beam footprint. These developments will further enhance the capability of the hybrid 
instrument to better analyze multiple chemical species over a wide spatial range.   
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5.7 FIGURES 
 
Figure 5.1. Schematic of the hybrid MALDI/C60-SIMS mass spectrometer and the attached 
C60+ ion gun. (A) Schematic of the hybrid instrument with the C60
+ ion gun attached. The 
rectilinear quadrupole ion guide, the entrance lens, and the exit lens are labeled.24 (B) Technical 
drawing of the C60
+ ion gun with deflector plates (boxed red) that enable the primary ion beam to 
be moved.  
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Figure 5.2. Overview of the virtual instrument for setting voltages on the rectilinear 
quadrupole. (A) The software is a state machine with five states. State 0 is the default state for 
setting a single voltage. States 1 through 4 are for scanning through a range of voltages for the RF, 
the entrance lens, the quadrupole DC offset, and the exit lens. (B) Front panel GUI for the virtual 
instrument. Tab 1 (top) is for setting a single voltage. Tabs 2 (bottom) through 5 are for scanning 
through voltages.  
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Figure 5.3. Power supply stability with and without self-correction over a 3 hour period for 
a constant software setting of 50 V. Voltages fluctuate by ~0.5 V without self-correction but 
remain constant once feedback measurements are used to correct for discrepancies between 
hardware and software settings.  
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Figure 5.4. The virtual instrument for deflecting the C60+ beam is used in a depth profiling 
experiment. (A) A flattened piece of indium covered with 3 nm of gold palladium was used to 
test the instrument’s depth profiling capability. (B) Indium signal in a 1 x 1 mm area before and 
after a 100 x 100 µm region was etched via C60
+
 bombardment. Indium signal is stronger overall 
post-etching, but it is strongest in the etched area (boxed white), showing precise control of the 
C60
+ beam position over that area. 
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CHAPTER 6 
 
MASS SPECTROMETRY IMAGING AND IDENTIFICATION OF PEPTIDES 
ASSOCIATED WITH CEPHALIC GANGLIA REGENERATION IN SCHMIDTEA 
MEDITERRANEA 
 
6.1 NOTES AND ACKNOWLEDGMENTS 
This chapter presents work done in collaboration with the Phil Newmark lab in the Department of 
Cell and Developmental Biology. Members of the Newmark lab, Dr. James Collins, who is now 
an assistant professor at the University of Texas Southwestern, Dr. Rachel Roberts-Galbraith, and 
Dr. David Forsthoefel were helpful for providing samples, microscopy training, and general 
scientific discussions. Dr. Elena Romanova, Dr. Stanislav Rubakhin, Ning Yang, and Sarah Dowd 
contributed to many aspects of this project, such as cryosectioning, peptide extraction, sample 
storage, HPLC-ESI-MS/MS analysis, and database searching. Funding for this project was provided 
by NIH through grant P30DA018310, and from the Phil Newmark lab through the Howard Hughes Medical 
Institute. 
 
6.2 INTRODUCTION 
The freshwater planarian Schmidtea mediterranea is a useful model organism for studying tissue 
regeneration. Like many types of planarians, S. mediterranea has a distribution of stem cells called 
neoblasts throughout their body, which enables them to recover missing body parts and regenerate 
into complete animals after almost any physical injury.1-3 S. mediterranea regeneration is complete 
and robust, as all organs and body polarity can be recreated and maintained,1,4-9 and damages 
associated with aging can also be repaired.8 Further, manipulating gene expression has been shown 
to enhance regeneration in certain types of planarians that have limited regeneration capability,4 
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and transplanting neoblasts can restore regeneration to planarians that have lost their endogenous 
neoblast population from radiation injury.10  
Studying planarian regeneration has interesting implications for biomedical research. 
Many diseases, in particular neurodegenerative diseases such as Alzheimer’s and Parkinson’s, do 
not have a cure.11 Beyond their regenerative capability, many genes in the planarian CNS are also 
conserved in humans,12 and some structures and functions, such as the use of signaling molecules 
like neuropeptides, are also similar.13-15 Analyzing planarian regeneration could therefore 
contribute to understanding human biology. S. mediterranea has been studied via multiple omics 
methodologies, and new microscopy protocols and biochemical assays specific to S. mediterranea 
have been developed.16,17 From these efforts, the S. mediterranea genome is sequenced,18 and its 
CNS in intact and regenerating states have been investigated using many techniques covering the 
genome, transcriptome, and proteome.1,4,6,7,10,12,19-28 The CNS of S. mediterranea is characterized 
by a bi-lobe anterior cephalic ganglia with two ventral nerve cords (VNC) that run along either 
side of the animal. When the cephalic ganglia is amputated, S. mediterranea will regenerate the 
ganglia while at the same time the remaining VNC will grow into the blastema to connect with the 
new ganglia,20 a process that occurs over a one to two week period.6,7,20,26,28 To direct proper CNS 
regeneration, the gene, nou-darake, is involved in restricting brain tissue regeneration to only the 
anterior end of the animal.26 Other biomolecules, such as small molecule neurotransmitters, 
neuropeptides, and anti-microbial peptides, have also been implicated.24,28-31 
Mass spectrometry (MS) is an untargeted and multiplex analytical method that allows de 
novo analysis of complex systems.32,33 MS can be conducted in an imaging modality (MSI) to 
complement mass spectrometry data with spatial information.32,34,35 Because of its large mass 
range and general tolerance to salt, MALDI is particularly well-suited for imaging biological 
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samples.33 In MALDI MSI, the MALDI laser is rastered across the sample to achieve position-
resolved MS.32,34,35 MALDI MSI has been previously utilized to study peptide and lipid changes 
associated with nervous system regeneration in medicinal leech.36,37 Changes in lipid and peptide 
profiles associated with regeneration were detected, and an interaction between the nerve cord and 
the surrounding blood sinus during regeneration was observed. Results from these studies 
demonstrate the feasibility of using MSI to study chemical changes associated with tissue 
regeneration on a spatial and temporal level.  
We have previously conducted an MS investigation of the prohormone complement of 
sexual and asexual strands of S. mediterranea.23 To build on that study, here we utilize MALDI 
MSI to visualize peptide distribution changes associated with cephalic ganglia regeneration. 
Chemical and structural trends are revealed by examining ion images, fluorescent images, and by 
conducting principal component analysis (PCA). Compounds that differ significantly during 
regeneration were determined and identified via peptidomics analysis of regenerating S. 
mediterranea. 
 
6.3 EXPERIMENTAL 
6.3.1 Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA) unless noted otherwise. 
6.3.2 Animal Culture and Cephalic Ganglia Amputation. Mature, asexual strains of S. 
mediterranea at ~1 cm in length were maintained in 20 oC 1.0X Montjuїc salt solution and starved 
for at least 1 week prior to analysis to avoid non-specific background signals from gut contents.23 
To initiate cephalic ganglia regeneration, planarians were amputated at the midpoint between the 
cephalic ganglia and the pharynx. The posterior portions of amputated planarians were then 
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returned to 1.0X Montjuїc salt solution to regenerate. For peptidomics analysis, 80 planarians were 
amputated, and the anterior and posterior portions were placed in separate containers of 1.0X 
Montjuїc salt solution. 
6.3.3 Tissue Embedding and Cryosectioning. Intact, 3, 6, and 12-day regenerated 
planarians were placed on a Parafilm M substrate and immobilized on ice. Once immobile, each 
animal was embedded in 10% gelatin and frozen in dry ice chilled ethanol. Longitudinal sequential 
tissue sections (20 µm) were taken at -16 oC using a Leica CM 3050 S cryostat (Leica 
Microsystems, Bannockburn, IL) and were individually thaw mounted onto separate (100) silicon 
wafers. For intact and 12-day regenerated planarians, all sections were examined under a dissection 
scope, and those with observed cephalic ganglia were further processed. For 3-day and 6-day 
regenerated planarians, the last four consecutive sections were used. 
6.3.4 Tissue Rinsing and Supercritical Drying. Sections to be imaged were rinsed for 10 
s in ice chilled 150 mM ammonium acetate buffer followed immediately by 30 s in 100% 
isopropanol. The rinsed sections were dried using an Autosamdri-931 supercritical dryer with 
isopropanol as the intermediate fluid and liquid carbon dioxide as the supercritical fluid (Tousimis, 
Rockville, MD). Supercritical drying was conducted by first submerging tissue sections in 10 mL 
of isopropanol in the supercritical drying chamber. The chamber was then slow filled with liquid 
carbon dioxide for 90 s before being fully filled at the regular flow rate for 30 s. Isopropanol was 
purged from the sample chamber with liquid carbon dioxide for 4 min. After purging, the chamber 
pressure and temperature were raised and held at above 1200 psi and 31 oC for 4 min. The chamber 
was returned to ambient condition by slowly bleeding pressure to 550 psi before venting fully.  
6.3.5 MALDI Matrix Application. The MALDI matrix α-cyano-4-hydroxycinnamic acid 
(CHCA) was sublimed onto the sample in a glass sublimation chamber (Ace Glass; Vineland, NJ). 
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The cold finger was chilled using an ice bath, and heating was conducted using a heating mantle 
powered with a variable autotransformer set to 55% of 120 V (Staco; Dayton, OH). A vacuum was 
created in the chamber using an Edwards 30 E2M30 rotary pump (Edwards ROC; Sanborn, NY). 
The setup ran for 18.5 min to create a coating of ~0.2 mg/cm2. To improve peptide extraction into 
the matrix, the matrix-coated samples were placed in a humid chamber with 1 mL of 5% acetic 
acid for 225 s at 85 oC following a previously described approach.38   
 6.3.6 MALDI Mass Spectrometry Imaging. Our protocols for MSI are similar to prior 
reports.39 Briefly, silicon wafers containing prepared samples were taped to a custom MALDI 
target using double-sided conductive copper tapes (Electrical Tape, 3M, St. Paul, MN). The 
custom MALDI target contains a shallow cutout, which allowed the wafer surface to be positioned 
at the same level as the target surface. MSI was conducted in positive mode using an 
UltrafleXtreme MALDI-TOF/TOF mass spectrometer (Bruker Daltonics; Billerica, MA) equipped 
with a Smartbeam II frequency tripled Nd:YAG solid state laser. The laser footprint was set to 
“small” at ~30 µm diameter. Mass spectra were acquired at 50 µm intervals, and signals from 250 
shots fired at 1000 Hz were summed. Images and mass spectra were processed using the 
flexAnalysis and flexImaging software packages (Bruker Daltonics; Billerica, MA). All ion 
images were normalized to the total ion count. 
 6.3.7 Nuclear Staining and Fluorescence Imaging. Thaw mounted planarian sections 
were submerged in 1 µg/mL of 4',6-diamidino-2-phenylindole (DAPI) for several minutes and 
fluorescently imaged using a Lumar.V12 stereoscope (Carl Zeiss, Oberkochen, Germany).  
 6.3.8 Principal Component Analysis and Determining Regeneration Markers. Given 
the information-rich nature of MSI data sets, statistical approaches such as PCA can be helpful in 
determining important markers.40 To conduct statistical analysis, regions of interest were first 
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selected based on signals related to the cephalic ganglia. If those signals were not present, then the 
region corresponding to the blastema were chosen. Relevant MALDI mass spectra were converted 
from the Container format to the XMass format and imported into the ClinProTools 2.2 software 
package (Bruker Daltonics; Billerica, MA) as separate groups based on biological replicates. 
Spectra were smoothed using the Savitzky Golay algorithm for 3 cycles with a m/z width of 0.1. 
Baseline subtraction was conducted using the Top Hat algorithm with 10% baseline width. Peak 
picking was conducted from the average spectrum of each spectra group with a signal to noise 
cutoff of 5. For each group, the similarity selection option was used to select the spectrum closest 
to the group average for PCA. To determine the ions that vary significantly between regeneration 
time points, the Anderson-Darling test (PAD) was first conducted on each peak to test if they are 
normally distributed. Signals that follow a normal distribution (PPAD ≥ 0.05) were tested for 
significance via ANOVA. Signals that are not normally distributed (PPAD ≤ 0.05) were tested for 
significance via the Kruskal-Wallis analysis of variance. 
6.3.9 Peptide Extraction from Regenerating Planarians. Anterior and posterior portions 
of 6-day regenerated planarians (n = 80) were combined and homogenized in 1 mL of acidified 
acetone (60:4:1 acetone:water:HCl) with pH adjusted to 4 using 5 M ammonium hydroxide.23 The 
homogenate was centrifuged (Eppendorf; Hauppauge, NY) at ~21000 g at 4 oC for 15 min. The 
supernatant was separated from the tissue pellet, dried, and reconstituted in 60 µL of 0.1% formic 
acid (FA). An oily phase and some undissolved residue were observed after reconstituting in 0.1% 
FA. These two portions were separately isolated from the primary extract. The tissue pellet, peptide 
extract, oily phase, and undissolved residue were frozen in -80 oC until further processing. 
6.3.10 HPLC Fractionation of Tissue Extract. Peptide extract (excluding the oily phase 
and the undissolved residue) was fractionated using a Breeze 2 HPLC system (Waters; Milford, 
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MA) with a reverse-phase column (Atlantis T3, C18, 2.1-mm inner diameter (i.d.) x 150-mm, 5-
µm particle size, 100 Å pore size; Waters). A portion (50 µL) of the extract was fractionated at a 
200 µL/min flow rate. The following gradients were used over a 60 min run by mixing solvent A 
(water + 1% acetonitrile (ACN) + 0.1% FA)  and B (ACN + 0.1% FA): 3% B at 0 – 5 min, 3 - 15% 
B at 5 – 10 min, 15 - 50% B at 10 - 45 min, 50 - 80% B at 45 - 48 min, 80% B at 48 - 53 min, 80 
– 3% B at 53 – 55 min, and 3% at 55 – 60 min. Fractions were collected every minute from 0 to 
45 minutes in to the run. All fractions were dried and separately reconstituted in 10 µL of 0.1% 
FA.  
6.3.11 Solid Phase Extraction. The oily phase and undissolved residue were each 
dissolved in 600 µL of 5% methanol and 0.1% FA and desalted via solid phase extraction 
(Discovery DSC-18; 1 mL volume; Supelco; Bellefonte, PA). The column was activated with 
methanol and cleaned three times with water. The sample was loaded onto the column and desalted 
three times with 5% ACN. Retained peptides were eluted sequentially using 30%, 50%, and 70% 
ACN. Eluent were dried and reconstituted in 0.1% FA.  
6.3.12 HPLC–ESI MS/MS of Planarian Peptide Extract. Fractionated tissue extracts, 
including the oily phase, were subjected to HPLC-ESI MS/MS analysis using a protocol similar to 
prior reports.23,41,42 A portion of each fraction (1 µL) was first evaluated using an Ultraflextreme 
MALDI-TOF/TOF mass spectrometer (Bruker Daltonics; Billerica, MA) for peptide content. 
Fractions were then divided into two groups based on the mass of the observed ions in the MALDI 
spectrum. Fractions containing smaller compounds were analyzed using a QTOF mass 
spectrometer (Maxis 4G or Maxis Impact; Bruker Daltonics; Billerica, MA) coupled to a Dionex 
UltiMate 3000 nanoLC system (Thermo Scientific; Waltham, MA) equipped with a reverse-phase 
analytical column (Magic C18AQ, C18, 0.1-mm i.d. x 150-mm, 3-µm particle size, 200 Å pore 
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size; Michrom).  Samples (1-2 uL) were loaded onto a peptide trap column (PepMap100, C18, 
300-µm i.d. × 5-mm, 5-µm particles, 100 Å pore size, Thermo Scientific) and desalted with a 
loading solvent (4% ACN and 0.05% FA) for 5 min before being sent through the analytical 
column. Separation was conducted at a uniform flow rate of 300 nL/min and a gradient of 20-50% 
solvent B (80% ACN, 0.05% FA, 0.001% TFA) over 75 min. Solvent A was 0.1% FA. The entire 
run was 120 min. MS analysis scanned at m/z 500-3000. Precursor isolation window for collision 
induced dissociation (CID) was m/z 8 for precursor ions smaller than m/z 1000, m/z 10 for 
precursor ions between m/z 1000 - 2000, and m/z 15 for ions larger than m/z 2000. Data-dependent 
precursor selection was used to restrict to three fragmentation spectra for the top three ions per 1 
min. 
Remaining peptide-containing fractions were analyzed via a 11 T FT-ICR MS (LTQ-FT 
Ultra, Thermo Scientific; Waltham, MA) coupled with a nanoLC system (Eksigent 1D plus, AB 
Sciex; Framingham, MA). Sample (1 µL) was mixed with 9 µL of loading solvent (5% ACN and 
0.2% FA), loaded onto a peptide trap column (IntegraFrit Sample Trap, Magic AQ particles, 150-
μm i.d. × 20-mm,  5-μm particle size, 100 Å pore size, New Objective, Woburn, MA) and desalted 
for 6 min with the loading solvent. The trap column was then placed in-line with the analytical 
column (PicoFrit column, Magic AQ particles, 75-μm i.d. × 150-mm, 5-μm particle size, 100 Å 
pore size, New Objective, Woburn, MA), and the sample was eluted over an analytical gradient of 
18-45% solvent B (95%/ ACN and 0.2% FA) over 60 min with a flow rate of 300 nL/min. The 
entire run was 95 min. Solvent A was 5% ACN and 0.2% FA. MS acquisition parameters include 
mass scan at m/z 300-2000 with a m/z 10 precursor isolation window for CID. Data-dependent 
precursor selection was restricted to the top three most intense ions. Dynamic exclusion was 
enabled with a repeat count of 3 and an exclusion duration of 120 s. 
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6.3.13 Bioinformatic Identification of Planarian Peptides. MS/MS base peak 
chromatograms from HPLC-ESI-QTOF analysis were processed using dataAnalysis (Bruker 
Daltonics; Billerica, MA) for compound spectra identification and charge deconvolution. The 
compound list was exported as Mascot generic files (.mgf) and loaded into PEAKS Studio 7.0 
(Bioinformatics Solutions Inc.; Waterloo, ON Canada) for searching against a S. mediterranea 
protein database containing 712 entries. Data set from HPLC-ESI-FT-ICR analysis was directly 
loaded into PEAKS Studio as the .raw format without preprocessing. The following search 
parameters were used: parent mass error tolerance: 50 ppm for spectra from QTOF and 15 ppm 
for spectra from FT-ICR, fragment mass error tolerance: 0.1 Da, charge options: no correction, 
enzyme: none, variable post-translational modifications (PTM): acetylation (K), acetylation (N-
term), acetylation (Protein N-term), amidation, oxidation, pyro-glu from E, pyro-glu from Q, and 
half of a disulfide bridge, max variable PTMs per peptide: 3.  
Other than matches against the protein database, de novo sequence tags generated by 
PEAKS Studio were searched against the S. mediterranea transcriptome database 
(http://planmine.mpi-cbg.de) and BLAST searched against sequences from other species. 
Sequence tags were first filtered to keep only those with average local confidence above 80%. 
Searching was further focused on matching residues with local confidence higher than 80% in 
order to emphasize matching high quality portions of the sequence. For those without BLAST 
results, the RNA sequence was first translated using the Expasy translate tool 
(http://web.expasy.org/translate). SignalP (http://www.cbs.dtu.dk/services/SignalP) was then used 
to predict if a characteristic signal peptide is present in the translated sequence.  
In addition to using PEAKS Studio, database searching for the HPLC-ESI-FT-ICR data set 
was also conducted using Prosight PC 2.0 (Thermo Scientific; Waltham, MA) against the S. 
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mediterranea protein database.43 Search parameters include an 82 Da precursor tolerance and 15 
ppm fragment mass tolerance without protease specificity and an E-value threshold of 10E-4. The 
Sequence Gazer tool in the ProSight software was used to manually determine PTMs on the 
peptides. 
 
6.4 RESULTS AND DISCUSSION 
Tissue regeneration is a complex process involving coordinating cell division and specialization, 
likely guided by a suite of biochemicals that varies spatially and temporally. MSI is well-suited 
for conducting de novo analysis of these complex processes because MSI is an untargeted and 
multiplex analytical method. In this study, we applied MALDI MSI to image peptide distribution 
changes associated with cephalic ganglia regeneration in S. mediterranea.  
 6.4.1 Workflow Optimization for Mass Spectrometry Imaging. A methodology was 
developed to conduct MALDI MSI on S. mediterranea tissue sections. Initial experiments 
observed a series of signals at ~m/z 1500 that were inconsistently distributed and inhibited the 
detection of other compounds (Figure 6.1). The identities of these ions are not known, and their 
distributions within the mass spectrum are not typical of peptides. Tissue sections were therefore 
rinsed prior to MALDI matrix application in order to remove these interfering chemicals. 
However, although rinsing tissue sections is a common sample cleanup procedure for MSI,44 S. 
mediterranea sections cracked when common drying techniques, such as a desiccator, were used. 
Supercritical drying was therefore used to dry the sections while also preserving section integrity 
(Figure 6.2). The final protocol involves a series of rinses starting with ammonium acetate buffer 
followed immediately by isopropanol. Rinsing with an ammonium buffer desalts samples to 
improve MS signal, and rinsing with alcohol is common for removing lipids to enhance peptide 
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and protein signals.44,45 In this case, the alcohol rinse further serves to dehydrate tissues prior to 
supercritical drying. The use of liquid carbon dioxide during the supercritical drying process serves 
as a final rinse. The combination of rinsing and supercritical drying was sufficient for removing 
the interfering signals at ~m/z 1500 and preventing the sections from cracking (Figure 6.1, 6.2).  
6.4.2 Mass Spectrometry Imaging Reveals Changing Peptide Distribution with 
Regeneration. Once our protocols were optimized, MSI was conducted on intact planarians and 
on amputated planarians that have been regenerating their cephalic ganglia for 3, 6, and 12 days. 
For tissue sections taken from intact and 12-day regenerated planarians, the cephalic ganglia could 
be seen under a dissection microscope and were always visible among at least one of the four most 
ventral sections. Tissue sections with visible cephalic ganglia were therefore used for MSI. The 
cephalic ganglia was not clearly visible under a dissection scope for sections from 3 and 6-day 
regenerated planarians. For these two time points, the four most ventral sections were used for 
MSI to be consistent with intact and 12-day regenerated planarians. 
Ion images for intact planarians show several ions that are localized to and around the 
cephalic ganglia (Figure 6.3). Among these, m/z 1223.9, 1525.1, and 1907.3, in particular, show 
strong intensity at the ganglia. Other signals localized just around the ganglia, such as m/z 2791.7, 
3345.6, and 3458.8, are also detected. These two sets of ions demonstrate that fully formed 
cephalic ganglia can be visualized via MSI. For 3-day and 6-day regenerated planarians, the 
cephalic ganglia is not observed, and most signals detected in intact planarians are not present 
(Figure 6.4). However, ions that are localized to and around the blastema, such as m/z 1000.6, can 
be detected. Two other ions, m/z 3344.9 and 3458.8, also show consistent localization toward the 
blastema in addition to being detected around the cephalic ganglia in intact planarians. 
Localization differences can be observed between 3-day and 6-day planarians. For example, 
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distributions for m/z 3344.9 and 3458.8 shift toward the most anterior edge of the animal after 6 
days of regeneration compared to after 3 days. In 12-day regenerated planarians, the cephalic 
ganglia is again observed along with most of the signals detected in intact planarians, but the 
cephalic ganglia is smaller, likely because the animal has shrunk during the 12 day period. 
Beyond the discussed ions, a series of signals around m/z 800-1200 with regularly spaced 
mass differences were also observed (Figure 6.5). These signals are different than what was 
observed when imaging planarian sections that were not rinsed. The distribution of these signals 
is noisy, but their intensity is strongest in regenerating planarians (3-day and 6-day), and they are 
often observed at the base of the blastema in 6-day regenerated planarians (Figure 6.5). The regular 
mass shifts observed for these ions are inconsistent with what is typically observed from peptides, 
but these signals are not present in blank gelatin sections that were processed in parallel with the 
sample (Figure 6.6). We therefore believe these signals are biological in origin and not 
contamination. 
Our MSI results are interesting compared to prior studies on planarian anterior 
regeneration, which show that the cephalic ganglia is visible and functional after around 6 days of 
regeneration.6,20 To validate our MSI results, we conducted DAPI imaging of planarian sections as 
a complementary imaging technique (Figure 6.7). Consistent with ion images, the cephalic ganglia 
is visible in intact and 12-day regenerated planarians but not in 3-day regenerated planarians. In 6-
day regenerated planarians, a structure that resembles the cephalic ganglia is observed. The 
structure is small and is more anterior in the tissue section than in intact planarians. However, its 
presence indicates that the planarians used in this study are regenerating as normal, and the newly 
formed ganglia is not physically destroyed during the embedding and sectioning process. Using 
the DAPI images as a guide, MSI results from 6-day regenerated planarians were reexamined. 
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Weak signal (near baseline) for m/z 1907.3, which is localized to the cephalic ganglia in intact 
planarians (Figure 6.3), was observed in parts of the blastema (Figure 6.8). The distribution of this 
signal is consistent with the general location of the cephalic ganglia toward the anterior end of the 
planarian, but image contrast is poor, likely due to the small ganglia size and weak ion intensity. 
Although the cephalic ganglia is present, the weak chemical signature suggests that regeneration 
is not complete. Even though past studies report that the cephalic ganglia is formed and functional 
after 6 days of regeneration, chemical differences can typically still be observed.21,28 For example, 
quantitative differences in neurotransmitter and metabolite content have been reported.28  
Combined with DAPI images, our MSI data set reveals structural and chemical trends 
associated with regeneration. After amputation, ion images show that the cephalic ganglia structure 
and signal return to near intact levels over a 12 day period. This timeframe is longer than the 
typically analyzed regeneration period of around 6 days. Our DAPI images show that the ganglia 
is present after 6 days, which in contrast with our MSI results suggests that although the ganglia 
structure is present, chemical differences still exist between intact and 6-day regenerated cephalic 
ganglia.  
6.4.3 Statistical Analysis Reveals Regeneration Chemical Trends. In conjunction with 
analyzing ion images, PCA was also conducted on the data set to highlight chemical changes. 
Regions of interest were first selected for each time point. For intact and 12-day regenerated 
planarians, mass spectra from the cephalic ganglia were selected. For 3-day and 6-day regenerated 
planarians, because the cephalic ganglia has either not regenerated or is only weakly visible, the 
region of interest were selected using several procedures. In samples in which the m/z 1907.3 signal 
is observed, spectra near the putative cephalic ganglia were selected. If m/z 1907.3 is not present, 
then all spectra from the blastema region are selected based on m/z 3458.8 signal. 
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A clear trend with regeneration is observed in the PCA score plot (Figure 6.9). Principal 
component 1 (PC 1), which accounts for over 30% of the total variance, separates intact and 12-
day regenerated planarians from 3 and 6-day regenerated planarians, indicating that regeneration 
is one of the largest factors for chemical variation. Data points for intact planarians are clustered 
together and overlap with data points from 12-day regenerated planarians. This pattern is 
consistent with ion images, in which similar signal and structure for the cephalic ganglia were 
observed for both time points. Data points for 3-day and 6-day regenerated planarians show more 
varied distributions on PC 1 and PC 2, perhaps reflecting a combination of biological and technical 
variance, such as differences in the amputation site and inter-animal variations during 
regeneration. PCA highlights how given enough time to regenerate, differences decrease and 
planarians eventually recover their original structural and chemical state. Overall, PCA reveals 
chemical trends that are associated with regeneration, and corroborates ion images in showing that 
intact and 12-day regenerated planarians are chemically similar.  
 Beyond PCA, which is useful for revealing general chemical trends, we also conducted a 
series of statistical tests to determine compounds that vary significantly between regeneration time 
points. To do so, the Anderson-Darling test was first conducted on each peak to test if they are 
normally distributed. Signals were then separated based on normality and tested for significance 
via either ANOVA (normally distributed signals) or the Kruskal-Wallis analysis of variance (not 
normally distributed signals). Interestingly, none of the significantly different compounds are 
normally distributed via the Anderson-Darling test. Table 6.1 lists signals that are significantly 
stronger in the cephalic ganglia. Ion images for these signals generally show good localization 
toward the cephalic ganglia in intact and 12-day regenerated planarians. Intensity ratios between 
regeneration and intact planarians show low intensities after 3 and 6 days of regeneration and 
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comparable intensities after 12 days, consistent with ion images and PCA. The predictive power 
of these compounds toward the cephalic ganglia was determined by calculating the area under the 
receiver operator characteristic curve (AUC). All AUC are over 0.9, indicating good predictive 
power. These characteristics indicate that the ions listed in Table 6.1 are good markers of the 
cephalic ganglia. Table 6.2 shows signals that trend in the opposite direction as those in Table 6.1. 
Intensity ratios show these signals become more intense after 3 and 6 days of regeneration before 
returning close to the intact level after 12 days, which suggests that these signals are more 
indicative of the blastema or forming cephalic ganglia. The AUC for these compounds are more 
varied but still show good predictive power with a few below 0.9. Other markers of the blastema 
are those with regularly spaced mass differences observed in ion images discussed earlier (Figure 
6.5, Table 6.3). These compounds are typically intense in 3 and 6-day regenerated planarians and 
have high AUC values. They are separated from the compounds in Table 6.2 because they do not 
appear to be peptides. 
Our statistical tests highlight the chemical trends associated with regeneration. PCA 
separates intact and regenerating planarians, and a series of statistical tests are used to reveal 
compounds that significantly differ during regeneration. Results show that intact and 12-day 
regenerated planarians are chemically similar and different from 3 and 6-day regenerated 
planarians. These results are consistent with ion images, in which the cephalic ganglia is observed 
after 12 days of regeneration but not clearly so after 3 and 6 days.   
 6.4.4 Peptidomics Analysis to Identify Regeneration Markers. Peptidomics analysis 
was conducted on regenerating planarians in order to identify the masses detected via MSI. 
Peptides from the anterior and posterior portions of 6-day regenerated S. mediterranea were 
extracted into acidified acetone, which was used to extract peptides in a previous study on 
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elucidating the prohormone complement of planarians.23 Combining the anterior and posterior 
portions allows peptides from both the cephalic ganglia and blastema to be extracted at once. To 
achieve an in-depth coverage of the peptidome, two-stage LC analysis was conducted on the 
peptide extract. All fractions from first stage LC were profiled via MALDI-TOF MS, and only 
those with putative peptide signals were further subjected to second-stage LC-ESI MS/MS 
analysis. During the extraction process, an oily phase and some undissolved residue were 
observed. These two parts were desalted via solid phase extraction and also profiled using MALDI-
TOF MS. Peptide signals were observed in the undissolved residue, which was therefore also 
subjected to LC-ESI MS/MS analysis. Obtained MS/MS spectra were searched against a 
previously established S. mediterranea protein database.23  
Peptidomics results were back-referenced to the imaging data set to identify the markers 
revealed from MSI (Table 6.1, 6.2). Identification results from this effort are presented in Table 
6.4. Not all MSI markers were detected during peptidomics analysis, likely a result of ionization 
differences between ESI and MALDI. For ions that are characteristic of the cephalic ganglia (Table 
6.1), MS/MS analysis identified most of these as peptides derived from known S. mediterranea 
prohormones, which is expected since these prohormones are generally located toward the cephalic 
ganglia.23 Among these peptides, the peptide derived from secreted peptide prohormone 4 (m/z 
1223.9; SPP-4 [33-42]) appears not to have recovered to the intact level even after 12 days of 
regeneration (Table 6.1, 6.4). Indeed, while peptides from other prohormones, such as EYE53-1, 
are not significantly different between intact and 12-day regenerated planarians, SPP-4 [33-42] 
remains at significantly lower intensity even 12 days after amputation (P=0.03). EYE53-1 is 
necessary for proper visual system function.46 This pattern suggests that although most structure 
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and chemical differences, such as the visual system, are recovered after 12 days of regeneration, 
chemical differences can still be observed and therefore not all functions may have been restored.  
Peptide markers that do not match entries in the protein database were also detected. In 
particular, all the peptide markers for the blastema (Table 6.2) do not match entries in the database, 
which may be because the database was constructed from intact planarians and not regenerating 
ones like those used in this study. Because there were no matches against the protein database, 
obtained de novo peptide sequence tags were searched against the planarian transcriptome, and 
their BLAST matches against sequences from other organisms were examined. Sequences 
presented in Table 6.4 are complete sequences produced via the PEAKS software package. 
However, because each sequence contains residues with varying amount of support from the 
associated MS/MS spectrum, it is typically difficult to find BLAST results that match the entire 
de novo sequence. The presented BLAST results therefore focuses on matching residues with local 
confidence above 80%, as indicated by the PEAKS algorithm. Focusing on high confident residues 
reduced impact on the search results by residues that are weakly supported by MS/MS. For 
example, sequences containing a single cysteine that is modified with half a disulfide bond are 
unexpected, as two cysteine residues are required to make a disulfide bond, and these samples 
were not treated to reduce disulfide bonds prior to analysis. In all such sequences, the modified 
cysteine residue has a low confidence score and were not focused on for the search. BLAST 
searching in this manner revealed proteins involved in a variety of functions. These include 
sequences with similarities to histone and other DNA and RNA binding domains. Although these 
proteins should normally be present in intact planarians, they likely play an important role during 
regeneration for synthesizing new proteins to replace the missing tissue. Other detected peptides 
contain similarities to proteins involved in cellular trafficking, such as ANTH-like domain and 
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regulator of vacuolar protein sorting (Vps). Sequences without BLAST matches were detected as 
well and are entered in Table 6.4 with their FASTA description from the transcriptome database. 
One of these contain a characteristic signal peptide near the N-terminus, suggesting that it may be 
destined for the secretory pathway.  
One of the markers associated with the blastema has sequence similarity to histone H4. 
Histone is a protein that helps compact DNA to form chromosomes, plays a role in regulating 
DNA transcription, and is involved with DNA replication during mitosis.47 In S. mediterranea, 
histone H4 RNA is used as a marker for neoblasts.3 Unlike other cells in planarians, neoblasts 
contain cytoplasmic chromatoid bodies, and ~80% of all chromatoid bodies contain histone H4 
mRNA.3 The exact function of chromatoid bodies is not known. However, it has been speculated 
that chromatoid bodies help regulate histone synthesis in neoblasts. During regeneration, neoblasts 
proliferate at the base of the blastema, but do not enter the actual blastema region until becoming 
descendants.48 Once differentiated to a target cell type, neoblasts lose their chromatoid bodies 
along with the associated histone RNA. Ion images show histone H4 signal increases toward the 
base of the blastema in 3-day regenerated S. mediterranea (Figure 6.10), where neoblasts are 
proliferating. This localization pattern corroborates increased histone synthesis during neoblast 
proliferation and may be evidence of unique regulation of histone synthesis in S. mediterranea. 
6.4.5 Peptidomics Analysis of Regenerating Planarians. Beyond identifying markers 
revealed from MSI, additional signals detected in peptidomics analysis include peptides from 
many known S. mediterranea proteins and prohormones (Table 6.5), such as secreted peptide 
prohormone (SPP), pedal peptide prohormone (PPP), and neuropeptide y prohormone (NPY). 
Peptides from these prohormones influence a large number of biological processes. PPP-derived 
peptides show sequence similarities to those from mollusks and may be involved in locomotion.49 
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For NPY, the S. mediterranea genome contains an expanded family of npy genes that encode NPF-
like and NPY-like peptides. In particular, peptides from the NPY-8 prohormone appear to be 
necessary for normal sexual development in the sexual strand of S. mediterranea.23 As expected, 
NPY-8 peptides are not detected in this study because the asexual strain was used. A large number 
of SPP peptides were detected. Among these are peptides from SPP-6, 7, 8, 9, and 17, which are 
encoded by paralogous genes and show similar localization in the CNS.23 Peptides from 1020HH 
and EYE53, which are both associated with photosensing, were detected as well.46 Other than 
prohormones, peptides from proteins like metallopeptidases, clathrin, and histone, are also 
observed. Metallopeptidases play a role in remodeling the extracellular matrix and have been 
implicated in regeneration in previous transcriptomics studies on planarian anterior regeneration.24 
Clathrin is involved in forming vesicles for intracellular trafficking.50 Similar to identifying MSI 
markers, peptides that do not match the protein database were sequenced de novo, searched against 
the planarian transcriptome, and their BLAST matches were examined. These tags were filtered to 
keep only sequences in which the average local confidence from all residues is higher than 80%, 
and searches were again focused on matching residues with local confidence over 80%. A 
summary of these matches are shown in Table 6.6. Several matches appear to be structural-related 
proteins such as actin and cadherin. Like MSI peptide markers, many also appear to be involved 
in protein synthesis, like chaperone proteins and various DNA and RNA binding proteins. Peptides 
with similarity to thymosin β-4 were also detected. Thymosin β-4 is involved in various aspects of 
cell differentiation and proliferation during wound repair.51 Our peptidomics results reveal several 
peptides that are consistent with an organism healing state, covering a variety of functions 
including tissue remodeling, protein synthesis, and general wound repair.24,51 
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6.5 CONCLUSIONS 
We have utilized MSI to conduct a multiplex and untargeted investigation of cephalic ganglia 
regeneration in S. mediterranea. Ion images reveal chemical and structural trends in peptide levels 
that have been supported by fluorescence imaging and PCA.  
Our results show that unlike prior studies on S. mediterranea anterior regeneration, the 
cephalic ganglia is not completely regenerated after 6 days, even though it is visible in fluorescence 
images. The combination of MSI and peptidomics analysis of regenerating planarians identified a 
number of peptides from multiple prohormones and proteins, covering a variety of functions such 
as protein synthesis and cellular trafficking that have changing levels during regeneration. In 
particular, we detected histone as a regeneration marker, indicating increased histone synthesis 
during neoblast proliferation and its unique regulation in neoblast biology. Future work will test 
the involvement of these peptides using knockdown and other approaches. Our analysis represents 
a de novo study of planarian anterior regeneration, uncovering the temporal, spatial, and chemical 
relationship of the regeneration process.  
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6.7 FIGURES 
 
Figure 6.1. Rinsing and supercritical drying removes interfering signals at m/z 1500-1600. 
Without rinsing, signals at m/z 1500-1600 interferes with the detection of other compounds. 
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Figure 6.2. Post-rinse drying using typical methods, such as a N2 stream or in a desiccator, 
caused tissue sections to crack, while supercritical drying preserved tissue section integrity. 
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Figure 6.3. Ion images for intact planarians. Many ions are localized to the cephalic ganglia or 
toward the anterior end of the planarian (shown above the red line). Ions that are localized just 
around the cephalic ganglia are also observed (shown below the red line).  
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Figure 6.4. Ion images for regenerating planarians at 3, 6, and 12 days after amputating the 
cephalic ganglia. Several ions are localized toward the blastema in 3-day (left column) and 6-day 
(middle column) regenerated planarians. The cephalic ganglia is visible after 12 days of 
regeneration (right column), only the anterior half of the planarian is imaged at this time point. 
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Figure 6.5. A series of signals around m/z 800-1200 with regularly spaced mass differences. 
These signals are generally observed at the base of the blastema in 6-day regenerated planarians. 
Selected ion images for 6-day regenerated planarians are shown at the lower half of the figure. The 
blastema is located at the top of the ion images and boxed red. 
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Figure 6.6. MALDI mass spectra of blank gelatin sample. No signal between m/z 800-1100 is 
observed. 
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Figure 6.7. Fluorescence images of DAPI-stained tissue sections from intact and regenerating 
planarians. The cephalic ganglia is visible in intact, 6-day regenerated, and 12-day regenerated 
planarians (red arrow). It is not visible after 3 days of regeneration. 
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Figure 6.8. Cephalic ganglia signal in 6-day regenerated planarians. Weak signal for the 
cephalic ganglia at m/z 1907.3 is observed in 6-day regenerated planarians. Image contrast for the 
cephalic ganglia is poor, likely because of the small ganglia size and low signal intensity.  
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Figure 6.9. PCA of intact and regenerating planarians. Data points for intact and 12-day 
regenerated planarians are separated from 3 and 6-day regenerated planarians on PC 1. This 
distribution pattern trends with how much regeneration has occurred and shows that regeneration 
is one of the largest factors for chemical variation. 
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Figure 6.10. Ion image for histone H4 in 3-day regenerated S. mediterranea. Localization 
trends toward the base of the blastema, where neoblasts are proliferating.  
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6.8 TABLES 
Table 6.1. Ions that are significantly more intense in the cephalic ganglia. 
a. P values calculated via the Kruskal-Wallis analysis of variance. 
b. P values calculated via the Anderson-Darling test for the normal distribution assumption. 
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Table 6.2. Ions that are significantly more intense in the blastema.
 
a. P values calculated via the Kruskal-Wallis analysis of variance. 
b. P values calculated via the Anderson-Darling test for the normal distribution assumption.  
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Table 6.3. Ions with regular mass differences that also differ significantly between 
regeneration time points. These ions are more intense in 3 and 6-day regenerated planarians but 
do not appear to be peptides.  
 
a. P values calculated via the Kruskal-Wallis analysis of variance. 
b. P values calculated via the Anderson-Darling test for the normal distribution assumption.  
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Table 6.4. Peptidomics identification of MALDI MSI regeneration markers.  
 
a. Entries in bold indicate matches against the S. mediterranea protein database. Underlined 
residues indicate local sequence confidence higher than 80%. Putative PTMs include amidation 
(a), acetylation (ac), oxidation (o), pyroglutamination (p), and half of a disulfide bond (*). 
Description includes annotations from the protein database and BLAST search results. Peptides 
without BLAST search results are described by their FASTA description and whether or not a 
characteristic signal peptide is present. 
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CHAPTER 7 
 
CLASSIFICATION OF LARGE CELLULAR POPULATIONS AND DISCOVERY OF 
RARE CELLS USING SINGLE CELL MATRIX-ASSISTED LASER 
DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY 
 
7.1 NOTES AND ACKNOWLEDGMENTS 
This chapter presents work on scaling up single cell MALDI mass spectrometry to enable 
classifying cell types based on characteristic peptide content. The material presented here is 
adapted from an article published in Analytical Chemistry (DOI: 10.1021/acs.analchem.5b01557) 
with coauthors D. J. Kissick, E. T. Jansson, T. J. Comi, E. V. Romanova, S. S. Rubakhin, and J. 
V. Sweedler. It is reprinted with permission from the American Chemical Society. The project 
builds on past work done in the Sweedler group by Dr. Eric Monroe, Dr. Kevin Tucker, and Dr. 
Tyler Zimmerman on stretch sample imaging. The work was done in collaboration with many 
members of the Sweedler group. Dr. Stanislav Rubakhin dissected the animals and prepared the 
cell population. Dr. David Kissick helped with optical microscopy and was a key contributor to 
data analysis. Dr. Elena Romanova conducted HPLC-MS/MS identification of unknown signals. 
Additional data were provided by Dr. Erik Jansson and Troy Comi, who are improving the 
developed approach on different cellular populations. Funding for this project was provided by 
NIH through grant P30DA018310. 
 
7.2 INTRODUCTION 
Cell-to-cell chemical variability and heterogeneity are fundamental features of multicellular 
organisms. Cells have historically been classified by their morphology and localization within an 
organism. However, a cell’s chemical content can also suggest cellular function and specialization. 
Further, even within supposedly homogeneous cell populations, chemical heterogeneities can be 
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observed due to a variety of endogenous and exogenous factors. Although chemical analyses of 
cells are often conducted on tissue homogenates, these assays may be less useful for cell 
classification because homogenization typically mixes many cell types as well as extracellular 
materials. Signals from rare cells can also be missed because their unique chemical content is 
diluted during homogenization. Single cell chemical analysis is therefore important for 
categorizing individual cells based on their chemical content. As a recent example, single cell 
transcriptomics uncovered molecularly distinct cellular classes in the cortex and the hippocampus, 
demonstrating the value of single cell analysis for molecular cellular classification.1  
Beyond the transcriptome, there also have been many advances in single cell metabolomics 
and peptidomics analyses, often using mass spectrometry (MS) and different separation methods.2-
4 The non-targeted and multiplexed nature of mass spectrometric methods makes them useful for 
single cell characterization, but many are serial approaches. Consequently, the required separation 
times and sampling processes have restricted investigations to relatively few cells,3,5-7 thereby 
limiting capabilities for categorizing populations of cells. Higher throughput methods have been 
developed. Mass cytometry, for example, enables classification of immune cell types based on a 
panel of markers,8 but the reliance on molecular probes requires a priori knowledge of the cellular 
chemical content and restricts the number of analytical channels available per analysis. Another 
high throughput approach, microarray MS, uses arrays of hydrophilic wells surrounded by an 
omniphobic material, depositing one to a few cells into each well,4 and has been used to study 
metabolites from single cell organisms like algae and yeast.9,10 Mass spectrometry imaging (MSI) 
is another option that can obtain thousands of spectra from tissues,11-14 although MSI has yet to be 
demonstrated for high throughput single cell profiling. 
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 In this work, we scale up single cell matrix-assisted laser desorption / ionization (MALDI) 
MS to enable label-free and high-throughput mass spectrometric categorization of cells in 
endocrine systems based on their peptide profiles. We analyzed a variety of endocrine and nervous 
system cell types, including cells from the rat pituitary and pancreatic islet of Langerhans, and the 
Aplysia californica central nervous system. These systems were chosen because there is detailed 
information on the peptide content of these cells and we have extensive experience working with 
these cell types,3,5,7 important factors in allowing the efficacy of our approach to be evaluated. The 
analysis begins by spreading a population of fluorescently labeled, intact cells onto a microscope 
slide so that the cells are randomly distributed. The population is optically imaged, and the cell 
coordinates are determined. The coordinates are then used to automate the MALDI-TOF MS 
analysis to target the individual cell or cells of interest. This approach is a refinement of the 
stretched sample method, in which MSI, or profiling, is conducted on tissue samples that are placed 
on an array of beads embedded on a Parafilm substrate and analyzed via MALDI MS.15-18 A similar 
approach has also been used for laser ablation electrospray ionization MSI.19  Instead of analyzing 
tissues or tissues on beads, here we focused on determining distinct subpopulations of cells based 
on their peptide profiles. Although a cell population prepared in this way can also be analyzed via 
traditional MSI, this targeted approach greatly reduces data size and complexity, and improves the 
quality of the data as MS acquisitions are only from the cells of interest (and not from cellular 
debris or other features). 
Along with optimizing the data collection process, we also worked on effective data 
mining. A challenge in analyzing single cell data sets involves finding both the major and minor 
patterns that characterize cell populations. We conducted principal component analysis (PCA) and 
PCA-based outlier detection, enabling identification of subpopulations and rare cells. Using this 
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data collection and analysis method, we profiled the peptide content of populations of hundreds to 
thousands of cells, classifying multiple cell types within the pituitary and pancreas, as well as 
revealing several rare cells having a unique cellular content. 
 
7.3 EXPERIMENTAL 
7.3.1 Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
unless noted otherwise. 
7.3.2 Preparation of Aplysia californica Neuronal Samples. Adult A. californica (175–
250 g; National Resource for Aplysia, Rosenstiel School of Marine & Atmospheric Science, 
Miami, FL) were kept in an aquarium containing continuously circulated and aerated seawater 
made using Instant Ocean Aquarium Sea Salt Mixture (http://www.instantocean.com, accessed – 
05/26/14), maintained at 14 oC. The central nervous system (CNS) was surgically isolated after 
animal anesthesia with isotonic MgCl2 solution injected into the body cavity. The CNS tissue was 
placed in artificial sea water (ASW) composed of 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 
mM MgCl2, 26 mM MgSO4 and 10 mM HEPES in Milli-Q water (Milli-Q filtration system; 
Millipore, Billerica, MA), with the pH adjusted to 7.8 using 1 M NaOH in Milli-Q water. Multiple 
neurons were mechanically isolated from the pleural and pedal ganglia after treatment with freshly 
prepared 1% (wt/vol) protease type IX dissolved in ASW supplemented with 100 units/mL 
penicillin G, 100 μg/mL streptomycin and 100 μg/mL gentamicin. The neurons were stabilized in 
a solution containing 33% glycerol and 67% ASW (v/v) and dispersed onto indium tin oxide 
(ITO)-coated glass slides. Excess extracellular glycerol was removed with a water rinse. 
7.3.3 Preparation of Rat Pituitary and Islets of Langerhans Cellular Populations.  The 
pituitary and islets of Langerhans cellular populations were extracted from male Sprague-Dawley 
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outbred rats (Rattus norvegicus, 2.5–3 months-old; Harlan Laboratories, Indianapolis, IN). 
Animals were housed on a 12-h light cycle and fed ad libitum. Euthanasia was performed in 
accordance with the protocols established by the University of Illinois Institutional Animal Care 
and Use Committee, and in accordance with all state and federal regulations for the humane care 
and treatment of animals.  
For pituitary isolation, rats were sacrificed by decapitation using a guillotine. The 
pituitaries were immediately surgically removed and placed into ∼2 mL of ice cold Modified Gey's 
balanced salt solution (mGBSS) containing 1.5 mM CaCl2, 4.9 mM KCl, 0.2 mM KH2PO4, 11 
mM MgCl2, 0.3 mM MgSO4, 138 mM NaCl, 27.7 mM NaHCO3, 0.8 mM NaH2PO4, and 25 mM 
HEPES dissolved in Milli-Q water (Millipore, Billerica, MA), with the pH adjusted to 7.2 using 
NaOH in Milli-Q water. Enzymatic treatment was done in an mGBSS solution containing 1% 
trypsin and 0.2% collagenase for 20 min at 37 oC, followed by 5 min incubation in mGBSS 
containing 1% trypsin, and another 5 min in 0.2% collagenase and 5 mg/mL of DNase I 
(Boehringer-Mannheim, Mannheim, Germany) dissolved in mGBSS. Finally, the sample was 
washed with and kept for 30–180 min in a mixture containing 33% glycerol and 67% mGBSS. 
The cell nucleus was stained by adding 10 µL of 1 mg/mL of Hoechst 33342. Gentle trituration 
with a wide-bore plastic Pasteur pipette was used to form the cell suspension, which was deposited 
onto indium tin oxide (ITO) slides. To remove excess extracellular glycerol, the samples were 
rinsed with 150 mM ammonium acetate buffer (pH 10), which minimizes damage to the cells,20 
and which was pH balanced to reduce removal of endogenous peptides. A total of four sample 
slides containing cells from four animals were used for analysis.  
Islets of Langerhans isolation was performed according to a previously described protocol 
with minor modifications.21 Briefly, the pancreas was injected with 2 ml of 1.4 mg/ml collagenase 
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P solution from Clostridium histolyticum (Clostridiopeptidase A, EC 3.4. 24. 3; Cat. No. 11 213 
857 001, Roche Diagnostics, Indianapolis, IN) dissolved in mGBSS. The injected pancreas was 
surgically dissected and placed in a 10 ml glass vial containing 3 ml of the collagenase P solution, 
and then incubated in a recirculating water bath for 20–30 min at 37 ºC. The resulting suspension 
was washed twice with mGBSS for 3 min at 300 × g, resuspended in 10 ml of mGBSS, and sieved 
through a 1 mm × 1 mm mesh into a Petri dish. Manual collection of islets of Langerhans into 2 
ml of mGBSS in a 35 mm Petri dish was performed with a micropipette under an inverted light 
microscope. To stain the nuclei, 2 µl of 1 mg/ml Hoechst 33342 was added to the dish, followed 
by incubation for 15 min at 15 ºC. Islets were then treated with 0.25% trypsin-EDTA for 20 min 
at 37 ºC. Islets were triturated into single cells and transferred to an ITO-slide, stabilized in a 40% 
glycerol, 60% mGBSS solution, and followed by washing with 150 mM ammonium acetate. 
7.3.4 Optical Imaging. Each dispersed cell population was imaged using an AxioVert 200 
fluorescence microscope (Carl Zeiss, Oberkochen, Germany) with an X-CITE 120 mercury lamp 
(Lumen Dynamics, Mississauga, Canada) and a 31000v2 DAPI filter set (Chroma Technology, 
Irvine, CA). A 10× objective was used to obtain a mosaic image with 10% overlap between 
neighboring images. Images were taken using an AxioCam HRC color camera (Carl Zeiss) set to 
a resolution of 4164 × 3120.  
7.3.5 Cell Localization. All mosaic optical images were stitched in ImageJ to output a list 
of relative offsets between images.22 Individual images were batch processed with the “color 
threshold” and “analyze particles” features in ImageJ to find the cell coordinates in each image. 
Cell coordinates from each image were added to the corresponding image offset to obtain the cell 
coordinates on the sample slide. 
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7.3.6 Geometry File Creation. Before fluorescence imaging, a silver sharpie was used to 
draw an ~5 mm-thick line along two opposite sides of the cell population. An UltrafleXtreme mass 
spectrometer (Bruker Daltonics, Billerica, MA) was used to generate multiple fiducial markers 
into each line by laser ablation.  
After microscopy imaging and cell localization, 3,000 rat pituitary cells or ~600 islets of 
Langerhans cells were randomly chosen from their respective cellular populations. For Aplysia 
cells, ~30 cells were chosen. The determined cell coordinates were used to create a custom 
geometry file for automatic single cell MALDI-TOF MS analysis. The geometry file was created 
using the Java JDK 1.6 Applet available at http://neuroproteomics.scs.illinois.edu/imaging.html, 
as described previously.15 All fiducial markers were used when calculating the scaling and rotation 
parameters, but only four markers were input into the applet. 
7.3.7 Matrix Application. For pituitary and islet of Langerhans cells, a solution of the 
MALDI matrix 2,5-dihydroxybenzoic acid (50 mg/mL) in 1:1 acetone:water plus 0.5% 
trifluoroacetic acid (TFA) was sprayed onto the samples using an artist’s airbrush (Paasche 
Airbrush Company, Chicago, IL) propelled with nitrogen at 40 psi. The airbrush was held ~60 cm 
from the sample, and the matrix coating was built up by alternatively spraying 1 and 2 mL of the 
matrix solution. The slide was rotated after each spray cycle and dried completely. Coating 
thickness was estimated by weighing the sample slide before and after matrix application and 
measuring the coated area. A MALDI matrix coating of 0.2–0.4 mg/cm2 was applied.  
Aplysia neurons were used to validate our ability to target single cells. The MALDI matrix 
α-cyano-4-hydroxycinnamic acid (CHCA) was sublimed onto the Aplysia neuron sample slide to 
create a uniform matrix layer that is easy to ablate with the MALDI laser. Sublimation was done 
in a glass sublimation chamber (Ace Glass, Vineland, NJ), heated with a heating mantle powered 
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using a variable autotransformer set to 55% of 120 V (Staco Energy Products Co., Dayton, OH). 
A vacuum was created using an Edwards 30 E2M30 rotary pump (Edwards, Sanborn, NY). The 
setup was run for 18.5 min to create a coating of ~0.2 mg/cm2. 
7.3.8 MALDI-TOF MS. MALDI-TOF MS analysis was conducted using the Bruker 
UltrafleXtreme mass spectrometer with a frequency tripled Nd-YAG solid state laser. The laser 
was set to the “small” footprint setting at an ~30 µm diameter. Acquisition was automated to each 
cell location using the autoXecute feature of the instrument and the custom geometry file generated 
earlier. For pituitary cells, signals from 250 laser shots fired at 1000 Hz were summed for each 
cell. Islets of Langerhans cells were analyzed with 1000 laser shots fired at 1000 Hz. Signals were 
summed from one spot on the cell for both types of cells. For Aplysia neurons, each neuron was 
profiled with a 3 × 3 spot array with 90 µm raster using 1000 laser shots fired at 1000 Hz. To 
confirm and identify the markers for pituitary subpopulations, tandem MS (MS/MS) was 
conducted on the pituitary extracts using the LIFT mode of the mass spectrometer with argon as 
the collision gas and an isolation window of 10 Da for the precursor ions. 
7.3.9 Pituitary Peptide Extraction. For the pituitary samples, we also identified the 
peptides present using larger samples, extracting the peptides and characterizing them via liquid 
chromatography (LC)–MS. Peptide extraction was conducted on two types of pituitary samples. 
To identify the unknown ion observed at m/z 2105.3, a suspension (100 µL) of dissociated rat 
anterior pituitary cells was homogenized in 200 µL of 10 mM HCl (Avantor, Center Valley, PA). 
The homogenate was centrifuged (Eppendorf, Hauppauge, NY) at ~21,000 g for 15 min at 4 oC. 
An aliquot (150 µL) of the supernatant was desalted using a C18 spin column (Thermo Scientific, 
Waltham, MA). The column was washed twice using 200 µL of 5% acetonitrile (ACN) and 0.1% 
formic acid (FA). Retained peptides were eluted with two volumes of 40 µL of 50% ACN and 
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0.1% FA, followed by two volumes of 40 µL of 70% ACN and 0.1% FA. The combined eluent 
was dried and reconstituted in 10 µL of 0.1% FA.  
To confirm other peptide markers, rat posterior and intermediate pituitary tissues were 
homogenized in 200 µL of 10 mM HCl and centrifuged at ~21,000 g for 15 min at 4 oC. The 
extract was analyzed with MS/MS using the UltrafleXtreme MALDI-TOF/TOF mass 
spectrometer.  
7.3.10 capLC-MALDI MS/MS. Peptide extract from dissociated rat anterior pituitary was 
subjected to LC–MS analysis to identify the unknown ion at m/z 2105.3. HPLC separation was 
conducted using a Dionex UltiMate 3000 Rapid Separation system (Thermo Scientific) equipped 
with a desalting/pre-concentrating setup and a UV detector. Samples were loaded onto a peptide 
trap column (Acclaim PepMap C18, 200-µm inner diameter (i.d.) × 2 cm, 5-µm particles, 100 Å 
pore size, Thermo Scientific) and washed for 5 min with a solution of 4% ACN and 0.05% FA. 
The peptide trap was then placed in-line with the analytical column and separation was conducted 
on a reversed phase capillary column (Acclaim PepMap RSLC, C18, 300-µm i.d. x 15 cm, 2 µm-
particle size, 100 Å pore size, Thermo Scientific). A total of 6 µL of the extract was separated at a 
uniform flow rate of 4 µL/min and a gradient of 4–55% solvent B (80% ACN, 0.05% FA, 0.001% 
TFA) over 35 min; the entire run time was 60 min at 45 ºC. Solvent A was 0.05% FA. Separation 
was monitored with a UV detector at 214 nm. LC fractions were automatically spotted onto a steel 
MALDI target plate pre-coated with DHB (1 mg/cm2 coating thickness applied via pneumatic 
spray) at 15 s intervals using a Proteineer fc fraction collector (Bruker Daltonics). Spots were 
profiled using the UltrafleXtreme MALDI-TOF/TOF mass spectrometer. 
7.3.11 capLC–ESI MS/MS and Bioinformatic Identification of Dissociated Pituitary 
Peptides. We used 2 µL of the same extract as for LC-MALDI MS/MS. Separation was performed 
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at a flow rate of 5 µL/min and 4–50% gradient B for 70 min at 45 ºC. MS and MS/MS data were 
collected on an amaZon speed ETD ion trap mass spectrometer (Bruker Daltonics) interfaced to 
the LC instrument via a standard ESI source. The parameters included a mass scan range of m/z 
300–2800, m/z 4 precursor isolation window, and smart fragmentation for optimized collision 
energy. Data-dependent precursor selection was restricted to two fragmentation spectra for the top 
three ions per 0.5 min, and preferred precursor masses (± 0.5), corresponding to the different 
charge states of m/z 2105, were activated. Base peak chromatograms for MS/MS from each run 
were processed for peak picking/compound identification, charge deconvolution and retention 
time range selection using the dataAnalysis software (Bruker Daltonics) and exported as Mascot 
generic files (.mgf). 
The .mgf files were loaded into PEAKS Studio 5.3 (Bioinformatics Solutions Inc., 
Waterloo, ON Canada) and processed for charge state correction and de novo tag identification. 
The tags were searched against the rat Uniprot database (http://www.uniprot.org/) with 33,475 
protein entries. The search parameters included 0.5 Da mass tolerance for precursor and fragment 
ions, no enzymes, and a maximum of three variable modifications (amidation, acetylation, 
pyroglutamylation (from Q and E, disulfide bond formation). The false discovery rate for peptide-
spectrum match was 3.2% and the average local confidence score for de novo sequencing was 
50%. Results were filtered with the Peaks peptide score (-10lgP) cutoff of 15, which was chosen 
according to the histogram of peptide-spectrum match score distribution relative to decoy hits and 
the plot of precursor mass error versus score. Additionally, the filtered results were manually 
checked for ion fragment/post-translational modification fit to eliminate false-positive 
identifications. The final peptide lists from the two analyses were combined. 
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7.3.12 Statistical Analysis. For all cell types, the raw mass spectra were first processed 
using two R packages, MALDIquant and MALDIquantForeign,23 in order to identify those without 
signal. Mass spectra were baseline subtracted using the Top Hat algorithm with a half-window size 
of 50, smoothed using the Savitzky-Golay algorithm with a half window size of 4, and peak picked 
with a minimum signal to noise ratio of 3. After peak picking, the intensity of the strongest peak 
was used to sort the mass spectral data set in increasing intensity. Spectra sorted in this manner 
were manually examined to exclude those without signal.  
The remaining mass spectra were processed and visualized using a custom Python script 
(see Appendix D). The spectra were down-binned to unit m/z resolution, baseline subtracted with 
a window of 10, and normalized to the total ion count before further analysis. PCA was used to 
categorize major cell subpopulations by projecting the data onto the heavily weighted principal 
vectors. Principal component (PC)-based outlier detection was performed to find rare cells.24 The 
same program also generated false-color peptide distribution maps of the population. Signal 
intensity is illustrated using a rainbow color scheme. To further enhance contrast, colors associated 
with lower intensities (blue and green) were also made more transparent using the GNU Image 
Manipulation Program (GIMP; see http://www.gimp.org). 
 
7.4 RESULTS AND DISCUSSION 
The goal of our approach is to classify populations of neurons and endocrine cells based 
on their peptide profiles in order to determine categories of cells (cell types) in a complex sample, 
as well as to identify unusual peptide profiles among the studied cells. MALDI appears well suited 
for this application because of its ability to profile the hormone and neuropeptide content of 
individual cells.7,25-28 The cell population is dispersed over a microscope slide so that the distance 
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between the cells is large enough to enable MALDI MS to assess individually isolated cells; next, 
each cell location is profiled via MALDI-TOF MS.  
7.4.1 Validating Single Cell Analysis using Neurons from Aplysia californica. To 
determine which part of the stretched sample method is amenable to the current approach, a 
preliminary experiment was conducted on ~30 bag cell neurons and pleural sensory neurons from 
A. californica because they are larger and easier to visualize. The goal was to demonstrate 
sufficient visualization and targeting accuracy for cellular features. The primary modification to 
the prior method was the optical imaging step. Although brightfield imaging was sufficient 
previously, it did not produce adequate image contrast for the variety of cell types and experimental 
conditions in this study. Without cellular labeling, a complex imaging set up was necessary to 
clearly visualize cells. In the case of the Aplysia neurons, autofluorescence and darkfield images 
were acquired. Cells were visualized as pink spots by restricting darkfield imaging to the red 
channel of the microscope camera and autofluorescence to the blue channel (Figure 7.1). To 
visualize targeting accuracy, the MALDI matrix CHCA was sublimed onto the slide to create a 
homogeneous coating, and cell locations were ablated using the MALDI laser.  
Figure 7.1 shows an overlay of two optical images taken before and after matrix ablation. 
The top layer is the pre-ablation darkfield and autofluorescence image. The bottom layer is a 
brightfield image showing laser ablated spots in the matrix. For these relatively large cells, a 3 × 
3 raster was used for each targeted location. There is good registry between the cells and ablated 
spots, demonstrating sufficient targeting accuracy. This result confirms that the method enables 
targeting of cells randomly localized on a slide. While encouraging, Figure 7.1 also shows the 
potential to co-analyze cell clusters and other debris along with single cells. These unwanted 
features can be removed by setting the boundaries for size and circularity in the “analyze particles” 
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function in ImageJ during cell finding. For example, an upper limit on particle size can be used to 
exclude cell clusters (Figure 7.2). 
7.4.2 High-throughput MALDI-TOF MS Analysis of Pituitary Cells. Once cell 
targeting was validated, we demonstrate the capability of the approach by analyzing populations 
of rat pituitary cells. The pituitary was chosen because it contains different morphological and 
functional regions, with many cell types expressing high levels of well-characterized cell-to-cell 
signaling peptides7,29-31 Challenges faced when working with these samples include their relatively 
small cell size (10–20 µm diameter) and cell optical transparency (Figure 7.3). Therefore, live 
pituitary cells were labeled with the nuclear stain Hoechst 33342 and stabilized with glycerol 
before being dispersed onto the slides. We have previously shown that glycerol stabilization helps 
to maintain cell integrity during sample preparation and improves MS measurement variability.5 
Nuclear staining enables cell coordinates to be determined from fluorescent images based on 
nucleus size and brightness. The stain did not produce interfering MS signals in the peptide mass 
range (Figure 7.4).  
To speed up the MALDI MS analysis while still demonstrating high-throughput 
capabilities, 3,000 cells were randomly chosen from each population and deposited on the four 
microscope slides. These cells were typically distributed over a roughly 2.5 × 4 cm area. If we 
used traditional MSI to analyze these cell populations, ~10,000,000 pixels would have been needed 
to image the area at 10 µm lateral resolution. This high a resolution would be necessary for 
spatially resolving single cells when using a raster pattern in imaging mode. Assuming the same 
MALDI MS conditions as used in this study, each pixel would need at least 0.25 s to be acquired 
(summing signals from 250 laser shots fired at 1000 Hz). These conditions would lead to an overall 
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data collection time of several hundred hours. With the targeted profiling technique presented here, 
the MS analysis can be done in about an hour.  
Each cell was profiled with a single MALDI MS acquisition. The laser spot was set at a 
diameter of ~30 µm, which is larger than typical pituitary cells, ensuring that the entire cell was 
sampled. This reduces signal variations that may result from only partially sampling a cell. Even 
from a single cell, several pituitary peptides were detected, including arginine vasopressin (AVP), 
oxytocin and alpha-melanocyte stimulating hormone (α-MSH) (Figure 7.5), which are markers of 
the posterior and intermediate pituitary. The identity of these peptides was confirmed via MALDI 
MS/MS (Figure 7.6). Melanotrophs in the intermediate pituitary express high amounts of peptides 
derived from the pro-opiomelanocortin (POMC) prohormone, such as α-MSH, joining peptide and 
β-endorphin.32 As is typical for melanotrophs, mass spectra with intense α-MSH signals also 
contain other POMC peptides (Figure 7.7). The detection of AVP and oxytocin in cells selected 
by nuclear stain and cell morphology is surprising. According to the classical view, AVP and 
oxytocin are expressed in the soma of distantly located hypothalamic neurons and then transported 
to their release sites in the posterior pituitary.33 Thus no AVP and oxytocin cell bodies were 
expected. The posterior pituitary is primarily composed of these hypothalamic-originating 
terminals and neurites rather than cells, so it is intriguing to find pituitary cells with AVP and 
oxytocin signals. It is possible that hypothalamic neuron terminals were co-localized with some 
pituitary cells, which is consistent with the weak to moderate co-appearance of POMC peptides 
with AVP in many spectra (Figure 7.8). However, several reports have demonstrated AVP-related 
immunostaining34 and vasopressin RNA35 in some pituicytes,36 and AVP may be internalized into 
some cells,37,38 and so either is a possibility. The current data do not resolve the source of these 
peptides.  
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7.4.3 Determination of Major Pituitary Cell Subpopulations using PCA. We also 
worked on effective data mining. Compared to traditional MSI, the data set collected with this 
approach is simplified and minimized because it contains only spectra from cells rather than a mix 
of spectra from cells, debris, media and empty spaces. PCA was conducted to classify cell types 
(Figure 7.9). Although more manual statistical methods, e.g., examining biaxial plots, can also be 
used, multivariate methods take into account the entire data set. Our non-supervised analysis 
facilitates the detection of features because it reveals those that are responsible for major patterns 
in the data. For the described data set, the chemical profiles obtained via MALDI MS revealed 
multiple pituitary cellular populations. The loading spectra have a strong contribution from ac-α-
MSH in PC 1, lipid-like signals for PC 2, and AVP for PC 3 (Figure 7.9B). This pattern is 
consistent with examining peptide distribution maps, with PC 1 highlighting melanotrophs, and 
PC 3 showing cells with strong AVP signal. PC 2 may be composed of cells from the anterior 
pituitary, where lipids may be the dominant chemical species observed in the targeted mass range. 
Another possibility may be partially lysed cells that still retain the stained nucleus. Although the 
pituitary contains distinct cell types with well-characterized content, the PCA shows a high degree 
of heterogeneity, with data points spreading out along the PCs to show a continuum of signal 
instead of an on-off behavior (Figure 7.9A). We have taken care to reduce measurement variations 
by validating our ability to target cells using an Aplysia neuronal population. Our previous work 
with the stretched sample method also corroborates our targeting accuracy.15-18 Together, these 
factors support the notion that the observed variations may be biological in origin rather than a 
measurement artifact.  
7.4.4 Determination of Chemically Distinct Rare Cells in the Pituitary. Examining the 
first few PCs is useful for finding major patterns; however, minor variations, such as chemically 
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rare cells, may be overlooked because they are not captured in the first few PCs. Mass spectra 
corresponding to rare cells may not strongly influence the largest principal vectors but may be 
identified by projecting the data onto the smallest principal vectors. In practice, with high 
dimensional data sets, it is often more computationally efficient to project onto the largest principal 
vectors, then back-project into the original data space, and finally, subtract the resulting spectra 
from the original. The difference reveals the parts of the data that were not captured by typical 
PCA.24 The number of PCs used for back-projection determines the sensitivity for detecting rare 
signals, with more PCs leading to the observation of more unique signals.  
This PCA-outlier detection approach was applied using the first 23 PCs (~90% of the total 
variance) for back-projection. Figure 7.10 shows the generated difference mass spectrum. 
Although some major pituitary peptides are still present, many uncommon signals are also visible. 
Several signals are tentatively labeled as contaminants (and not from cells) by examining the 
relevant mass spectra and the ion distribution pattern on the slide. Table 7.1 summarizes the 
peptide-containing cell types found using traditional and extended PCA. Other than melanotrophs, 
each cell type is labeled with their distinguishing peptide marker. The characteristic ions for each 
population are listed in Table 7.2. Cells identified as melanotrophs, or those containing AVP and 
oxytocin signals, are classified as major cell populations. AVP and oxytocin-exhibiting cells are 
separated into two groups because some differences were seen in their spatial distribution. A 
characteristic ion at m/z 2264.2 was detected in a large portion of melanotrophs and used to classify 
a subpopulation of melanotrophs. For rare cells, it is not surprising that most of the apparent 
biomarkers detected were not identified. One exception is the signal at m/z 1622.8, which matches 
by mass to unmodified α-MSH. Most α-MSH in the intermediate pituitary is acetylated, but the 
non-acetylated form is also present,39 and has been observed in prior MSI studies of the pituitary.31 
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Revealing these rare cells in conjunction with larger subpopulations demonstrates the usefulness 
of our PCA-based statistical workflow to highlight major and minor patterns. 
Another interesting signal at m/z 2105.3 was detected in many cells and does not appear to 
have originated from the intermediate or posterior pituitary. Using LC–MALDI MS/MS, we 
identified this ion as a putative somatotropin-related peptide. However, only a portion of the 
sequence is supported by genomic data (Figure 7.11). This assignment suggests the detection of 
somatotrophs from the anterior pituitary. LC–ESI MS/MS measurements on the same sample 
uncovered a number of other pituitary peptides, including known somatotropin-related peptides 
(Table 7.3). Peptidomic analysis revealed peptides from the prolactin prohormone, suggesting the 
presence of lactotrophs in the sample. Both somatotrophs and lactotrophs are acidophiles, while 
other major cell types in the anterior pituitary more readily take up basophilic stains.40 Peptides 
from prohormones known to be expressed in basophiles (corticotropin, thyrotropin, lutropin and 
follicle-stimulating hormone) were not detected in our peptidomic experiments. It is possible that 
the predominant detection of peptides from acidophilic cell types may have been caused by the 
acidic extraction and separation conditions. 
7.4.5 Determination of Islets of Langerhans Cell Populations. In order to explore 
whether the approach will work with smaller cells, we studied the rat pancreatic islet of 
Langerhans. As the islet cells are smaller than cells from pituitary, being between 3–6 µm in 
diameter, these represent a more difficult challenge for accurate cell targeting. In these cases, we 
dispersed cells from individual islets for each experiment. 
PCA was performed on a MALDI MS dataset with spectra from ~600 single cells. PC 1, 
2, and 3 distinguished cell types based on known pancreatic prohormones (Figure 7.12, Table 
7.4).41,42 In the loading spectrum for PC 1, peptides characteristic for beta cells (insulin 1 and 2 
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prohormones) separated cells containing  peptides characteristic for alpha cells (the glucagon 
prohormone), with the peptides having opposite loading signs. Beta cells also have higher scores 
on PC 3 than alpha cells. In PC 2, the somatostatin-14 peptide, characteristic of delta cells, 
appeared with an opposite sign to the loading for insulin peptide from beta cells, hence separating 
these cell types as well. Although these three cells types are separated via PCA, gamma cells, 
which are characterized by the pancreatic hormone, appear convoluted in the same direction as 
alpha cells in the score plot. The loading for pancreatic hormone in PC 1 has the same sign as the 
glucagon prohormone peptide, and the loading in PC 2 is close to zero. Gamma cells are much less 
abundant than other cell types in islets of Langerhans throughout a majority of the rat pancreas.41 
We expect that the low count of these observations did not provide enough data variability to 
separate this cell type from others, and explains why alpha and gamma cells are grouped together 
in the score plot. Our results show successful categorization of most cell types from the rat 
pancreatic islet of Langerhans, further demonstrating the method’s capability to conduct 
population-level single cell analysis, and to classify cells based on peptide biomarkers. 
 
7.5 CONCLUSIONS 
We have developed a novel approach that combines in-vitro live cell labeling, optical 
microscopy, image processing, high throughput single cell mass spectrometry, and multivariate 
statistical analysis, to enable cellular classification via multiplexed analysis of cell peptide content. 
Cells in a randomly distributed population were individually examined by finding the cell 
coordinates using optical microscopy, and performing automated single cell MALDI-TOF MS 
analysis. The entire cell is profiled via MALDI MS, and the MS data obtained from hundreds to 
thousands of single cells allows cellular subpopulations and rare cells to be revealed. We 
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demonstrate this method on multiple cell populations from the rat pituitary and pancreatic islet of 
Langerhans, and the A. californica nervous system.  
The multiplexed chemical data that is generated, which includes spatial information, has 
parallels to data obtained using MSI. However, the approach described here saves time and 
improves specificity by examining only the cells of interest. One could use more specific stains 
than the nuclear stains used here. For example, stains that differentiate glia and neurons can be 
used that enable populations of cells to be classified based on the localization stain, and then their 
chemical differences compared. In addition, although we have categorized cells here based only 
on their peptide profiles, morphological information generated during optical cell finding may 
contribute another dimension for cell classification. Beyond the endocrine cell populations covered 
here, this approach may be used to conduct chemical classification of many cell types across 
multiple species and can easily be extended to lipids and other molecular classes that are detected 
via MALDI MS. 
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7.7 FIGURES 
 
Figure 7.1.  An overlay of two images of dispersed Aplysia californica neurons on a 
microscope slide. The top layer is a combined darkfield and autofluorescence image taken before 
MALDI matrix application. The bottom layer is a brightfield image of the same sample after matrix 
application and MALDI-TOF MS analysis. Cells are visualized as pink spots in the darkfield and 
autofluorescence image. MALDI laser ablation marks (3 × 3 grids) are visualized as white spots 
in the matrix layer (gray spots in this overlaid image). There is good registry between cell locations 
and laser marks, showing our ability to target cells for MALDI MS.   
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Figure 7.2. The particle size and circularity settings in the “Analyze Particles” function of 
ImageJ can be used to remove unwanted features from the analysis. In the case of cell clusters, 
an upper limit on particle size can be used to exclude them.  
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Figure 7.3. Transmission optical microphotograph of representative cells from enzymatically 
dissociated rat pituitary. Cells are labeled with arrows and a putative nucleus released from a 
damaged cell is labeled with an asterisk. 
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Figure 7.4. Mass spectrum of a solution containing the nuclear dye Hoechst 33342 from m/z 
600–8000. No interfering signals in the analyzed molecular mass range were observed. 
  
m/z 
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Figure 7.5. Spatial distribution maps for peptides detected in a dispersed population of 
pituitary cells. Distribution of (A) AVP-containing cells and (B) ac-α-MSH-containing 
melanotrophs. Signal intensity is color coded and increases from blue to red, with blue indicating 
noise level. The intensity of the color scale is distinct for each ion.  
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Figure 7.6. MALDI-TOF MS/MS analysis of peptide markers from intermediate and 
posterior pituitary extracts. (A) ac-α-MSH (Ac-Ac-SYSMEHFRWGKPV); (B) AVP 
(CYFQNCPRGa); (C) oxytocin (CYIQNCPLGa). 
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Figure 7.6. (cont.) 
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Figure 7.7. Mass spectrum acquired from a melanotroph. Several peptides from the POMC 
prohormone are detected, including α-MSH, joining peptide (J-peptide), corticotropin-like 
intermediate peptide (CLIP), and β-endorphin. 
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Figure 7.8. Representative mass spectrum exhibiting AVP, oxytocin, and POMC-derived peptide 
signals, indicating possible cross contamination between cell types or co-localization of cellular 
structures, such presynaptic buttons attached to the examined cells. 
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Figure 7.9. PCA of the MS data set acquired from the pituitary cell population. (A) Score 
plot projected onto the PC 1 by PC 2 plane, with a rainbow color scale indicating scores on PC 3 
(warmer color = higher PC 3 score). PC1: 49.1% variance, PC2: 10.7% variance, PC3: 6.0% 
variance. (B) Loading spectra for PCs 1, 2 and 3. Blue: PC 1; black: PC 2; red: PC 3.  
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Figure 7.10. Difference mass spectrum for the studied pituitary cell population after 
accounting for 90% of the total variance (23 PCs were used for back-projection). Known 
pituitary peptides are labeled; other unidentified ions are labeled with their m/z ratios. Possible 
contaminant signals are marked by asterisks.   
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Figure 7.11. MS/MS analysis of an unidentified signal at m/z 2105.3. (A) De novo sequencing 
and mass error for assigned fragments. (B) Sequence for somatotropin in rat. Only a portion of the 
proposed sequence from de novo sequencing is present (red). 
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Figure 7.12. PCA of the MS data set acquired from the cell population of an islet of 
Langerhans. (A) Score plot projected onto PC 1 by the PC 2 plane, with a rainbow color scale 
indicating scores on PC 3 (warmer color = higher PC 3 score). PC1: 27.4% variance; PC2: 19.8% 
variance; PC3: 15.2% variance. (B) Loading spectra for PCs. Blue: PC 1; black: PC 2; red: PC 3. 
Peak annotations–1: somatostatin-14; 2: insulin 1 A+B [M+2H]2+; 3: insulin 2 C-peptide; 4: insulin 
1 C-peptide; 5: glicentin-related polypeptide; 6: glucagon; 7: pancreatic hormone; 8: insulin 1 and 
2 A+B chains. 
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7.8 TABLES 
Table 7.1. Major cell populations, a subpopulation of melanotrophs, and rare cells found in 
the rat pituitary using peptide biomarkers revealed via traditional PCA and the extended 
PCA approach. Each presented biomarker classifies a cell population, subpopulation or a rare cell 
type. Only cells with peptide signals are classified.  
Major Cell Population 
Biomarkers 
Subpopulation 
POMC peptides 
(melanotrophs) 
POMC peptides & m/z 
2264.2 (melanotrophs) 
AVP - 
oxytocin - 
m/z 2105.3 - 
Rare Cells 
m/z 944.5 m/z 3175.1 
m/z 1125.6 m/z 3455.3 
m/z 1622.8 
(unmodified α-MSH) 
m/z 5882.6 
m/z 2491.4  
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Table 7.2. Characteristic ions for major cell populations. Cell populations include 
melanotrophs from the intermediate pituitary, AVP-containing and oxytocin-containing cells from 
the posterior pituitary, and unidentified m/z 2105-containing cells.  
Melanotroph AVP-containing Oxytocin-containing m/z 2105-containing 
m/z 
(observed) 
ID 
m/z 
(observed) 
ID 
m/z 
(observed) 
ID 
m/z 
(observed) 
ID 
1338.8 
amidated, 
γ-MSH 
1084.5 AVP 1007.6 
oxytocin 
(H+) 
2104.3 
POMC 
(141-162) 
1665.0 
amidated, 
α-MSH 
  
1028.5 
oxytocin 
(Na+) 
  
1706.9 
amidated, 
acetylated 
α-MSH 
      
1883.0 
amidated, 
joining 
peptide (1-
18) 
      
2506.5 CLIP       
2586.5 
phosphoryl
ated CLIP 
      
2900.8 
Ac-β-
endorphin 
(1-26) 
      
3038.0 
Ac-β-
endorphin 
(1-27) 
      
 
  
175 
 
 
Table 7.3. Identified proteins from LC–ESI MS/MS conducted on dissociated rat anterior 
pituitary cells. Bolded entries include secretogranin, somatotropin and prolactin. Somatotropin 
and prolactin are expressed in somatotrophs and lactotrophs, respectively, in the anterior pituitary.  
Accession 
Score 
(%) 
-10lgP Mass Description 
A1Z0K8|A1Z0K8_RAT 98.7 84.02 31747.42 
Beta-actin (Fragment)  
OS=Rattus norvegicus   
GN=Actg1 PE=2 SV=1 
B0BMT0|B0BMT0_RAT 79.3 47.16 42008.97 
RCG47746, isoform CRA_a 
OS=Rattus norvegicus   
GN=Acta2 PE=2 SV=1 
B1H216|B1H216_RAT 98.4 89.04 15328.52 
Hemoglobin alpha, adult chain 2 
OS=Rattus norvegicus   
GN=Hba1 PE=2 SV=1 
B2RYR2|B2RYR2_RAT 98.3 101.38 24656.31 
Growth hormone  
OS=Rattus norvegicus   
GN=Gh1 PE=2 SV=1 
B2RYT1|B2RYT1_RAT 99 88.74 25681.52 
Prl protein  
OS=Rattus norvegicus   
GN=Prl PE=2 SV=1 
B5DEM6|B5DEM6_RAT 99 88.74 25752.6 
Prolactin  
OS=Rattus norvegicus   
GN=Prl PE=2 SV=1 
D3Z8J4|D3Z8J4_RAT 53.3 22.82 104957.64 
Protein RGD1305422  
OS=Rattus norvegicus  
GN=RGD1305422 PE=2 SV=1 
D3ZA47|D3ZA47_RAT 53.3 22.82 106504.43 
Protein RGD1305422  
OS=Rattus norvegicus  
GN=RGD1305422 PE=2 SV=1 
D3ZLY9|D3ZLY9_RAT 26.3 29.1 13920.16 
Histone H2B OS=Rattus 
norvegicus   
GN=Hist1h2bl PE=3 SV=2 
D3ZNH4|D3ZNH4_RAT 26.3 29.1 15493.03 
Histone H2B  
OS=Rattus norvegicus  
GN=Hist1h2bo PE=3 SV=1 
D3ZNZ9|D3ZNZ9_RAT 26.3 29.1 13994.2 
Histone H2B  
OS=Rattus norvegicus  
GN=Hist3h2ba PE=3 SV=1 
D3ZWM5|D3ZWM5_RAT 26.3 29.1 13964.21 
Histone H2B  
OS=Rattus norvegicus  
GN=Hist1h2bb PE=3 SV=2 
D4A817|D4A817_RAT 26.3 29.1 13908.15 
Histone H2B  
OS=Rattus norvegicus  
GN=Hist1h2bh PE=3 SV=2 
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Table 7.3. (cont.) 
G3V7X2|G3V7X2_RAT 98.7 85.38 71001.3 
Secretogranin 2, isoform CRA_a 
OS=Rattus norvegicus  GN=Scg2 
PE=4 SV=1 
G3V8B3|G3V8B3_RAT 26.3 29.1 13906.13 
Histone H2B  
OS=Rattus norvegicus  
GN=LOC684797 PE=3 SV=1 
G3V9C7|G3V9C7_RAT 26.3 29.1 13890.13 
Histone H2B  
OS=Rattus norvegicus  
GN=Hist1h2bk PE=3 SV=1 
M0R4L7|M0R4L7_RAT 26.3 29.1 13910.12 
Protein Hist1h2bf  
OS=Rattus norvegicus  
GN=Hist1h2bf PE=4 SV=1 
M0R5B4|M0R5B4_RAT 80.2 56.8 38605.6 
Uncharacterized protein 
OS=Rattus norvegicus   
PE=4 SV=1 
M0R757|M0R757_RAT 95.5 53.04 50107.93 
Protein LOC100360413 
OS=Rattus norvegicus  
GN=LOC100360413 PE=4 SV=1 
M0R7B4|M0R7B4_RAT 59.3 34.26 23211.92 
Protein LOC684828  
OS=Rattus norvegicus  
GN=LOC684828 PE=4 SV=1 
M0RAE3|M0RAE3_RAT 53.3 22.82 97773.02 
Protein RGD1305422  
OS=Rattus norvegicus  
GN=RGD1305422 PE=4 SV=1 
M0RBQ5|M0RBQ5_RAT 26.3 29.1 13908.1 
Protein Hist3h2bb  
OS= Rattus norvegicus  
GN=Hist3h2bb PE=4 SV=1 
Q4KM71|Q4KM71_RAT 50 26.75 75486.94 
Splicing factor proline/glutamine 
rich (Polypyrimidine tract binding 
protein associated)  
OS=Rattus norvegicus  
Q6P7R4|Q6P7R4_RAT 98.7 85.38 66663.5 
Scg2 protein  
OS= Rattus norvegicus   
GN=Scg2 PE=2 SV=1 
sp|A9UMV8|H2AJ_RAT 73 75.88 14045.44 
Histone H2A.J  
OS= Rattus norvegicus   
GN=H2afj PE=2 SV=1 
sp|P01237|PRL_RAT 99 88.74 25752.6 
Prolactin  
OS= Rattus norvegicus   
GN=Prl PE=1 SV=1 
sp|P01244|SOMA_RAT 98.3 101.38 24656.31 
Somatotropin  
OS= Rattus norvegicus   
GN=Gh1 PE=1 SV=1 
sp|P01946|HBA_RAT 98.4 89.04 15328.52 
Hemoglobin subunit alpha-1/2 
OS=Rattus norvegicus   
GN=Hba1 PE=1 SV=3 
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Table 7.3. (cont.) 
sp|P02091|HBB1_RAT 98.5 95.41 15979.38 
Hemoglobin subunit beta-1  
OS= Rattus norvegicus   
GN=Hbb PE=1 SV=3 
sp|P02262|H2A1_RAT 73 75.88 14077.44 
Histone H2A type 1  
OS= Rattus norvegicus   
PE=1 SV=2 
sp|P05065|ALDOA_RAT 60.7 36.63 39351.96 
Fructose-bisphosphate aldolase A 
OS=Rattus norvegicus   
GN=Aldoa PE=1 SV=2 
sp|P06761|GRP78_RAT 60.3 34.27 72347.09 
78 kDa glucose-regulated protein 
OS=Rattus norvegicus   
GN=Hspa5 PE=1 SV=1 
sp|P0C169|H2A1C_RAT 73 75.88 14105.46 
Histone H2A type 1-C  
OS=Rattus norvegicus   
PE=1 SV=2 
sp|P0C170|H2A1E_RAT 73 75.88 14119.49 
Histone H2A type 1-E  
OS=Rattus norvegicus   
PE=1 SV=2 
sp|P0CC09|H2A2A_RAT 73 75.88 14095.48 
Histone H2A type 2-A  
OS=Rattus norvegicus  
GN=Hist2h2aa3 PE=1 SV=1 
sp|P10362|SCG2_RAT 93.8 60.59 71031.33 
Secretogranin-2  
OS=Rattus norvegicus   
GN=Scg2 PE=2 SV=1 
sp|P15865|H14_RAT 81.8 51.29 21987.33 
Histone H1.4  
OS=Rattus norvegicus  
GN=Hist1h1e PE=1 SV=3 
sp|P60711|ACTB_RAT 98.7 84.02 41736.75 
Actin, cytoplasmic 1 OS=Rattus 
norvegicus  GN=Actb PE=1 SV=1 
sp|P61983|1433G_RAT 50.8 26.92 28302.58 
14-3-3 protein gamma  
OS=Rattus norvegicus  
GN=Ywhag PE=1 SV=2 
sp|P62630|EF1A1_RAT 95.5 53.04 50113.89 
Elongation factor 1-alpha 1 
OS=Rattus norvegicus  
GN=Eef1a1 PE=1 SV=1 
sp|P62738|ACTA_RAT 79.3 47.16 42008.97 
Actin, aortic smooth muscle 
OS=Rattus norvegicus   
GN=Acta2 PE=2 SV=1 
sp|P62804|H4_RAT 85.1 35.22 11367.34 
Histone H4  
OS=Rattus norvegicus  
GN=Hist1h4b PE=1 SV=2 
sp|P63102|1433Z_RAT 60.7 37.14 27771.13 
14-3-3 protein zeta/delta 
OS=Rattus norvegicus  
GN=Ywhaz PE=1 SV=1 
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Table 7.3. (cont.) 
sp|P63259|ACTG_RAT 98.7 84.02 41792.86 
Actin, cytoplasmic 2  
OS=Rattus norvegicus   
GN=Actg1 PE=1 SV=1 
sp|P63269|ACTH_RAT 79.3 47.16 41876.9 
Actin, gamma-enteric smooth 
muscle  
OS=Rattus norvegicus   
GN=Actg2 PE=2 SV=1 
sp|P68035|ACTC_RAT 79.3 47.16 42018.99 
Actin, alpha cardiac muscle 1 
OS=Rattus norvegicus   
GN=Actc1 PE=2 SV=1 
sp|P68136|ACTS_RAT 79.3 47.16 42051.05 
Actin, alpha skeletal muscle 
OS=Rattus norvegicus   
GN=Acta1 PE=1 SV=1 
sp|P68255|1433T_RAT 50.8 26.92 27778.27 
14-3-3 protein theta  
OS=Rattus norvegicus  
GN=Ywhaq PE=1 SV=1 
sp|P68511|1433F_RAT 50.8 26.92 28211.72 
14-3-3 protein eta  
OS=Rattus norvegicus  
GN=Ywhah PE=1 SV=2 
sp|Q00715|H2B1_RAT 26.3 29.1 13990.21 
Histone H2B type 1  
OS=Rattus norvegicus   
PE=1 SV=2 
sp|Q00728|H2A4_RAT 73 75.88 14283.6 
Histone H2A type 4  
OS=Rattus norvegicus   
PE=2 SV=2 
sp|Q4FZT6|H2A3_RAT 73 75.88 14121.46 
Histone H2A type 3  
OS=Rattus norvegicus   
PE=2 SV=3 
sp|Q64598|H2A1F_RAT 73 75.88 14175.55 
Histone H2A type 1-F  
OS=Rattus norvegicus   
PE=3 SV=3 
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Table 7.4. Cell populations in the rat pancreatic islet of Langerhans classified using peptide 
biomarkers. Peptide signals characteristic of all four cell types were detected.  
Cell Type Biomarkers 
Alpha 
Glucagon 
Glicentin-related 
polypeptide 
Beta 
Insulin 1 A+B chain 
Insulin 2 A+B chain 
Insulin 1 C-peptide 
Insulin 2 C-peptide 
Gamma Pancreatic hormone 
Delta Somatostatin-14 
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APPENDIX A 
NICHROME WIRE HEATER FOR MATRIX SUBLIMATION 
A.1 OVERVIEW 
In order to sublime MALDI matrix onto a sample, it is necessary to heat up a reservoir of matrix 
while placing the cooled sample over the matrix. The heated matrix sublimes in to the gas phase 
and condenses onto the cold sample. Heating is often done using a heating mantle, but the slow 
heating and cooling time limits the number of sample that can be prepared at a time. This appendix 
outlines a nichrome wire heater used in place of the heating mantle for subliming MALDI matrix. 
It heats up and cools down more quickly than the heating mantle, allowing a series of samples to 
be quickly processed. The heater has been used successfully for applying α-cyano-4-
hydroxycinnamic acid (CHCA) to spinal cord sections (chapter 3), and for generating a coating of 
2,5,-diydroxybenzoic acid (DHB) for thin film MALDI sample preparation (chapter 4).  
 
A.2 CONSTRUCTING THE NICHROME WIRE HEATER 
The heater has physical dimensions of 1 x 3 in and is constructed by winding 2 ft of nichrome wire 
(NiCr60; 21 AWG; Mor Electrical Company/Heaters Plus) in a serpentine manner (Figure A.1A). 
The wire is sandwiched between two glass slides held together with small binder clips. 
 
A.3 OPERATING THE NICHROME WIRE HEATER 
The heater is placed inside the sublimation chamber underneath the matrix reservoir. The two ends 
of the nichrome wire are connected to a DC power supply (CS13005x5; Circuit Specialists, Mesa, 
Az) outside of the sublimation chamber, with the connections passing through a custom port at the 
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side of the chamber (Figure A.1B). Data from the nichrome wire manufacturer indicate that passing 
a current of 3.14 A will cause the nichrome wire to heat to 204 oC.  
The system is operational with the existing set-up, but the current is unstable during 
operation, which may be due to the high system current and temperature. This can be corrected by 
manually monitoring the current and adjusting the power supply voltage as necessary during 
matrix application. It can also be time consuming to switch matrices because the heater 
complicates chamber cleaning. Future developments can resolve these issues by constructing 
dedicated chambers and heaters for different matrices, and by replacing the relevant electrical 
connections to make the system more tolerant of high current and temperature. 
 
A.4 MATRIX COATING CHARACTERIZATION 
Figure A.2 shows the deposition rate of α-cyano-4-hydroxycinnamic acid (CHCA) and 2,5-
dihydroxybenzoic acid (DHB) under different sublimation conditions.  
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A.5 FIGURES 
 
Figure A.1. Nichrome wire heater design and sublimation chamber set-up. (A). The heater is 
constructed by winding 2 ft. of nichrome wire in a serpentine manner and sandwiching it between 
two glass slides. (B) The sublimation chamber is set up with the (a) heater inside the chamber. The 
(b) sample is cooled using a cold finger. Two (c) electrical connections to a DC power supply are 
fed into the chamber to power the heater. 
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Figure A.2. Deposition of CHCA and DHB using the nichrome wire heater with different 
sublimation times. The heater operated with 3.75 A to sublimed CHCA, and 3 A to sublime DHB. 
The cold finger of the sublimation chamber was cooled using an ice bath. A vacuum was pulled 
on the system using an Edwards 30 E2M30 rotary pump. After the designated time, the setup was 
allowed to cool for 30 s before venting to atmosphere.  
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APPENDIX B
REMOTE CONTROL OF THE RECTILINEAR QUADRUPOLE ION GUIDE
B.1 OVERVIEW
This appendix outlines the block diagram of a LabVIEW virtual instrument (VI) for controlling a 
rectilinear quadrupole ion guide. This work is part of a larger project  in the Sweedler  group  on 
constructing a hybrid MALDI/C60-SIMS instrument.
1 The ion guide is added to a MALDI triple 
quadrupole time-of-flight mass spectrometer in order to provide space for accommodating a C60
+ 
ion gun. The VI enables constant voltages to be set, and a range of voltages to be scanned. Four 
voltages can be set to control the entrance lens, the exit lens, the quadrupole RF, and the quadrupole 
DC offset. The instrument as published requires manually setting the power supply that controls 
the quadrupole.1 The VI does not have to be used for typical instrument operation since the 
quadrupole voltages usually do not have to be adjusted, but the VI can be used to improve 
instrument capability. Remotely controlling the quadrupole reduces physical instrument operation 
to simplify use, and the capability to scan through voltages facilitates optimizing ion transmission 
by automatically switching through many quadrupole settings while the total ion current is 
monitored.  
 
B.2 DATA ACQUISITION MODULES AND POWER SUPPLIES 
The VI controls two National Instruments data acquisition modules (DAQ; Figure B.1): a cDAQ-
9264 (designated “DAQ 1”) voltage output module, and a USB-6008 DAQ (designated “DAQ 2”). 
The cDAQ-9264 has 16 analog output channels each ranging from -10 - 10 V. The USB-6008 has 
6 analog inputs and 2 analog outputs. The analog inputs have an input range of -10 V – 10 V, and 
the outputs produces 0 – 5 V. The outputs on the USB-6008 are not used in this VI. The two DAQs 
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are used to control the power supplies that power the quadrupole (Ardara Technologies; Ardara, 
PA). Two power supplies are used: a 2.8 MHz radio frequency (RF) power supply, and an 8 
channel DC power supply. The cDAQ-9264 directly controls both power supplies. The USB-6008 
takes feedbacks from the power supplies to adjust the cDAQ-9264 output. Table B.1 shows the 
physical terminals that are used on each DAQ. Differential mode is used for input measurements, 
and single ended ground reference (RSE) is used for voltage outputs. 
 
B.3 OPERATING THE VIRTUAL INSTRUMENT 
The VI can be used to dictate a constant voltage output or scan through a range of voltages. To set 
a constant voltage, select tab 1 on the front panel and enter the desired voltages. The RF power 
supply can range from 0 to 1000 V, and all DC voltages range from -400 to 400 V. To scan through 
voltages, select one of the scanning tabs (tabs 2 – 4) and enter the starting voltage, ending voltage, 
voltage step size, and scan rate. 
 
B.4 VIRTUAL INSTRUMENT BLOCK DIAGRAM 
B.4.1 State Machine Structure and Switching Between States. The block diagram 
consists of a while loop enclosing a case structure. There are five states within the case structure 
numbered 0 to 4.  State 0 is the default state and contains code for setting constant voltages and 
for calculating the scan time needed for voltage scans. The other four states are used for scanning 
voltages: state 1 scans the quadrupole RF, state 2 scans the entrance lens, state 3 scans the 
quadrupole DC offset, and state 4 scans the exit lens. When a scan is initiated, the VI switches to 
the relevant state for scanning and returns to state 0 when the scan is finished. A Boolean control 
is used to dictate which state to switch to for scanning (Figure B.2).  
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B.4.2 Setting Constant Power Supply Voltages. The block diagram for setting constant 
power supply voltages is in state 0 (Figure B.3). The user enters the desired power supply voltages, 
and the code roughly calculates the necessary DAQ 1 output by dividing the user values by 100 
(Figure B.3). Ideally, the voltage output between DAQ 1 and the settings on the power supplies 
can be related in a straightforward manner (e.g. 5 V from DAQ 1 leads to 500 V on the power 
supply). However, this is not the case (e.g. 5 V from DAQ 1 leads to 435 V). To compensate for 
this discrepancy, a while loop is made inside state 0 of the case structure. In this loop, feedback 
voltage measurements from the power supplies are taken using DAQ 2 (Figure B.4, referred to as 
Readback). These feedback voltages (ranging 0 – 1 V for RF and -4 – 4 V for all DC voltages) 
reflect the actual power supply voltages. Once acquired, they are converted to the power supply 
settings using empirically determined conversion factors called on as sub VIs (Figure B.4; boxed 
red). The conversion factors are shown in Table B.2. Feedback measurements are taken at 2500 
Hz, and 500 measurements are averaged together at a time. The converted voltages are compared 
against the user settings, and the differences are divided by 100 and used to adjust DAQ 1 outputs 
(Figure B.5). This process is iterated until the feedback voltages equal the user settings. 
This VI can maintain a stable power supply output over many hours of continuous 
operation. However, even with using the feedback measurements to adjust DAQ 1, voltage outputs 
from the 8 channel DC power supply are often still around 2 V higher than dictated by the user. 
This discrepancy is dealt with by subtracting out the relevant voltage during the self-correction 
process (Figure B.5). For the entrance lens, 0.022 V is subtracted from DAQ 1. The quad and the 
exit lenses require a 0.018 V subtraction. 
B.4.3 Scanning Through Power Supply Voltages. In addition to setting constant 
voltages, the VI can also scan through a range of voltages for optimizing ion transmission. Scans 
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are conducted by switching the VI to different states using a Boolean control. The block diagram 
for scanning through the quadrupole RF is shown as an example in Figure B.6. The code for 
scanning uses a for loop, which runs the enclosed code a fixed number of iterations. The blue letter 
N in the upper left corner of the loop records the number of iterations that will run, and the letter i 
indicates the current iteration count. The scan is finished when N = i. At that point, the power 
supply is set to 0 V, and the VI returns to state 0. 
Because voltage scanning is only used to get a rough idea of optimized settings, feedback 
voltages are not used to correct the DAQ 1 output during scanning. Rather, another set of 
empirically determined formulas is used to directly convert the desired power supply voltage to 
the necessary DAQ 1 voltage (Table B.3). Two conversion factors are used to scan through RF to 
cover the entire voltage range. This results in adequate accuracy for voltage scanning.   
 
B.5 ADDITIONAL CONSIDERATIONS 
 
The VI as developed may be modified to further enhance instrument operation. The self-correcting 
process may be improved to remove the remaining discrepancy between software and hardware 
settings (Chapter 5). New functions may also be added, such as the capability to jump between 
voltages to optimize transmission of distinct mass ranges, allowing improved mass selection to 
reduce interfering signals.  
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B.7 FIGURES 
 
Figure B.1. Two DAQs are used to control the power supplies that power the rectilinear 
quadrupole. The cDAQ-9264 (DAQ 1) controls the power supplies, and the USB-6008 (DAQ 2) 
takes feedback measurements from the power supplies. 
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Figure B.2. Boolean control for switching between states in the VI. State 1 scans the quadrupole 
RF. State 2 scans the entrance lens. State 3 scans the quadrupole DC offset. State 4 scans the exit 
lens. 
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Figure B.3. Block diagram for the user to set power supply voltages. The VI roughly calculates 
the necessary DAQ output by dividing the user input by 100. 
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Figure B.4. Taking feedback measurements from the power supplies. The sub VIs (boxed red) 
are used to convert the feedback measurements to the power supply outputs. 
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Figure B.6. Scanning through quadrupole RF. Different states are used to scan different parts 
of the quadrupole. 
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B.8 TABLES 
Table B.1. DAQ terminals used for controlling the power supplies. 
 
  
 cDAQ-9264 USB-6008 
RF AO0 AI0 
Entrance AO1 AI1 
Quad AO2 AI2 
Exit AO3 AI3 
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Table B.2. Conversion factors to convert the feedback voltages to the power supply outputs. 
These conversion factors are called on as sub VIs in the self-correction process.  
 
  
Readback Conversion Function 
RF 𝑦 = 0.9915𝑥2 + 1001.2𝑥 − 2.3437 
Entrance 𝑦 = 0.7572𝑥2 + 98.697𝑥 − 3.0646 
Quad 𝑦 = −0.1126𝑥2 + 99.236𝑥 − 2.8411 
Exit 𝑦 = −1.3093𝑥2 + 99.434𝑥 − 2.6787 
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Table B.3. Conversion factors to convert power supply outputs to DAQ 1 outputs.  
 
 
  
Voltage Setting Conversion Function 
RF (0 – 400 V) 𝑦 = −9.05 ∗ 10−7𝑥2 + 9.37 ∗ 10−3𝑥 − 1.25 ∗ 10−2 
RF (400 – 1000 V) 𝑦 = −1.12 ∗ 10−6𝑥2 + 9.96 ∗ 10−3𝑥 − 2.00 ∗ 10−1 
Entrance 𝑦 = 1.27459 ∗ 10−2𝑥 − 1.21314 ∗ 10−2 
Quad 𝑦 = −5.12303 ∗ 10−9𝑥2 + 1.27498 ∗ 10−2𝑥 − 1.20969 ∗ 10−2 
Exit 𝑦 = −1.00368 ∗ 10−8𝑥2 + 1.27308 ∗ 10−2𝑥 − 1.3560 ∗ 10−2 
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APPENDIX C 
RASTERING THE C60+ PRIMARY ION BEAM 
C.1 OVERVIEW 
This appendix outlines the block diagram of a LabVIEW virtual instrument (VI) for rastering the 
C60
+ ion beam in a serpentine manner. This work is part of a larger project in the Sweedler group 
on constructing a hybrid MALDI/ C60-SIMS instrument. Instrument performance from hardware 
modifications have been previously published.1 Here, a VI for rastering the primary C60 ion beam 
is described for further enhancing instrument operation. The current sample stage on the 
instrument limits rastering distance to 10 µm. The VI improves rastering distance to ~5 µm by 
keeping the sample stage stationary and instead moving the ion beam. Currently, the VI has only 
been used in a depth profiling experiment, in which layers of materials are sputtered away in 
between image acquisition. Enabling high resolution imaging will require further software 
developments to sync rastering with mass spectrometry data acquisition and to bypass the position 
feedback system in the instrument software. 
 
C.2 DATA ACQUISITION MODULES AND POWER SUPPLIES 
To raster the ion beam, four raster plates inside the ion gun are connected to 4 channels of an 8 
channel DC power supply (Ardara Technologies; Ardara, PA). Beam deflection is achieved by 
setting opposite facing deflector plates to a voltage that is opposite in sign but equal in magnitude 
(e.g. ±1 V). A VI is developed to control the power supply using a National Instruments cDAQ-
9264 voltage output module. The cDAQ-9264 has 16 analog output channels each ranging from -
10 to 10 V. The DAQ terminals used to control the power supply are shown in Table C.1. Two 
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power supply channels are used for deflection in each dimension (X and Y). The relationship 
between deflection distance and power supply voltage is roughly 1 µm = ±0.2 V. 
 
C.3 OPERATING THE VIRTUAL INSTRUMENT 
The VI deflects the C60
+ ion beam in a serpentine path (Figure C.1). Due to the way the ion gun is 
mounted, the X and Y directions are flipped in the current software version. The front panel of the 
VI consists of two tabs. The first tab is used to set parameters for rastering. The second tab is for 
the user to see the voltage outputs from the DAQ and the power supply. To set up rastering on the 
first tab, the input boxes “Set X Raster Start” and “Set Y Raster Start” are set to 0 to indicate no 
deflection at the start of the experiment. “Set X Raster End” is typically positive to move the beam 
up in X, and “Set Y Raster End” must always be negative and less than “Set Y Raster Start”. At 
the end of the raster, all deflections can be reset to zero by clicking “Reset X and Y”.  
 
C.4 VIRTUAL INSTRUMENT BLOCK DIAGRAM 
C.4.1 State Machine Structure and Operation. The block diagram for the VI consists of 
a while loop enclosing a case structure containing five states. Raster parameters are entered in state 
0 (default state). During a raster, the VI cycles through four states (states 1 – 4), where the beam 
is systematically deflected in X and Y to make a serpentine path. The VI automatically returns to 
state 0 once Y reaches the designated “Y End” location. State 5 is used to reset deflection to zero.  
C.4.2 Set Raster Parameters (State 0). Raster parameters are set as deflection distances 
and step sizes in micrometers. Once set, the parameters are converted to the necessary DAQ 
voltages by dividing by 500 (a combination of dividing by 100 because 1 V on the power supply 
roughly equals 0.01 V on the DAQ and dividing by 5 because 1 micrometer of deflection equals 
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0.2 V on the power supply; Figure C.2B). The scan time is also calculated. The block diagram for 
setting raster parameters are shown in Figure C.2.   
C.4.3 Rastering in the X Dimension (States 1 and 3). Using a for loop, in states 1 and 3 
the VI cycles through a range of voltages using raster parameters indicated in state 0 (Figure C.3). 
States 1 and 3 raster X in opposite directions. In both states, two DAQ terminals are used to set 
two opposite-facing deflector plates. Raster parameters are first converted to the necessary power 
supply outputs using the 1 µm = 0.2 V relationship. Sub VIs are then used to convert the calculated 
power supply outputs to DAQ voltages. The conversion factors are shown in Table C.2.  
C.4.4 Stepping in the Y Dimension (States 2 and 4). In states 2 and 4 the VI moves one 
step in Y as indicated in state 0 (Figure C.4). States 2 and 4 are identical except that state 2 leads 
to state 3, and state 4 leads to state 1. Similar to states 1 and 3, two DAQ terminals are used to 
control two opposite-facing deflector plates. Sub VIs are used to convert the necessary power 
supply outputs to DAQ voltages (Table C.2). 
C.4.5 Ending a Raster and Returning to State 0. The VI automatically returns to state 0 
when it reaches its destination as set in Y (Figure C.5). Because the destination is defined in the Y 
dimension, the VI can only return to state 0 when it is in states 2 and 4. Once in state 0, state 5 can 
be manually entered to reset all voltages to 0, removing all deflections (Figure C.6). 
 
C.5 ADDITIONAL CONSIDERATIONS 
The VI described is currently used for C60-SIMS depth profiling, but it can also be used for imaging 
at higher lateral resolution than what is capable with the instrument’s sample stage. Future 
developments to enable this feature will require syncing rastering steps with mass spectrometry 
data acquisition and bypassing the position-feedback system built into the instrument software. 
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Further, voltage instabilities and discrepancies that currently exist between hardware and software 
settings limit rastering lateral resolution to ~5 µm (Chpater 5). Multiple options may be pursued 
to improve rastering performance. In terms of software development, the self-correcting protocol 
used to control the rectilinear quadrupole on the instrument may be added (Appendix A). Hardware 
wise, a higher performing power supply with a more precise and stable voltage control may be 
used. These improvements may allow rastering to be done at the ion gun’s focus limit of ~1 µm. 
  
202 
  
 
C.6 References 
(1)  Lanni, E. J.; Dunham, S. J.; Nemes, P.; Rubakhin, S. S.; Sweedler, J. V. J. Am. Soc. Mass 
Spectrom. 2014, 1-11. 
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C.7 FIGURES 
 
Figure C.1.  C60+ beam deflection path. 
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Figure C.2.  Block diagram for setting raster parameters. (A) Scan time is calculated based on 
deflection distance, step size, and scan rate. (B) Parameters are entered as micrometers and are 
converted to the necessary DAQ voltage by dividing by 500.  
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Figure C.3. Example block diagram for rastering in X (states 1 and 3). Raster parameters from 
state 0 are converted to DAQ voltages. Two DAQ terminals are used to control two opposite-
facing deflector plates (X(+) and X(-)). 
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Figure C.4. Example block diagram for stepping in the Y dimension (states 2 and 4). Raster 
parameters from state 0 are converted to DAQ voltages. Two DAQ terminals are used to control 
two opposite-facing deflector plates (Y(+) and Y(-)). 
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Figure C.5.  Boolean control to return to state 0. The VI automatically returns to state 0 when 
rastering reaches its destination in the Y dimension. This control is only present when the VI is in 
states 2 and 4. 
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Figure C.6.  Resetting X and Y to no deflection (state 5). This state is manually entered from 
state 0 to reset all voltages to 0.  
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C.8 TABLES 
Table C.1. DAQ terminals used for rastering the C60+ primary ion beam. Each terminal is 
connected to a separate deflector plate. 
 
  
Terminal Direction 
AO4 X (+) 
AO5 X (-) 
AO6 Y (+) 
AO7 Y (-) 
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Table C.2. Conversion factors to convert from deflection power supply voltages to the proper 
DAQ voltages.  
 
  
Terminal Conversion factor 
AO4 (X(+)) 𝑦 = 2𝐸 − 5𝑥2 + 0.0124𝑥 + 0.0084 
AO5 (X(-)) 𝑦 = 2𝐸 − 5𝑥2 + 0.0124𝑥 + 0.0084 
AO6 (Y(+)) 𝑦 = 3𝐸 − 5𝑥2 + 0.0123𝑥 + 0.0092 
AO7 (Y(-)) 𝑦 = 2𝐸 − 5𝑥2 + 0.0124𝑥 + 0.0086 
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APPENDIX D 
PYTHON SCRIPT TO CONDUCT PCA OUTLIER DETECTION 
D.1 OVERVIEW 
This Python script is written by Dr. David Kissick and is used to detect rare signals in a collection 
of MALDI MS spectra. It is used in Chapter 7 for finding single cell spectra containing unique 
signal. It requires the modules tkinter, itertools, re, os, numpy scipy and matplotlib to be installed. 
The program is designed to load Bruker data files in the XMass format generated by flexControl 
3.4 (build 135) and comma separated files exported from flexAnalysis 3.4 (build 70). Loading 
other data formats may require the data reading section to be modified.  
 
D.2 OPERATING THE SCRIPT 
When first initialized, the user is prompted to select a data directory, an upper and lower bound 
for the mass range to analyze, and the number of principal components for outlier analysis. It is 
possible to edit the script to change the normalization methods (line 138) and to modify the top 
hat background estimation (line 128).  
Once analysis parameters are set, PCA and PCA-based outlier detection are conducted and 
three plotting windows are generated. These include (window name in parentheses): the raw data 
plot and principal component data projection (Raw Spectra and PC Space), outlier spectra and 
individual spectra compared to the reconstruction error (Outlier and Spectra Plots), and a scatter 
plot of the locations from which the spectra were acquired (Selected m/z Range Image). The 
number of principal components used in the outlier detection process can be changed by scrolling 
over the outlier spectrum. Selecting a range on the outlier spectrum or the data/reconstruction error 
spectrum changes the color scale of the scatter plot to correspond to the signal intensity of that 
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range. Selecting a point from the scatter plot updates the spectrum and reconstruction error 
spectrum that is displayed. 
 
D.3 SCRIPT 
import tkinter 
tk_parent = tkinter.Tk() 
tk_parent.withdraw() 
from tkinter import filedialog 
import itertools 
import re 
import os 
import numpy as np 
from scipy import ndimage, linalg 
import pylab as pl 
import matplotlib 
from matplotlib.colors import Normalize as cnm 
from matplotlib.cm import ScalarMappable as scm 
 
# take parameters from a Bruker param file and generate the m/z scale 
def tof2mass(tof, ML1, ML2, ML3): 
 A = ML3 
 B = np.sqrt(1E12/ML1) 
 C = ML2 - tof 
 if (A == 0): return ((C * C)/(B * B)) 
 else: return (((-B + np.sqrt((B * B) - (4 * A * C))) / (2 * A))**2) 
 
# Sum a range of data to decrease to reduce number of points per spectrum 
def bin_data(mz_scale, data, mass_res = 1): 
 mz_min = int(mz_scale[0]) 
 mz_max = int(mz_scale[-1]) 
 bin_width = data.shape[1] // ((mz_max - mz_min) // mass_res) 
 new_res = np.empty((mz_max - mz_min) // mass_res) 
 output = np.empty((data.shape[0], new_res.shape[0])) 
 for i in list(range(int((mz_max - mz_min) // mass_res))): 
  new_res[i] = np.mean(mz_scale[bin_width * i: bin_width * (i + 1)]) 
  output[:,i] = np.sum(data[:, bin_width * i: bin_width * (i + 1)], axis = 1) 
 return (new_res, output) 
 
folder = filedialog.askdirectory(parent = tk_parent, initialdir = '/data', title = "Select a Data 
Directory") + '/' 
tk_parent.destroy() 
files = os.listdir(folder) 
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# This section handles reading in the data 
# If the dataset has been opened before, this section saves it as a compressed numpy archive to 
save time in reopening and disk space. 
# If a compressed file is not found, then it looks for Bruker files or exported *.csv files. Ideally, 
all the data would saved and read in from a more open/ standardized format... 
if "raw_scale_locations_data.npz" not in files: 
 raw_locations = np.empty([len(files), 2]) 
 # There are two ways that I'm seen these folders named, on with x_ and y_ delimiters and 
one with X Y delimiters. 
 # These two regex's will find these patterns, but you may need to add more if these 
delimiters change. 
 find_locations_x_y_ = re.compile('x_[\-0-9]{1,}y_[\-0-9]{1,}') 
 find_locations_XY = re.compile('X[\-0-9]{1,}Y[\-0-9]{1,}') 
 tmp = 0 
 for i in files: tmp += os.path.isdir(folder + i) 
 if tmp / len(files) == 1: 
  try: 
   for i, f in enumerate(files): 
    raw_locations[i,:] = find_locations_x_y_.findall(f)[0][2:].split('y_') 
  except IndexError: 
   for i, f in enumerate(files): 
    raw_locations[i,:] = find_locations_XY.findall(f)[0][1:].split('Y') 
  # This script is going to assume that all of the MS runs had exactly the 
  # same parameters as the first location in the list. 
  parameters = open(folder + files[0] + "/1/1SRef/acqu").read() 
  parse_var = parameters.find('$ML1= ') 
  ML1 = float(parameters[parse_var + 6:parse_var + 20].split(' ')[0]) 
  parse_var = parameters.find('$ML2= ') 
  ML2 = float(parameters[parse_var + 6:parse_var + 20].split(' ')[0]) 
  parse_var = parameters.find('$ML3= ') 
  ML3 = float(parameters[parse_var + 6:parse_var + 20].split(' ')[0]) 
  parse_var = parameters.find('$DELAY= ') 
  DELAY = int(parameters[parse_var + 8:parse_var + 22].split(' ')[0]) 
  parse_var = parameters.find('$DW= ') 
  DW = float(parameters[parse_var + 5:parse_var + 19].split(' ')[0]) 
  parse_var = parameters.find('$TD= ') 
  TD = int(parameters[parse_var + 5:parse_var + 19].split(' ')[0]) 
  raw_mz_scale = tof2mass(DELAY + np.arange(TD) * DW, ML1, ML2, ML3) 
  # Adjust the datatype to np.uint16 if you are running out of RAM 
  raw_data = np.empty((len(files), TD), dtype = np.int32) 
  for i, f in enumerate(files): 
   raw_data[i] = np.fromfile(folder + f + "/1/1SRef/fid", dtype = np.int32) 
 elif tmp == 0: 
  first = np.fromfile(folder + files[0], sep = ' ').reshape([-1,2]) 
  raw_mz_scale = first[:,0] 
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  # Adjust the datatype to np.uint16 if you are running out of RAM 
  raw_data = np.empty((len(files), first.shape[0]), dtype = np.int32) 
  del first 
  try: 
   for i, f in enumerate(files): 
    raw_locations[i,:] = find_locations_x_y_.findall(f)[0][2:].split('y_') 
    raw_data[i] = np.fromfile(folder + f, sep = ' ').reshape([-1,2])[:,1] 
  except IndexError: 
   for i, f in enumerate(files): 
    raw_locations[i,:] = find_locations_XY.findall(f)[0][1:].split('Y') 
    raw_data[i] = np.fromfile(folder + f, sep = ' ').reshape([-1,2])[:,1] 
 else: 
  raise ValueError('The selected directory must contain only folders of only files') 
 # There is a bug in NumPy that won't let you add larger than 1GB section to their npz 
format. This gets around that. 
 oneGB_split = raw_data.size * raw_data.dtype.itemsize // (1024 ** 3) + 1 
 split_rng = raw_data.shape[0] // oneGB_split + 1 
 rd = [raw_mz_scale, raw_locations] 
 for i in list(range(oneGB_split)): 
  rd.append(raw_data[i * split_rng: (i + 1) * split_rng]) 
 try: 
  rd.append(labels) 
 except: 
  pass 
 np.savez_compressed(folder + "raw_scale_locations_data.npz", *rd) 
 del rd 
 del tmp 
else: 
 tmp = np.load(folder + "raw_scale_locations_data.npz") 
 raw_mz_scale = tmp['arr_0'] 
 raw_locations = tmp['arr_1'] 
 raw_data = tmp['arr_2'] 
 i = 3 
 while True: 
  try: 
   raw_data = np.vstack([raw_data, tmp['arr_' + str(i)]]) 
  except KeyError: 
   break 
  except: 
   labels = tmp['arr_' + str(i)] 
   break 
  i += 1 
 del tmp, i 
 
mz_scale, data = bin_data(raw_mz_scale, raw_data, 1) 
locations = raw_locations 
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del raw_mz_scale, raw_data, raw_locations 
 
# Perform TopHat baseline estimation, note: the window size is in pixels, not mass, so adjust in 
carefully 
tophatWindow = 10 
baseline = ndimage.grey_dilation(ndimage.grey_erosion(data, size = (0, tophatWindow)), size = 
(0, tophatWindow)) 
data -= baseline 
del baseline 
 
lower_bound = float(input("Lower m/z bound?\n")) 
upper_bound = float(input("Upper m/z bound?\n")) 
rng_data = list(range((mz_scale>=max(lower_bound, mz_scale[0])).argmax(), 1 + 
(mz_scale>=min(upper_bound, mz_scale[-1])).argmax())) 
 
# Choose different normalization methods by uncommenting one of the following three 
# 1. mean of area with no signal, note: you should change the range depending on your data 
#~ lower = 2103 
#~ upper = 2107 
#~ normalize = data[:, list(range((mz_scale>=max(lower, mz_scale[0])).argmax(), 1 + 
(mz_scale>=min(upper, mz_scale[-1])).argmax()))].max(axis = 1) 
# 2. Total ion count 
normalize = data.mean(axis = 1) 
# 3. total low mass ion count, note: this seems super-extra hacky, but doesn't all normalization?! 
#~ normalize = data[:,:1000].mean(axis = 1) 
# 4. ion count in data range 
#~ normalize = data[:,rng_data].mean(axis = 1) 
 
for i in list(range(data.shape[0])): 
 data[i, :] /= normalize[i] 
 
# subtract the mean of each dimension (i.e. mass) to prepare for PCA 
data_centered = data - data.mean(axis = 0) 
 
A = data_centered[:,rng_data] 
B = np.dot(A.T, A) 
C = linalg.eigh(B) 
# I changed the eigen decomposition function and it changed the order of the eigenvalues, so I 
threw in this order variable to make sure they always appear lowest to highest. 
order = C[0].argsort()[::-1] 
# rescale eigenvals to percent 
percent = (C[0][order] * 100 / np.sum(C[0])) 
 
# Select ranges of principal compenents 
q = None 
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while q != 'y': 
 N = int(input('Select range of principal components to use: ')) 
 rng_PC = list(range(N)) 
 print('The first', N, 'principal components account for ' + str(percent[rng_PC].sum()) + '% 
of the variance') 
 q = input('Is this acceptable? (y/n)') 
PC = C[1][:, order][:,rng_PC] 
D = np.dot(A, PC) 
E = np.dot(D, PC.T) 
diff = A - E 
 
#make custom color map 
cmap = matplotlib.cm.get_cmap('jet', 256) 
cmap_vals = cmap(np.arange(256)) 
cmap_vals[np.arange(256), 3] = np.arange(.1, 1, (1 - .1) / 256.) 
alpha_cmap = matplotlib.colors.LinearSegmentedColormap.from_list('alphaMap', cmap_vals) 
 
# fig1 displays the raw selected spectra and the data projected onto the first two principal 
components  
fig1, (ax1_1, ax1_2) = pl.subplots(2) 
fig1.canvas.set_window_title('Raw Spectra and PC Space') 
spectrum, = ax1_1.plot(mz_scale, data[0]) 
ax1_1.set_xlim(mz_scale[0], mz_scale[-1]) 
ax1_1.set_ylim(0, 20) 
scatter = ax1_2.scatter(D[:,0], D[:,1], c = D[:,2], edgecolor = (0,0,0,0), picker = True) 
def onpick(event): 
 ind = event.ind 
 spectrum.set_ydata(data[event.ind[0]]) 
 fig1.canvas.draw() 
 print(event.ind[0], locations[event.ind[0]]) 
# fig1 updates when a point from PC space is selected 
fig1.canvas.mpl_connect('pick_event', onpick) 
 
# fig2 displays the outlier spectrum constructed from the entire data set 
# and the selected spectrum and the reconstruction error. 
# It is possible to select mass ranges on either plot to change the color scale of fig3 
fig2 = pl.figure() 
ax2_1 = fig2.add_subplot(2,1,1) 
ax2_2 = fig2.add_subplot(2,1,2, sharex = ax2_1) 
fig2.canvas.set_window_title('Outlier and Spectra Plots') 
 
# fig3 is a scatter plot of the locations of the cells. The color depends on the selected range in 
fig2. 
# selecting points from this plot updates the selected spectrum that is displayed. 
fig3, ax3 = pl.subplots(1) 
fig3.canvas.set_window_title('Selected m/z Range Image') 
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diff_spec, = ax2_1.plot(mz_scale[rng_data], diff.max(axis = 0)) 
select_spec, = ax2_2.plot(mz_scale[rng_data], data[0][rng_data]) 
select_spec_diff, = ax2_2.plot(mz_scale[rng_data], diff[0]) 
ax2_1.set_xlim(mz_scale[rng_data][0], mz_scale[rng_data][-1]) 
ax2_2.set_xlim(mz_scale[rng_data][0], mz_scale[rng_data][-1]) 
 
im = ax3.scatter(locations[:,0], locations[:,1], c = data[:,0], cmap = alpha_cmap, edgecolors = 
(0,0,0,0), picker = True) 
ax3.invert_yaxis() 
 
red_x1 = 0 
red_x2 = 0 
red_highlight = ax2_1.axvspan(red_x1, red_x2, color = 'red', alpha = .5) 
idx = 0 
 
def on_press(event): 
 global red_x1 
 if event.button == 1: 
  red_x1 = event.xdata 
 
def on_release(event): 
 global red_x1, red_x2, red_highlight 
 if red_x1 is not None: 
  if event.button == 1: 
   if event.xdata is not None: red_x2 = event.xdata 
   else: red_x2 = red_x1 
  
 red_highlight.set_xy([[red_x1,0],[red_x1,1],[red_x2,1],[red_x2,0],[red_x1,0]]) 
   mz_rng = [(mz_scale>red_x1).argmax(), (mz_scale>red_x2).argmax()] 
   print([mz_scale[mz_rng[0]], mz_scale[mz_rng[1]]]) 
   colors = np.log(data[:, min(mz_rng):max(mz_rng) + 1].mean(axis = 1)) 
   colors = (colors - colors.min()) / (colors.max() - colors.min()) 
   im.set_facecolors(im.cmap(colors)) 
   scatter.set_facecolors(im.cmap(colors)) 
   fig1.canvas.draw() 
   fig2.canvas.draw() 
   fig3.canvas.draw() 
 
# scrolling over fig2 adjusts the number of principal components that are use in the data 
recontruction. 
def on_scroll(event): 
 global N, A, percent, idx 
 if N > 1 or event.step > 0:  
  N += event.step 
  print(N, percent[:N].sum()) 
  rng_PC = list(range(N)) 
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  PC = C[1][:, order][:,rng_PC] 
  D = np.dot(A, PC) 
  E = np.dot(D, PC.T) 
  diff = A - E 
  select_spec.set_ydata(data[idx][rng_data]) 
  select_spec_diff.set_ydata(diff[idx]) 
  diff_spec.set_ydata(diff.max(axis = 0)) 
  fig2.canvas.draw() 
 
def image_click(event): 
 global select_spec, idx 
 idx = event.ind[0] 
 select_spec.set_ydata(data[idx][rng_data]) 
 select_spec_diff.set_ydata(diff[idx]) 
 print(event.ind) 
 fig2.canvas.draw() 
 
fig2.canvas.mpl_connect('scroll_event', on_scroll) 
fig2.canvas.mpl_connect('button_press_event', on_press) 
fig2.canvas.mpl_connect('button_release_event', on_release) 
fig3.canvas.mpl_connect('pick_event', image_click) 
pl.show() 
 
# make spectrum type plots of the principal components. 
def plot_PCs(PC =  C[1][:, order], N = [0, 1, 2], percent = None): 
 fig, ax = pl.subplots(1) 
 fig.canvas.set_window_title('Principal Components ' + str(N)[1:-1]) 
 N = list(N) 
 for n in N: 
  if percent is not None: 
   ax.plot(mz_scale[rng_data], PC[:, n] * percent[n]) 
  else: 
   ax.plot(mz_scale[rng_data], PC[:, n]) 
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